

BOARD OF DIRECTORS

Sharon Walsh, PhD, President
Stephen T. Higgins, PhD, Past-President
Linda J. Porrino, PhD, President-Elect
Stephen G. Holtzman, PhD, Treasurer
Patrick M. Beardsley, PhD
Steven R. Childers, PhD
Theodore J. Cicero, PhD
Richard De La Garza, II, PhD
Toby K. Eisenstein, PhD
David A. Fiellin, MD

A. Thomas McLellan, PhD
Geoffrey K. Mumford, PhD
Michael A. Nader, PhD
Edward V. Nunes, MD
Alison Oliveto-Beaudoin, PhD
Richard A. Rawson, PhD
Maxine L. Stitzer, PhD
Eric C. Strain, MD
Dace S. Svikis, PhD

EXECUTIVE OFFICER

Martin W. Adler, PhD

SCIENTIFIC PROGRAM COMMITTEE

Sari Izenwasser, PhD, Chair
Martin W. Adler, PhD, ex officio
Ellen B. Geller, MA, ex officio
Alan Budney, PhD
Sandra Comer, PhD
Mark Greenwald, PhD
Kathleen Kantak, PhD
Michelle Lofwall, MD
Lance McMahon, PhD
Dace Svikis, PhD
Jennifer Tidey, PhD
Ellen Unterwald, PhD
Elise Weerts, PhD
Friedbert Weiss, PhD

Saturday, June 20, 2009

PRE-MEETING SATELLITES

*The International Study Group Investigating
Drugs as Reinforcers (ISGIDAR)*

Chaired by Elise Weerts

*9 th Annual Meeting Center for Substance Abuse
Treatment (CSAT)*

Chaired by Cathy Crowley

*The 14th Annual NIDA International Forum on
Building International Research on Drug Abuse:
Progress through Collaboration*

Chaired by Steven Gust

*Treating Addiction during Pregnancy: Exploring Multinational
Perspectives to Build a Treatment Approach Consensus*

Chaired by Hendree Jones

Bonanza A

**Bonanza B and
Southern Pacific B/F**

**Ponderosa B and
Pavilion C/E**

**Bonanza A
8:00 - 10:00 PM**

CPDD REGISTRATION

Ponderosa A

Saturday, June 20

**1:30 PM - 5:00 PM
(Pool Area) 7:00 PM - 7:30 PM**

Sunday, June 21

**8:00 AM - 12:00 PM
1:30 PM - 5:00 PM**

Monday, June 22

**8:00 AM - 12:00 PM
1:30 PM - 5:00 PM**

Tuesday, June 23

8:00 AM - 1:00 PM

Wednesday, June 24

**8:00 AM - 12:00 PM
1:30 PM - 5:00 PM**

Thursday, June 25

8:00 AM - 1:00 PM

**OPENING RECEPTION
(Cash Bar)**

**7:00 - 9:00 PM
Pool Area**

Sunday, June 21, 2009

**CSAT Travel Awards Breakfast
(By Invitation Only)**

**Poolside Terrace
7:00 - 8:00 AM**

Plenary Session

**Rose Ballroom A
8:30 - 11:00 AM**

- 8:30 *Welcome, CPDD President*
Sharon L. Walsh
- 8:45 *Report from the National Institute on Drug Abuse*
Nora Volkow, NIDA
- 9:15 *Presentation of the CPDD/NIDA Media Award to Nancy Campbell*
Introduction by Marc J. Kaufman
- 9:25 *Presentation of the Joseph Cochin Young Investigator Award to Laura Bohn*
Introduction by Linda Dykstra
- 9:30 *Presentation of the Mentorship Award to George Bigelow*
Introduction by Stephen Higgins
- 9:35 *Presentation of the Nathan B. Eddy Award to Robert L. Balster*
Introduction by Louis Harris
- 9:40 *Nathan B. Eddy Award Lecture*
Robert L. Balster

**EARLY CAREER INVESTIGATOR
AWARDS LUNCHEON
(By Invitation Only)**

**Poolside Terrace
11:30 AM - 1:00 PM**

Presidential Symposium

**Rose Ballroom A
1:00 - 3:00 PM**

**OPIOID RECEPTORS FROM THE CUTTING EDGE TO THE CLINIC:
KNOCKOUTS, CROSSTALK AND BEHAVIOR**

Chair: Sharon L. Walsh

- 1:00 *Our shifting view of the nature of the opioid receptors*
Christopher Evans, University of California, Los Angeles, Los Angeles, CA
- 1:20 *Cellular mechanisms of opioid receptor regulation*
Mark Van Zastrow, University of California, San Francisco, CA
- 1:40 *Novel mouse model of human OPRM1 polymorphism (A118G)*
Julie Blendy, University of Pennsylvania, Philadelphia, PA
- 2:00 *Involvement of the endogenous opioid system in nicotine reward*
Rafael Maldonado, Universitat Pompeu Fabra, Barcelona, Spain
- 2:20 *Discussant*
Nora Volkow, Director of NIDA

BADGES MUST BE WORN IN ALL SCIENTIFIC SESSIONS

Symposium I

Ponderosa B
3:15 - 5:15 PM

HOW DOES STRESS CONTRIBUTE TO ADDICTION VULNERABILITY? STUDIES FROM ADOLESCENT AND ADULT SAMPLES

Chairs: Rajita Sinha and Kathleen T. Brady

- 3:15 *Racial differences in stress, emotional regulation and DSM-IV substance abuse and dependence in young, low-income women*
Helen Wu, University of Texas Medical School-Houston, Galveston, TX
- 3:40 *Hypothalamic-pituitary-adrenal axis and substance use among adolescents: The TRAILS study*
Anja Huizink, Erasmus Medical Center, Rotterdam, CB Rotterdam, Netherlands
- 4:05 *Stress response and risk for substance use in prenatally cocaine-exposed and non-exposed adolescents*
Tara Chaplin, Linda Mayes, Yale University School of Medicine, New Haven, CT
- 4:30 *Altered nucleus accumbens activity in individuals with high childhood trauma is predictive of addictive behaviors*
Rajita Sinha, Zhiru Jia, Yale Stress Center, Yale University School of Medicine, New Haven, CT
- 4:55 *Discussant*
Kathleen T. Brady, Medical University of South Carolina, Charleston, SC

Symposium II

Bonanza
3:15 - 5:15 PM

VIRTUAL MODELING: A NEW FRONTIER FOR INVESTIGATING DRUG-RECEPTOR INTERACTIONS

Chair: Christopher K. Surratt

- 3:15 *Uptake inhibitor interactions in the primary and "staging area" substrate pockets of the plasma membrane monoamine transporters*
Christopher K. Surratt, Duquesne University, Mylan School of Pharmacy, Pittsburgh, PA
- 3:40 *Ligand-receptor docking of epibatidine analogs to a nicotinic acetylcholine receptor model*
S. Wayne Mascarella, Research Triangle Institute, Research Triangle Park, NC
- 4:05 *Understanding sigma receptor ligand interactions*
Christopher McCurdy, University of Mississippi School of Pharmacy, University, MS
- 4:30 *A structural model of salvinorin A recognition at the kappa opioid receptor*
David M. Ferguson, University of Minnesota, Minneapolis, MN
- 4:55 *Discussant*
F. Ivy Carroll, Research Triangle Institute, Research Triangle Park, NC

BADGES MUST BE WORN IN ALL SCIENTIFIC SESSIONS

Oral Communications 1

**Rose Ballroom A
3:15 - 5:15 PM**

A FULL HOUSE OF NOVEL TREATMENTS

Chairs: Susan C. Sonne and Kevin Gray

- 3:15 *Extended-release naltrexone for treatment of alcohol dependence in primary care*
J. D. Lee, E. Grossman, D. DiRocco, J. Rotrosen, D. Stevens, M. Gourevitch, Medicine, NYU School of Medicine, New York, NY
- 3:30 *The use of acamprosate vs placebo in alcoholics with comorbid anxiety or depression*
S. C. Sonne¹, J. S. Potter², R. N. Rosenthal³, C. Tyson¹, ¹Medical University of South Carolina, Charleston, SC, ²McLean Hospital, Belmont, MA, ³Columbia University, New York, NY
- 3:45 *A randomized placebo-controlled trial of sertraline and sertraline plus gabapentin in depressed, recently abstinent cocaine-dependent patients*
M. J. Mancino, Z. Feldman, M. Chopra, C. S. Cargile, A. Oliveto, Psychiatry, University of Arkansas for Medical Sciences, Little Rock, AR
- 4:00 *Atomoxetine in marijuana-dependent adults with ADHD*
A. McRae-Clark¹, R. E. Carter², T. K. Killeen¹, M. J. Carpenter¹, K. T. Brady¹, ¹Psychiatry, Medical University of South Carolina, Charleston, SC, ²Biometry, Medical University of South Carolina, Charleston, SC
- 4:15 *Bupropion SR and contingency management in adolescent smokers: Main findings*
K. M. Gray¹, M. J. Carpenter¹, N. L. Baker¹, E. M. Klintworth¹, A. S. Leinbach¹, H. P. Upadhyaya^{1,2}, ¹Medical University of South Carolina, Charleston, SC, ²Eli Lilly and Company, Indianapolis, IN
- 4:30 *Dextroamphetamine as a treatment for methamphetamine dependence*
G. P. Galloway, L. Fiske, J. D. Siegrist, M. J. Baggott, K. Flower, R. Buscemi, D. Polcin, J. Mendelson, Addiction Pharmacology, California Pacific Medical Center Research Institute, San Francisco, CA
- 4:45 *Long-acting vs. oral naltrexone for preventing heroin addiction relapse*
E. Krupitsky¹, E. Zvartau¹, E. Verbitskaya¹, V. Egorova¹, D. Masalov¹, M. Tsoi¹, A. Burakov¹, N. Bushara¹, T. Romanova¹, T. Slavina¹, A. Tyurina¹, V. Palatkin¹, G. E. Woody², ¹Addictions, Pavlov State Medical University, St. Petersburg, Russia, ²Psychiatry, University of Pennsylvania, Philadelphia, PA

Oral Communications 2

**Rose Ballroom B
3:15 - 5:15 PM**

AGING AND DEATH: THE DECK IS STACKED

Chairs: Stefan Kertesz and Howard Chilcoat

- 3:15 *Prescription drug use among baby boomers: Insights from clinician interviews*
C. L. Striley, K. S. Leung, V. Satyanarayana, A. Ben Abdallah, L. B. Cottler, Psychiatry, Washington University School of Medicine, St. Louis, MO
- 3:30 *Trajectories of illicit drug use among adults in the general population (the CARDIA study)*
S. Kertesz^{1,2}, M. Pletcher³, B. Jones⁴, J. Tucker², Y. Khodneva², ¹Birmingham VAMC, Birmingham, AL, ²University of Alabama, Birmingham, AL, ³University of California, San Francisco, CA, ⁴Carnegie-Mellon University, Pittsburgh, PA

- 3:45 *Testing pathways between alcohol and opioid dependence*
H. Chilcoat^{1,3}, N. Dasgupta^{2,1}, S. S. Martins³, ¹Worldwide Epidemiology, GlaxoSmithKline, Research Triangle Park, NC, ²Epidemiology, University of North Carolina, Chapel Hill, NC, ³Mental Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD
- 4:00 *Late injection drug use initiators: Epidemiological trends and risk factors*
A. Kral^{1,2}, L. Wenger¹, L. Carpenter¹, P. Bourgois³, M. Iguchi^{5,4}, R. Bluthenthal^{4,6}, ¹RTI International, San Francisco, CA, ²University of California, San Francisco, CA, ³University of Pennsylvania, Philadelphia, PA, ⁴RAND, Santa Monica, CA, ⁵University of California, Los Angeles, CA, ⁶California State University, Dominguez Hills, Los Angeles, CA
- 4:15 *Persistence of cocaine use once it starts: Initial findings from epidemiological research*
E. Meyer, J. Anthony, Epidemiology, Michigan State University, East Lansing, MI
- 4:30 *Age effects on heroin and prescription opioid abuse among enrollees into methadone maintenance treatment*
C. Cleland¹, A. Rosenblum¹, C. Fong¹, M. Parrino², S. Magura^{3,1}, ¹National Development and Research Institutes, Inc., New York, NY, ²American Association for the Treatment of Opioid Dependence, New York, NY, ³Western Michigan University, Kalamazoo, MI
- 4:45 *Medical examiner methadone-related drug deaths: Single vs polydrug abuse*
M. J. Wunsch¹, P. A. Nuzzo¹, G. Behonick², S. L. Walsh¹, ¹Behavioral Sciences, Center on Drug and Alcohol Research, University of Kentucky, Lexington, KY, ²Forensic Toxicology, University of Massachusetts, Worcester, MA
- 5:00 *Age and its relationship with cause of death among opiate users*
T. Clausen¹, H. Waal¹, M. Gossop^{2,1}, ¹Norwegian Centre for Addiction Research, University of Oslo, Oslo, Norway, ²National Addiction Centre, Maudsley Hospital/Institute of Psychiatry, Kings College, London, United Kingdom

Primm-Singleton Travel Awardees Meeting

**Genoa
6:30 - 8:00 PM**

ASPET MIXER

**Poolside Terrace
6:30 - 8:00 PM**

**AMERICAN SOCIETY FOR PHARMACOLOGY AND
EXPERIMENTAL THERAPEUTICS (ASPET)**

Workshop I

Ponderosa B
8:00 - 10:00 PM

INTERVENTIONS FOR PARENTS WITH SUBSTANCE USE DISORDERS: NEW FINDINGS FROM CLINICAL RESEARCH

Chair: Nancy Suchman

Fathers too! A parent-intervention for drug-abusing men

Thomas McMahon, Yale Child Study Center, Yale University School of Medicine, West Haven, CT

Project SUPPORT: A parenting intervention for mothers in drug treatment

Mary-Louise Kerwin, Rowan University and Treatment Research Institute, Glassboro, NJ

Learning sobriety together for substance-abusing women: Effects on children's adjustment

Michelle Kelley, Old Dominion University, Norfolk, VA

Attachment-based program for substance-using mothers of infants and toddlers: Treatment approach, outcomes and integrity in a randomized clinical trial

Nancy Suchman, Yale University School of Medicine, West Haven, CT

Discussant

Karol Kaltenbach, Jefferson Medical College, Thomas Jefferson University, Philadelphia, PA

Workshop II

Bonanza
8:00 - 10:00 PM

FIT TO BE TIED: ABUSE POTENTIAL OF ANTIEPILEPTICS?

Chairs: Edward M. Sellers and Jack Henningfield

Evidence for abuse of anti-epileptics

Edward M. Sellers, Kendle Early Phase (Toronto), Toronto, ON, Canada

Medical need and "euphoria-related" adverse events of anti-epileptics

Deborah Leiderman, CNS Drug Consulting LLC, McLean, VA

Selecting the best measures of abuse liability in human abuse liability studies: Application to anti-epileptics

Kerri A. Schoedel, Kendle Early Phase (Toronto), Toronto, ON, Canada

The puzzling case of levetiracetam

Douglas Feltner, Pfizer Global Research and Development, Novi, MI

Case study: Lacosamide

Pamela Doty, Schwarz Biosciences, Inc., Research Triangle Park, NC

Workshop III

**Rose Ballroom A
8:00 - 10:00 PM**

WHAT'S NEW AT NIDA AND NIH: A PEEK INTO THE BLACK BOX

Chair: Gerald McLaughlin

Workshop IV

**Rose Ballroom B
8:00 - 10:00 PM**

**LEADERSHIP IN THE MAKING: IMPACT AND INSIGHTS FROM
LEADERSHIP DEVELOPMENT PROGRAMS FOR LEADERS OF
ADDICTION SERVICES**

Chairs: Anne-Helene Skinstad and Pamela Waters

Leadership training: A foundation for the development of a network of African-American addiction service leaders

Paula Horvatic, Virginia Commonwealth University, Richmond, VA

A retrospective study of the impact of the Southern Coast ATTC's leadership development program

Pamela Waters, Southern Coast ATTC, Tallahassee, FL

The change leader academy: Developing change leaders for NIATx

Eldon Edmundson, Oregon Health and Science University, Portland, OR

The change leader academy: Developing change leaders for NIATx

Dennis McCarty, Oregon Health and Science University, Portland, OR

Leadership development for women and men. Any different?

Anne-Helene Skinstad, The University of Iowa, Iowa City, IA

Leaders and tradition: Native American mentors' experience in the Mountain West ATTC leadership institute: Implications for developing culturally competent leaders in the substance abuse treatment workforce

Nancy Roget, University of Nevada, Reno, Reno, NV

Symposium III

Ponderosa B
8:45 - 9:45 AM

UNCONTROLLED INTERSECTION: PROBLEM GAMBLING AND DRUG ABUSE

Chairs: Ken Winters and Linda B. Cottler

- 8:45 *Overview of the association of drug abuse and pathological gambling*
Ken Winters, University of Minnesota-Fairview, Minneapolis, MN
- 9:05 *Is level of gambling related to reductions in crack cocaine use among community-recruited female drug users?*
Linda B. Cottler, Washington University, St. Louis, MO
- 9:25 *The Alberta leisure, lifestyle, lifecycle cohort: The first waves*
Nady El-guebay, Foothills Addiction Center, University of Calgary, Calgary, AB, Canada

Symposium IV

Bonanza
8:45 - 9:45 AM

DRUG WITHDRAWAL, REINFORCING EFFECTS, AND VULNERABILITY TO RELAPSE: NEW METHODS AND INSIGHTS

Chair: Lance McMahon

- 8:45 *Withdrawal-associated increases in the relative reinforcing effects of heroin*
S. Stevens Negus, Pharmacology and Toxicology, Virginia Commonwealth University, Richmond, VA
- 9:05 *Role of withdrawal in relapse to marijuana use*
Margaret Haney, New York State Psychiatric Institute, College of Physicians and Surgeons of Columbia University, New York, NY
- 9:25 *New methods and insights: Characterizing tobacco withdrawal and relapse vulnerability*
David Gilbert, Psychology, Southern Illinois University Carbondale, Carbondale, IL

Oral Communications 3

Rose Ballroom A
8:45 - 9:45 AM

PREDICTION OF ADDICTION

Chairs: Theodore Cicero and William W. Stoops

- 8:45 *Geographic and contextual factors of prescription opioid abuse: Results from ASI-MV® Connect*
T. C. Green¹, J. S. Brownstein², S. F. Butler², ¹Yale School of Public Health, Medford, MA, ²Inflexxion, Inc., Newton, MA
- 9:00 *Secondhand exposure to smoked opium*
M. S. Gold¹, D. M. Martin², N. A. Graham³, B. A. Goldberger⁴, ¹Psychiatry, University of Florida College of Medicine, Gainesville, FL, ²Drug Detection Solutions, LLC, Lansdale, PA, ³Psychiatry, University of Florida College of Medicine, Gainesville, FL, ⁴Pathology, Immunology and Laboratory Medicine, University of Florida College of Medicine, Gainesville, FL
- 9:15 *Abuse Deterrent Adjusted Measurement Model: ADAMM™*
R. A. Black, S. H. Budman, T. A. Cassidy, S. F. Butler, Inflexxion, Inc., Newton, MA

9:30 *Relative abuse potential of intravenous oxycodone, hydrocodone and morphine in non-dependent opioid abusers*

W. W. Stoops^{1,2}, K. W. Hatton³, M. R. Lofwall^{1,2,4}, P. A. Nuzzo¹, S. L. Walsh^{1,2,4}, ¹Behavioral Science, University of Kentucky, Lexington, KY, ²Center for Drug and Alcohol Research, University of Kentucky, Lexington, KY, ³Anesthesiology, University of Kentucky, Lexington, KY, ⁴Psychiatry, University of Kentucky, Lexington, KY

Oral Communications 4

**Rose Ballroom B
8:45 - 9:45 AM**

PROGRAMS AND POLICIES

Chairs: Steven Ondersma and Dennis McCarty

8:45 *Evidence-based practices in substance abuse treatment: Staff familiarity, opinions, and training*
J. May¹, A. Breland¹, D. Farrell-Moore¹, F. Taxman³, J. R. Koch², D. Svikis², ¹Richmond Behavioral Health Authority, Richmond, VA, ²Virginia Commonwealth University, Richmond, VA, ³George Mason University, Fairfax, VA

9:00 *Using coaches to develop EBP skills for providers treating patients with co-occurring mental health and substance use disorders*
S. Larkins, T. E. Freese, S. Cousins, R. Rawson, Integrated Substance Abuse Programs, University of California, Los Angeles, Los Angeles, CA

9:15 *Educating addiction providers to use the NIATx Process Improvement Model to enhance client services*
A. Pulvermacher¹, T. Zastowny², E. Edmundson³, L. Madden^{4,5}, J. H. Ford¹, D. H. Gustafson¹, D. McCarty³, ¹University of Wisconsin - Madison, Madison, WI, ²University of Rochester, Rochester, NY, ³Oregon Health and Science University, Portland, OR, ⁴APT Foundation, New Haven, CT, ⁵Yale University, New Haven, CT

9:30 *Implementation of medication-assisted treatment in Maine and Missouri: The Advancing Recovery program*
D. McCarty¹, D. Brucker², M. Hile³, T. Morris⁴, L. Frazier², A. Abraham⁵, T. Molfenter⁷, L. Schmidt⁶, P. Roman⁵, ¹Oregon Health and Science University, Portland, OR, ²Maine Office of Substance Abuse, Augusta, ME, ³Missouri Institute of Mental Health, St Louis, MO, ⁴Division of Alcohol and Drug Abuse, Missouri Dept of Mental Health, Springfield, MO, ⁵Institute for Behavioral Research, University of Georgia, Athens, GA, ⁶Institute for Health Policy Studies, University of California, San Francisco, CA, ⁷NIATx, University of Wisconsin, Madison, WI

Symposium V

**Ponderosa B
10:00 AM - 12:00 PM**

SPECIAL SYMPOSIUM HONORING THE MEMORY OF BILLY MARTIN, PHD

HOT TOPICS IN CANNABINOID RESEARCH: FROM CHEMISTRY TO THE CLINIC

Chair: Mary Abood

10:00 *Introduction*
Louis Harris, Virginia Commonwealth University, Richmond, VA

10:20 *Pieces of a cannabinoid puzzle: CB1-selective agonists with antagonist structures*
Jenny Wiley, Virginia Commonwealth University, Richmond, VA

- 10:40 *Ligand-assisted protein structure: Studies on the endocannabinoid proteins*
Alexandros Makriyannis, Northeastern University, Boston, MA
- 11:00 *The enzymatic regulation of endocannabinoid signaling*
Benjamin Cravatt, The Scripps Research Institute, La Jolla, CA
- 11:20 *Treating addictive disorders by modulation of endogenous systems*
Charles O'Brien, Center for Studies of Addiction, University of Pennsylvania, Philadelphia, PA
- 11:40 *Discussants*
Mary Abood¹, Louis Harris², ¹Temple University School of Medicine, Philadelphia, PA,
²Virginia Commonwealth University, Richmond, VA

Oral Communications 5

Rose Ballroom B
10:00 AM - 12:00 PM

RISKY BUSINESS: HIV/AIDS AND BEHAVIOR

Chairs: Christian Hopper and Stuart King

- 10:00 *HIV transmission risk behaviors among opioid-dependent HIV-infected individuals entering integrated buprenorphine and HIV care*
A. A. Chaudhry¹, M. Botsko³, L. Weiss³, J. Egan³, J. Mitty⁵, B. Estrada⁴, G. Lucas¹,
T. Woodson¹, T. Flanigan⁵, D. Fiellin², ¹Medicine, Johns Hopkins University, Baltimore, MD,
²Medicine, Yale University, New Haven, CT, ³New York Academy of Medicine, New York, NY,
⁴Impact Consultants, Tucson, AZ, ⁵Medicine, Brown University, Providence, RI
- 10:15 *Development of injection HIV risk behaviors in adolescents followed into young adulthood*
C. Hopper¹, H. Gelhorn¹, T. Crowley¹, M. Stallings², S. Young², J. Hewitt², ¹University of Colorado, Aurora, CO, ²Institute for Behavior Genetics, University of Colorado Boulder, Boulder, CO
- 10:30 *Relationship influence and HIV risk behavior among re-entering women offenders*
M. Staton-Tindall¹, L. Frisman², H. Lin², C. Leukefeld¹, C. Oser¹, J. Havens¹, M. Prendergast³,
H. Surratt⁴, J. Clarke⁵, ¹University of Kentucky, Lexington, KY, ²Connecticut Department of Mental Hospital and Addiction Services, Hartford, CT, ³University of California, Los Angeles, CA, ⁴University of Delaware, Wilmington, DE, ⁵Brown University, Providence, RI
- 10:45 *The impact of gender and other baseline characteristics on AIDS risk perception ratings*
S. King¹, B. Brown^{2,1}, R. Schwartz¹, K. O'Grady³, E. C. Katz^{4,1}, ¹Friends Research Inst., Baltimore, MD, ²Univ. of North Carolina, Wilmington, NC, ³Univ. of Maryland, College Park, MD, ⁴Psychology, Towson University, Towson, MD
- 11:00 *Gender differences in HIV risk behaviors among drug abusers*
A. Brooks¹, C. Meade², J. Potter², Y. Lokhnygina³, D. Calsyn⁴, S. Greenfield³, ¹University of Arizona, Tucson, AZ, ²McLean Hospital, Belmont, MA, ³Duke University, Durham, NC, ⁴University of Washington, Seattle, WA
- 11:15 *Interventions to reduce HIV risk and drug use among heterosexual methamphetamine users: Preliminary results from a pilot study*
K. F. Corsi¹, W. K. Lehman¹, R. E. Booth¹, S. Shoptaw², ¹Psychiatry, University of Colorado Denver, Denver, CO, ²Family Medicine and Psychiatry, David Geffen School of Medicine at University of California, Los Angeles, CA
- 11:30 *Predictors of alcohol- and/or drug-related consensual and unwanted sexual encounters*
D. Tzall, E. C. Katz, Psychology, Towson University, Towson, MD

- 11:45 *Contingency management reduces substance use and increases healthy behaviors among homeless, out-of-treatment MSM*
C. J. Reback^{1,2}, J. A. Peck^{1,2}, R. Dierst-Davies¹, M. Nuño³, J. B. Kamien¹, L. Amass¹, ¹Friends Research Institute, Los Angeles, CA, ²Integrated Substance Abuse Programs, University of California, Los Angeles, CA, ³Neurosurgery, Cedars-Sinai Medical Center, Los Angeles, CA

Oral Communications 6

Bonanza

10:00 AM - 12:00 PM

SPINNING THE WHEELS OF CRIMINAL JUSTICE

Chairs: Carl G. Leukefeld and Jennifer R. Havens

- 10:00 *Criminalization of addiction and mental illness: Do not pass go, go directly to jail*
R. Crecelius^{1,2}, A. Ben Abdallah¹, C. W. Striley¹, C. O'Leary¹, L. B. Cottler¹, ¹Epidemiology and Prevention Research Group, Washington University School of Medicine, St. Louis, MO, ²Division of Corrections, City of St. Louis, St. Louis, MO
- 10:15 *Substance use, posttraumatic stress disorder and violent crime*
E. L. Barrett, K. Mills, M. Teesson, National Drug and Alcohol Research Centre (NDARC), University of New South Wales, Sydney, NSW, Australia
- 10:30 *Evaluation of criminal justice diversion: California's Proposition 36*
D. Urada, E. Evans, J. Yang, J. Fan, B. Conner, M. D. Anglin, R. Rawson, B. Rutkowski, J. Hunter, A. Hawken, C. Teruya, R. Gonzales, M. Campos, M. L. Brecht, Integrated Substance Abuse Programs, University of California, Los Angeles, CA
- 10:45 *A randomized controlled trial on naltrexone implants and methadone maintenance among heroin-dependent inmates: Results 6 months after prison release*
P. P. Lobmaier^{1,2}, N. Kunøe², M. Gossop³, H. Waal², ¹Addiction Medicine, Aker University Hospital Trust, Oslo, Norway, ²Norwegian Centre for Addiction Research, University of Oslo, Oslo, Norway, ³National Addiction Centre, Institute of Psychiatry, King's College, London, United Kingdom
- 11:00 *Modified TC for persons with co-occurring disorders: Meta-analysis*
S. Sacks, K. McKendrick, Center for the Integration of Research and Practice, National Development and Research Institutes, Inc, New York, NY
- 11:15 *Factors associated with hepatitis C seropositivity among incarcerated women re-entering the community*
J. R. Havens¹, M. Tindall¹, C. Oser¹, J. Mooney¹, H. Knudsen¹, J. Duvall¹, J. Inciardi², H. Surratt², J. Clarke³, L. Frisman⁴, C. Leukefeld¹, ¹CDAR, University of Kentucky, Lexington, KY, ²University of Delaware, Newark, DE, ³Brown University, Providence, RI, ⁴University of Connecticut, Hartford, CT
- 11:30 *Thirty-day outcomes: A randomized trial of women's relationships and HIV*
C. Leukefeld¹, J. Havens¹, C. Oser¹, M. Tindall¹, H. Knudsen¹, H. Palmer¹, H. Surratt², J. Clarke³, L. Frisman⁴, ¹University of Kentucky, Lexington, KY, ²University of Delaware, Coral Gables, FL, ³Brown University, Providence, RI, ⁴University of Connecticut, Hartford, CT
- 11:45 *The impact of parole officer-offender relationships on recidivism and substance use: Results from a randomized trial*
A. G. Rhodes¹, F. S. Taxman¹, P. D. Friedmann², ¹Administration of Justice, George Mason University, Manassas, VA, ²Alpert Medical School, Brown University, Providence, RI

Oral Communications 7**Rose Ballroom A
10:00 AM - 12:00 PM****A ROYAL FLUSH OF PRESCRIPTION OPIOID EPIDEMIOLOGY**

Chairs: Stephen F. Butler and Kathryn A. Saulsgiver

- 10:00 *Relative rates of prescription opioid abuse: Comparison of public health databases*
S. F. Butler, J. S. Brownstein, Inflexxion, Inc, Newton, MA
- 10:15 *The risk of developing a dependence syndrome in recent onset users of analgesic compounds*
O. A. Adelaja¹, N. S. Miller², J. C. Anthony¹, ¹Epidemiology, Michigan State University, East Lansing, MI, ²Medicine, Michigan State University, East Lansing, MI
- 10:30 *Prevalence of pain among prescription-opioid abusers*
K. A. Saulsgiver, K. Dunn, S. Sigmon, S. Higgins, Psychiatry, University of Vermont, Burlington, VT
- 10:45 *Partying on Rx: Changes in prescription drug use and mental distress in a natural history study of club drug users*
S. P. Kurtz, D. J. O'Connell, H. L. Surratt, J. A. Inciardi, J. C. Weaver, N. W. Bakken, Center for Drug and Alcohol Studies, University of Delaware, Coral Gables, FL
- 11:00 *Prescription opioid use among convicted drinking drivers*
B. Brands^{1,2,3}, R. F. Zalcman², R. E. Mann^{2,3}, G. Stoduto², R. K. Thomas², ¹Office of Research and Surveillance, Health Canada, Ottawa, ON, Canada, ²Centre for Addiction and Mental Health, Toronto, ON, Canada, ³University of Toronto, Toronto, ON, Canada
- 11:15 *Gender differences in prescription opioid dependence: A pilot study*
S. E. Back, K. T. Brady, Z. B. Stroud, Psychiatry, Medical University of South Carolina, Charleston, SC
- 11:30 *Motives for non-medical prescription opioid use among RADARS® System College Survey respondents—indication of a substance abuse disorder?*
A. Montoya¹, L. M. Zolot¹, J. E. Bailey¹, R. C. Dart^{1,2}, ¹Rocky Mountain Poison and Drug Center, Denver Health, Denver, CO, ²University of Colorado, School of Medicine, Aurora, CO
- 11:45 *Randomized, double-blind trial evaluating buprenorphine taper for prescription opioid abuse*
S. C. Sigmon^{1,2}, K. Dunn², K. Saulsgiver¹, S. Heil^{1,2}, S. Higgins^{1,2}, ¹Psychiatry, University of Vermont, Burlington, VT, ²Psychology, University of Vermont, Burlington, VT

POSTER SESSION I (Lunch)**Pavilion
12:00 - 2:00 PM****Odd-numbered posters manned first hour;
Even-numbered, second hour****Set-up time begins Sunday no earlier than 12:00 PM
Must be removed by Monday no later than 2:30 PM****ADOLESCENCE**

- 1 *Waking at night to smoke in adolescent and adult smokers*
M. E. Mooney, A. J. Oliver, D. K. Hatsukami, Psychiatry, University of Minnesota, Minneapolis, MN
- 2 *Sustained attention is related to treatment outcomes for adolescent cigarette smokers*
C. Collins, K. Leraas, S. Fields, S. Imhoff, B. Reynolds, Nationwide Childrens Hospital, Columbus, OH

- 3 *Characteristics of adolescent marijuana smokers: Endorsing the need, and willing to participate in a MJ quit program*
A. Sheer¹, C. Collins¹, D. Gorelick¹, J. Schroeder¹, E. Moolchan², ¹NIDA/NIH, Baltimore, MD, ²Alkermes, Inc., Cambridge, MA
- 4 *Delivering prevention for alcohol and cannabis over the Internet*
N. C. Newton¹, M. Teesson¹, G. Andrews², L. E. Vogl¹, ¹National Drug and Alcohol Research Centre, University of New South Wales, Sydney, NSW, Australia, ²Clinical Research Unit for Anxiety and Depression, University of New South Wales, Sydney, NSW, Australia
- 5 *Disinhibition and reward sensitivity in relation to alcohol consumption by university undergraduates*
M. Lyvers, C. Czerczyk, A. Follent, P. Lodge, H. Duff, Psychology, Bond University, Gold Coast, QLD, Australia
- 6 *Crack cocaine use among Montreal street youth*
C. Paquette¹, É. Roy^{1,2}, G. Petit^{1,3}, ¹Toxicomanie, Université de Sherbrooke, Longueuil, QC, Canada, ²Direction de santé publique de Montréal, Montréal, QC, Canada, ³Direction de santé publique et de l'évaluation de l'Estrie, Sherbrooke, QC, Canada
- 7 *Predictors of alcohol initiation among Hispanic adolescents in Puerto Rico*
T. D. Matos¹, R. R. Robles¹, J. C. Reyes-Pulliza^{2,1}, J. L. Negron-Ayala¹, J. M. Calderon¹, M. A. Cruz¹, ¹IRESA, Universidad Central del Caribe, Bayamon, PR, ²Epidemiology, School of Public Health, San Juan, PR
- 8 *Youth drug abuse treatment and prevention needs in Jalisco, Mexico*
O. Campollo^{1,3}, P. Sheikhattari², C. Alvarez-González¹, J. Toro¹, H. Sánchez³, F. A. Wagner², ¹Center of Studies on Alcohol and Addictions, University of Guadalajara, Guadalajara, Mexico, ²Center for Health Disparities Solutions, Morgan State University, Baltimore, MD, ³Clínica para Dejar de Fumar, Antiguo Hospital Civil de Guadalajara, Guadalajara, Mexico
- 9 *Associated factors of non-use of drugs among children and youth in street circumstances in Brazil*
Y. G. Moura, E. Opaleye, Z. Sanchez, C. Carlini, A. Noto, Psychobiology, UNIFESP, São Paulo, Brazil
- 10 *Recreational use of benzydamine: A national cross-sectional survey among children and youth in street circumstances in Brazil*
E. S. Opaleye, Z. Sanchez, Y. Moura, A. Noto, Psychobiology, UNIFESP, Sao Paulo, Brazil
- 11 *Incidence of drug use among school adolescents in Bogotá, Colombia*
C. Lopez-Quintero, Y. Neumark, School of Public Health, Hebrew University of Jerusalem, Jerusalem, Israel
- 12 *Inhalant drug use among Israeli youth*
Y. Neumark¹, R. Bar-Hamburger², ¹School of Public Health, Hebrew University of Jerusalem, Jerusalem, Israel, ²Anti-Drug Authority of Israel, Jerusalem, Israel
- 13 *Drug market activity influence on adolescent school conduct*
R. J. Evans, L. J. Floyd, E. Hill, W. Latimer, Mental Health, Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD
- 14 *Neighborhood disadvantage and substance use among adolescents*
S. Salomonsen-Sautel¹, S. K. Mikulich-Gilbertson¹, P. D. Riggs¹, C. Thurstone², ¹University of Colorado Denver, Aurora, CO, ²Denver Health, Denver, CO

- 15 *Troubled parents, motivated adolescents: Predicting motivation to change substance use among runaways*
N. Slesnick, S. Bartle-Haring, H. Budde, A. Letcher, D. Bantchevska, R. Garren, Human Development and Family Science, The Ohio State University, Columbus, OH
- 16 *Outreach family intervention for young out-of-treatment drug users*
R. Santis¹, C. G. Hidalgo², A. Jaramillo², V. Hayden¹, A. Lasagna², E. Anselmo¹, M. T. Espinoza¹, T. Rodriguez¹, D. de la Paz¹, J. Salas¹, C. Quiroga¹, P. González¹, P. P. Farías¹,
¹Psychiatry, Pontificia Universidad Católica de Chile, Santiago, Chile, ²School of Psychology, Pontificia Universidad Católica de Chile, Santiago, Chile
- 17 *How does religiosity prevent substance use among adolescents?*
Z. V. Sanchez, E. Opaleye, Y. Moura, T. Chaves, A. Noto, S. Nappo, Psychobiology, UNIFESP, Sao Paulo, Brazil
- 18 *Findings from a randomized clinical trial examining Assertive Continuing Care with two types of outpatient treatment for adolescents*
S. H. Godley, L. Passetti, R. Funk, M. Godley, B. Garner, B. Hunter, Chestnut Health Systems, Normal, IL
- 19 *Results from a one-session HIV risk reduction intervention in adolescents with substance use disorder*
C. Thurstone¹, P. D. Riggs², S. K. Mikulich-Gilbertson², S. Salomonse-Sautel², C. Klein²,
¹Denver Health and Hospital Authority, Denver, CO, ²University of Colorado Denver, Aurora, CO

FOOD AND OBESITY

- 20 *Neuroimaging of brain activation in response to food cues in obese children*
E. Charboneau^{1,2}, A. Bauernfeind¹, E. Castellanos¹, M. S. Dietrich³, G. Plemmons⁴, S. Park⁵, P. R. Martin^{1,2}, R. L. Cowan^{1,2}, ¹Psychiatric Neuroimaging Program, Vanderbilt School of Medicine, Nashville, TN, ²Vanderbilt Addiction Center, Vanderbilt School of Medicine, Nashville, TN, ³Biostatistics, Vanderbilt University, Nashville, TN, ⁴Childhood Weight Management Clinic, Vanderbilt Children's Hospital, Nashville, TN, ⁵Psychology, Vanderbilt University, Nashville, TN
- 21 *Addiction to food: The relationship between delay discounting, obesity, and the binge eating scale*
B. A. Jones, W. Bickel, R. Yi, R. Landes, D. West, Psychiatry, UAMS, Little Rock, AR
- 22 *Validation of a questionnaire for sugar addiction*
M. C. Rosa^{2,1}, C. M. Gomes⁴, S. B. Slavutzky³, F. H. Kessler¹, E. F. Ferreira², F. Pechansky¹,
¹Psychiatry, Federal University of Rio Grande do Sul, Porto Alegre, Brazil, ²Social and Preventive Dentistry, Federal University of Minas Gerais, Belo Horizonte, Brazil, ³Social and Preventive Dentistry, Federal University of Rio Grande do Sul, Porto Alegre, Brazil, ⁴Psychology, Federal University of Minas Gerais, Belo Horizonte, Brazil
- 23 *Are injection-related risk behaviors and food insecurity associated?*
C. Strike^{1,4}, A. Sarnocinska Hart¹, S. Anstice⁵, C. Wender², B. Lester³, N. Scrivo³, J. Luce¹, M. Millson⁴, ¹Health Systems Research and Consulting, Centre for Addiction and Mental Health, Toronto, ON, Canada, ²My Sisters' Place, London, ON, Canada, ³AIDS Committee of London, London, ON, Canada, ⁴Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada, ⁵School of Social Work, University of Toronto, Toronto, ON, Canada

- 24 *The use of appetite suppressant among health sciences undergraduate students in Southern Brazil*
C. Zubaran¹, I. Tres², E. C. de Toni², R. Pereira², K. N. Persch², K. Foresti², ¹School of Medicine, University of Western Sydney, Sydney, NSW, Australia, ²University of Caxias do Sul, Caxias do Sul, Brazil
- 25 *Lack of abuse potential of tesofensine in recreational stimulant users*
E. Sellers¹, D. Meier², B. Chakraborty¹, P. Manniche², K. A. Schoedel¹, ¹Clinical Pharmacology, Kendle Early Phase, Toronto, ON, Canada, ²NeuroSearch A/S, Ballerup, Denmark
- 26 *Addiction to food: Potential use of 18-methoxycoronaridine to treat obesity*
O. Taraschenko, I. Maisonneuve, S. Glick, Albany Medical College, Albany, NY
- 27 *Sugar dependence in low- vs. high-saccharin-consuming rats*
V. Yakovenko, C. D. Chapman, N. K. Dess, Occidental College, Los Angeles, CA
- 28 *Food restriction differentially modifies the behavioral effects of the dopamine receptor agonist quinpirole in rats*
M. Baladi, C. P. France, Pharmacology, University of Texas Health Science Center, San Antonio, TX

METHYLPHENIDATE

- 29 *Role of the dopamine receptor subtypes in the expression of the discriminative stimulus effect induced by U-50,488H or methamphetamine*
K. Yoshizawa^{1,2}, M. Miyatake¹, T. Mori¹, K. Fukuda², N. Kuzumaki¹, M. Narita¹, T. Suzuki¹, ¹Toxicology, Hoshi University School of Pharmacy and Pharmaceutical Science, Tokyo, Japan, ²Pharmaceutical Service, Chiba-Hokusoh Hospital Nippon Medical School, Chiba, Japan
- 30 *Distinct mechanism of methamphetamine- and methylphenidate-induced dopamine-related neurotoxicity*
T. Suzuki, D. Ikegami, M. Asato, M. Narita, M. Saeki, N. Kuzumaki, M. Narita, Toxicology, Hoshi University School of Pharmacy and Pharmaceutical Science, Tokyo, Japan
- 31 *Early methylphenidate exposure enhances cocaine self-administration but not cocaine-induced conditioned place preference in young adult rats*
S. A. Baella, C. M. Farley, M. S. Herbert, L. R. Horn, R. H. Campbell, C. A. Crawford, Psychology, California State University, San Bernardino, San Bernardino, CA
- 32 *Effects of oral vs. intraperitoneal methylphenidate on locomotor activity and conditioned place preference in rats*
T. E. Wooters, M. Walton, M. T. Bardo, Psychology, University of Kentucky, Lexington, KY

CLUB DRUGS

- 33 *The acute subjective effects of combined benzylpiperazine and trifluoromethylphenylpiperazine on healthy males*
B. R. Russell¹, H. Lee¹, R. Wan¹, W. Koak¹, K. Kim¹, S. Govan¹, R. R. Kydd², ¹School of Pharmacy, The University of Auckland, Auckland, New Zealand, ²Psychological Medicine, The University of Auckland, Auckland, New Zealand
- 34 *The acute effects of combined benzylpiperazine and trifluoromethylphenylpiperazine on human P300 event-related potentials*
H. Lee¹, R. R. Kydd², B. R. Russell¹, ¹School of Pharmacy, The University of Auckland, Auckland, New Zealand, ²Psychological Medicine, The University of Auckland, Auckland, New Zealand

- 35 *Acute effects of benzylpiperazine on cognition and executive functioning using functional magnetic resonance imaging using the Stroop paradigm-results from the pilot study*
L. E. Curley¹, N. McNair¹, R. R. Kydd², I. J. Kirk³, B. R. Russell¹, ¹School of Pharmacy, The University of Auckland, Auckland, New Zealand, ²Psychological Medicine, The University of Auckland, Auckland, New Zealand, ³Psychology, The University of Auckland, Auckland, New Zealand
- 36 *Is moderate substance use associated with altered executive functioning in a population-based sample of young adults?*
C. G. Schütz¹, F. Indlekofer², M. Piechatzek², M. Daamen³, C. Glasmacher², R. Lieb⁴, H. Pfister⁴, O. Tucha⁵, K. W. Lange⁶, H. U. Wittchen^{7,4}, ¹Institute of Mental Health, University of British Columbia, Vancouver, BC, Canada, ²Psychiatry, Ludwig-Maximilians-University, Munich, Germany, ³Max-Planck-Institute for Psychiatry, Munich, Germany, ⁴Radiology, University of Bonn, Bonn, Germany, ⁵School of Psychology, University Plymouth, Plymouth, United Kingdom, ⁶Experimental Psychology, University of Regensburg, Regensburg, Germany, ⁷Psychiatry, University of Dresden, Dresden, Germany
- 37 *Effects of methamphetamine and MDMA on speech*
G. F. Marrone^{1,3}, J. S. Pardo^{2,3}, R. M. Krauss², C. L. Hart^{1,2}, ¹College of Physicians and Surgeons of Columbia University, NY State Psychiatric Institute, New York, NY, ²Columbia University, New York, NY, ³Barnard College, New York, NY
- 38 *Effects of 3,4-methylenedioxymethamphetamine on arginine vasopressin in healthy volunteers*
M. J. Baggott^{1,2}, J. Mendelson¹, K. J. Garrison¹, G. P. Galloway¹, ¹Addiction Pharmacology, California Pacific Medical Center Research Institute, San Francisco, CA, ²Hellen Wills Neuroscience Institute, University of California Berkeley, Berkeley, CA
- 39 *Thermoregulatory and behavioral effects of MDMA in Flinders Sensitive Line rats*
E. J. Jaehne, I. Majumder, A. Salem, R. J. Irvine, Discipline of Pharmacology, School of Medical Sciences, University of Adelaide, Adelaide, SA, Australia
- 40 *MDMA reduces serotonin transporter cell surface expression via a p38MAP-kinase-independent mechanism*
B. M. Kivell, P. Bosch, B. Lake, D. Day, S. Schenk, J. H. Miller, Victoria University of Wellington, Wellington, New Zealand

METHAMPHETAMINE/AMPHETAMINE - ANIMALS

- 41 *Repeated methamphetamine alters prefrontal cortex neurotransmission*
K. D. Lominac^{1,2}, K. K. Szumlinski^{1,2}, ¹Psychology, University of California, Santa Barbara, Santa Barbara, CA, ²Neuroscience Research Institute, University of California, Santa Barbara, Santa Barbara, CA
- 42 *Effects of (-)-trans-PAT, a novel 5-HT_{2C} agonist and 5-HT_{2A/2B} antagonist/inverse agonist, on amphetamine-induced locomotor activity in rats*
D. Morgan¹, J. P. DuPree¹, Z. Sun², R. G. Booth², ¹Psychiatry, University of Florida College of Medicine, Gainesville, FL, ²Medicinal Chemistry, University of Florida College of Pharmacy, Gainesville, FL
- 43 *Chronic antagonism of 5-HT_{2C} receptors enhance drug-seeking behavior in rats trained to self-administer methamphetamine*
S. M. Graves^{1,2}, T. C. Napier^{1,2}, ¹Pharmacology, Rush University Medical Center, Chicago, IL, ²Center for Compulsive Behavior and Addiction, Rush University Medical Center, Chicago, IL

- 44 *Lobeline potentiates the methamphetamine-induced decrease in extracellular DOPAC in the nucleus accumbens shell*
N. M. Neugebauer^{1,2}, M. T. Bardo², L. P. Dwoskin³, ¹Psychiatry, Yale University School of Medicine, New Haven, CT, ²Psychology, University of Kentucky, Lexington, KY, ³College of Pharmacy, University of Kentucky, Lexington, KY
- 45 *Identification of “agonist” and “antagonist” allosteric modulators of amphetamine-induced dopamine release*
R. B. Rothman¹, S. Ananthan², C. M. Dersch¹, J. S. Partilla¹, ¹Clinical Psychopharmacology Section, IRP, NIDA, NIH, Baltimore, MD, ²Organic Chemistry Department, Southern Research Institute, Birmingham, AL
- 46 *Behavioral-stimulant and neurochemical effects of monoamine releasers with varying selectivity for dopamine and serotonin in squirrel monkeys*
H. L. Kimmel^{1,2}, D. F. Manvich², M. Zhou², M. E. Pontell², B. E. Blough³, L. L. Howell^{1,2,4}, ¹Pharmacology, Emory University School of Medicine, Atlanta, GA, ²Yerkes National Primate Research Center, Emory University, Atlanta, GA, ³Center for Organic and Medicinal Chemistry, RTI International, Research Triangle Park, NC, ⁴Psychiatry and Behavioral Sciences, Emory University School of Medicine, Atlanta, GA
- 47 *Sigma antagonists, AC927 and CM156, protect against methamphetamine-induced serotonin depletion while attenuating hyperthermia*
M. J. Seminerio¹, N. Kaushal¹, J. Shaikh¹, M. Medina¹, A. Coop², C. McCurdy³, R. Matsumoto¹, ¹West Virginia University, Morgantown, WV, ²University of Maryland, Baltimore, MD, ³University of Mississippi, Oxford, MS
- 48 *Response to novelty predicts both responding for a visual stimulus and self-administration of a low dose of methamphetamine in rats*
A. M. Gancarz, M. A. San George, L. Ashrafioun, A. C. Thompson, J. B. Richards, Psychology and Research Institute on Addictions, University at Buffalo, Buffalo, NY
- 49 *Methamphetamine impairs sexually conditioned approach in male Japanese quail*
B. L. Bolin, C. K. Akins, Psychology, University of Kentucky, Lexington, KY
- 50 *Valproic acid attenuates acute amphetamine-induced locomotion in mice*
N. Enman, J. S. Miller, E. M. Unterwald, Pharmacology and Center for Substance Abuse Research, Temple University School of Medicine, Philadelphia, PA
- 51 *Reinstatement of amphetamine self-administration by MDMA and its isomers in rhesus monkeys*
J. C. McClung¹, L. L. Howell^{1,2}, ¹Yerkes National Primate Research Center, Emory University, Atlanta, GA, ²Psychiatry and Behavioral Sciences, Emory University School of Medicine, Atlanta, GA

OPIOIDS: ANIMALS

- 52 *Strain- and heroin-induced effects on endogenous opioid and GABA A receptor mRNA levels in the caudate putamen of C57BL/6J and 129P3/J mice*
S. D. Schlussman, O. Levran, Y. Zhang, A. Ho, M. J. Kreek, The Laboratory of the Biology of Addictive Diseases, The Rockefeller University, New York, NY
- 53 *Partial ablation of mu-opioid receptor-rich striosomes results in behavioral deficits on a motor skill learning task*
C. Lawhorn^{1,2}, D. M. Smith³, L. L. Brown^{2,3}, ¹Laboratory of the Biology of Addictive Diseases, Rockefeller University, New York, NY, ²Dominick P. Purpura Department of Neuroscience, Albert Einstein College of Medicine, Bronx, NY, ³Saul R. Korey Department of Neurology, Albert Einstein College of Medicine, Bronx, NY

- 54 *Suppression of dopamine-related side effects of morphine by atypical antipsychotic drugs including a dopamine system stabilizer*
K. Torigoe¹, M. Narita¹, D. Takei¹, M. Shiokawa^{1,2}, Y. Matsushima¹, S. Takagi¹, M. Narita¹, T. Suzuki¹, T. Amano^{1,3}, N. Kuzumaki¹, T. Suzuki¹, ¹Toxicology, Hoshi Univ. Sch. Pharm. Pharmaceut. Sci., Tokyo, Japan, ²Pharmacy, St. Luke's International Hospital, Tokyo, Japan, ³Molecular and Pharmacological Neuroscience, Division of Integrated Medical Science, Graduate School of Biomedical Sciences, Hiroshima University, Hiroshima, Japan
- 55 *Therapeutic implications of delta opioid receptor expression in the VTA of EtOH-drinking or morphine-injected Lewis rats*
J. M. Mitchell^{1,2}, H. L. Fields^{1,2}, A. R. Coker¹, J. R. Driscoll¹, E. B. Margolis¹, ¹Ernest Gallo Clinic and Research Center, Emeryville, CA, ²University of California, San Francisco, CA
- 56 *Intravenous self-administration of etonitazene alone and combined with cocaine in rhesus monkeys: Comparison with heroin and antagonism by naltrexone and naloxonazine*
C. Achat-Mendes, G. R. Valdez, D. M. Platt, J. K. Rowlett, R. D. Spealman, Harvard Medical School, Southborough, MA

GENETICS

- 57 *Ethnic diversity of OPRM1 gene promoter DNA methylation and its association with subjects in methadone treatment*
D. A. Nielsen^{2,1}, S. Hamon³, V. Yuferov¹, C. Jackson¹, A. Ho¹, J. Ott³, M. J. Kreek¹, ¹The Laboratory of the Biology of Addictive Diseases, The Rockefeller University, New York, NY, ²Menninger Department of Psychiatry and Behavioral Sciences, Baylor College of Medicine, Houston, TX, ³The Laboratory of Statistical Genetics, The Rockefeller University, New York, NY
- 58 *Difference in allelic frequency in two ethnic groups and analysis of possible association of the 830 bp indel polymorphism in the OPRK1 promoter with cocaine and/or alcohol dependence*
V. Yuferov¹, S. Hamon², O. Levrant¹, A. Ho¹, J. Ott², M. J. Kreek¹, ¹The Laboratory of the Biology of Addictive Diseases, The Rockefeller University, New York, NY, ²Laboratory of Statistical Genetics, The Rockefeller University, New York, NY
- 59 *CM156, a novel antagonist of σ receptors, attenuates cocaine-induced conditioned place preference: Behavioral evaluations and molecular analysis*
Y. Xu¹, M. Elliott¹, J. Shaikh¹, C. R. McCurdy², R. R. Matsumoto^{1,2}, ¹Basic Pharmaceutical Sciences, West Virginia University, Morgantown, WV, ²School of Pharmacy, The University of Mississippi, University, MS
- 60 *Alpha-2A adrenoceptors play a role in behavioral flexibility in mice, but are not required for improvements caused by atomoxetine*
A. S. James¹, C. A. Jairl¹, E. Seu¹, J. Jentsch^{1,2}, ¹Psychology, University of California, Los Angeles, CA, ²Psychiatry and Biobehavioral Science, University of California, Los Angeles, CA
- 61 *The special case of the mu opioid receptor and the evolution of the opioid receptor family*
C. W. Stevens, Pharmacology and Physiology, Oklahoma State University Center for Health Sciences, Tulsa, OK

DRUG INTERACTIONS/POLYDRUG ABUSE

- 62 *Changes in cigarette use among cocaine abusers in a pharmacologic treatment trial*
L. R. Rothenberg², D. J. Brooks², D. Feldman², A. Bisaga^{1,2}, J. Mariani^{1,2}, F. R. Levin^{1,2}, ¹Psychiatry, Columbia University, New York, NY, ²Substance Abuse, New York State Psychiatric Institute, New York, NY

- 63 *Effects of acute oral caffeine pretreatment on response to intravenous nicotine and cocaine in stimulant users*
M. W. Johnson, E. C. Strain, R. R. Griffiths, Behavioral Pharmacology Research Unit, Johns Hopkins University School of Medicine, Baltimore, MD
- 64 *The relationship between nicotine use and opioid-dependence treatment during the early phase of primary care buprenorphine stabilization*
B. R. Bryan¹, E. W. Gunderson^{1,2}, S. K. Vosburg¹, G. Perez¹, L. Archibald¹, F. R. Levin¹,
¹Division on Substance Abuse, Columbia University New York State Psychiatric Institute, New York, NY, ²Psychiatry and Neurobehavioral Sciences Department of Medicine, University of Virginia, Charlottesville, VA
- 65 *Mu-opioid receptors on red blood cells of cocaine users*
D. Gorelick¹, A. Zeiger², P. Matthews², J. Slock¹, K. Preston¹, J. Frost³, ¹NIDA IRP, Baltimore, MD, ²Thomas Jefferson University, Philadelphia, PA, ³Johns Hopkins University, Baltimore, MD
- 66 *Effects of verapamil and diltiazem in methadone-maintained humans under a naloxone novel-response discrimination procedure*
A. Oliveto¹, M. J. Mancino¹, C. Cargile¹, W. B. Gentry², ¹Psychiatry, University of Arkansas Medical School, Little Rock, AR, ²Anesthesiology, Pharmacology and Toxicology, University of Arkansas Medical School, Little Rock, AR
- 67 *Coping styles of substance abusers seeking organ transplantation*
H. Newville^{1,2}, D. L. Haller^{2,3}, M. C. Acosta^{2,3}, ¹Psychology, Ferkauf Graduate School of Psychology, Yeshiva University, Bronx, NY, New York, NY, ²Psychiatry, St. Luke's-Roosevelt, New York, NY, ³Psychiatry, Columbia University, New York, NY
- 68 *Acceptability of an MI-based telephone intervention for substance-abusing transplant patients*
M. C. Acosta^{1,2}, D. L. Haller^{1,2}, ¹Psychiatry, St. Luke's-Roosevelt, New York, NY, ²Psychiatry, Columbia University, New York, NY
- 69 *Longitudinal patterns and correlates of smoking in formerly polysubstance-dependent individuals*
A. B. Laudet, Center for the Study of Addictions and Recovery, NDRI, New York, NY
- 70 *Cocaine dependence and concurrent marijuana use: A comparison of clinical characteristics*
J. A. Lindsay¹, J. M. Schmitz¹, A. L. Stotts¹, C. Green¹, D. Herin², ¹Psychiatry and Behavioral Sciences, University of Texas Health Science Center at Houston, Houston, TX, ²Psychiatry, University of Minnesota, Minneapolis, MN
- 71 *The effect of teacher-rated attention-concentration problems in grades 1 through 6 on latent class growth trajectories of hallucinogens, ecstasy/MDMA, ketamine, sedatives, amphetamines/stimulants, analgesics, tranquilizers, inhalants, cocaine, and heroin for females aged 19-20*
V. J. Tsamis^{1,2}, N. Ialongo¹, G. Rebok¹, S. Kellam¹, ¹Mental Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, ²Psychology, Stevenson University, Stevenson, MD
- 72 *The relationship between increased exercise and reduced substance use*
M. J. Dennis¹, M. L. Dennis², ¹Heartland Community College, Normal, IL, ²GAIN Coordinating Center, Chestnut Health Systems, Normal, IL
- 73 *Assignment of involuntary payees in a voluntary money management intervention*
M. I. Rosen^{1,2}, K. Ablondi^{1,2}, A. C. Black^{1,2}, B. J. Rounsaville^{1,2}, R. A. Rosenheck^{2,1},
¹Psychiatry, Yale University School of Medicine, New Haven, CT, ²Psychiatry, VA Connecticut Healthcare System, West Haven, CT

- 74 *Predictors of job-seeking behaviors*
A. A. Forcehimes¹, J. M. Houck¹, M. P. Bogenschutz¹, D. Svikis², K. Foley³, ¹CASAA, University of New Mexico, Albuquerque, NM, ²Virginia Commonwealth University, Richmond, VA, ³Na’Nizhoozhi Center Inc., Gallup, NM
- 75 *Longitudinal changes in attachment, social support, parenting attitudes, and psychological functioning among women drug abusers*
E. Hall, M. Prendergast, U. Warda, N. Messina, E. Nelson, L. Gregorio, C. Gonzalez, University of California, Los Angeles, CA
- 76 *Congruence of self-reported drug use with urine toxicology screening in a substance abuse treatment population*
R. C. Desmond¹, B. Brands^{2,3}, B. Rush^{1,3}, ¹Centre for Addiction and Mental Health, Toronto, ON, Canada, ²Health Canada, Ottawa, ON, Canada, ³University of Toronto, Toronto, ON, Canada

GENDER/SEX DIFFERENCES

- 77 *Sources of income for chronic drug users*
C. B. McCoy, M. Comerford, Epidemiology and Public Health, University of Miami, Miami, FL
- 78 *Comparing group process in the single-gender Women’s Recovery Group versus mixed-gender Group Drug Counseling*
S. F. Greenfield^{1,2}, L. E. Kuper¹, A. M. Cummings¹, R. Gallop³, ¹McLean Hospital, Belmont, MA, ²Psychiatry, Harvard Medical School, Boston, MA, ³West Chester University, West Chester, PA
- 79 *Gender differences in physical/sexual abuse in outpatients with SUDs: Correlates with medical and psychiatric symptoms*
L. Islam¹, A. Sepulveda¹, A. Alvanzo², L. Keyser-Marcus¹, T. Rieckman³, M. Stitzer², D. Svikis¹, ¹Psychology, Virginia Commonwealth University, Richmond, VA, ²Psychiatry & Medicine, Johns Hopkins, Baltimore, MD, ³Public Health, Oregon Health and Science University, Portland, OR
- 80 *Characteristics of clients with co-occurring disorders in addiction treatment: A comparison by gender*
L. Mangrum, Addiction Research Institute, University of Texas Health Science Center Houston, Austin, TX
- 81 *Gender differences in suicidal ideation and opioid-use disorder among non-medical opioid users with lifetime major depression*
S. J. Kuramoto¹, H. D. Chilcoat^{1,2}, J. Ko¹, S. S. Martins¹, ¹Mental Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, ²GlaxoSmithKline WorldWide Epidemiology, GlaxoSmithKline, Research Triangle Park, NC
- 82 *Gender differences in situational activities associated with heroin and cocaine use among methadone-maintained outpatients*
A. Mitola, D. Epstein, J. Willner-Reid, K. L. Preston, National Institute on Drug Abuse, Intramural Research Program, Baltimore, MD
- 83 *Gender differences at presentation for treatment-seeking opiate dependence*
L. Haynes¹, A. Walquist¹, R. Carter¹, S. Back¹, M. Hillhouse², ¹Medical University of South Carolina, Charleston, SC, ²University of California, Los Angeles, CA

- 84 *Examination of social contextual variables as risk factors in the relationship between gender and crack/cocaine*
E. K. Reynolds¹, C. E. Kopetz¹, S. B. Daughters², C. W. Lejuez¹, ¹Psychology, University of Maryland, College Park, MD, ²School of Public Health, University of Maryland, College Park, MD
- 85 *An investigation of the gender-specific relationship between childhood trauma and low distress tolerance among low-income minority substance users*
T. Geiger, S. B. Daughters, M. A. Bornovalova, C. W. Lejuez, University of Maryland, College Park, MD
- 86 *Males, females, recent-onset drug dependence, and psychological distress: Epidemiological evidence from the United States, 2006*
M. Radovanovic^{1,2}, J. C. Anthony¹, ¹Epidemiology, Michigan State University, East Lansing, MI, ²Psychiatric Office Rudnik, Ljubljana, Slovenia
- 87 *Gender differences in patterns of alcohol dependence symptoms: Evidence from a latent empirical approach*
J. Ko¹, S. Martins¹, S. Kuramoto¹, H. Chilcoat², ¹Mental Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, ²GlaxoSmithKline WorldWide Epidemiology, GlaxoSmithKline, Research Triangle Park, NC
- 88 *Gender differences in past month marijuana use between individual and team sport participants among 10th graders: United States, 2006*
O. J. Santiago¹, C. F. Rios-Bedoya², D. L. Feltz¹, F. A. Fiestas³, ¹Kinesiology, Michigan State University, East Lansing, MI, ²Family Medicine, Michigan State University, East Lansing, MI, ³Epidemiology, Michigan State University, East Lansing, MI
- 89 *Gender differences in tobacco use and smoking risk factors among Spanish adolescents*
O. Garcia-Rodriguez¹, R. Suárez Vázquez², L. Ciller Valverde², ¹University of Barcelona, Barcelona, Spain, ²Health Promotion Studies Center (CEPS), Barcelona, Spain
- 90 *Male-female differences in tobacco dependence experiences: Epidemiological evidence from the United States, 2006*
M. M. Catacora, J. C. Anthony, Epidemiology, Michigan State University, East Lansing, MI
- 91 *Sex differences in response to intravenous nicotine in smokers*
M. Sofuoglu¹, M. Mooney², ¹Yale University, West Haven, CT, ²Psychiatry, University of Minnesota, Minneapolis, MN
- 92 *Basal and cocaine-induced sex differences in the DARPP-32 pathway*
L. Zhou^{2,3}, W. Sun^{1,3}, A. Nazarian^{1,3}, S. Jenab^{1,3}, V. Quinones-Jenab^{1,3}, ¹Psychology, Hunter College of City University of New York, New York, NY, ²Biology, Hunter College of City University of New York, New York, NY, ³Graduate Center of City University of New York, New York, NY
- 93 *Sex differences in approach-avoidance behavior in the runway model of cocaine self-administration*
Z. Su, K. A. Kersetter, D. Guzman, T. Kippin, A. Ettenberg, Psychology, University of California-Santa Barbara, Santa Barbara, CA
- 94 *The effects of allopregnanolone on cocaine self-administration under a progressive-ratio schedule in female rats*
N. Holtz, J. Anker, M. Carroll, University of Minnesota, Minneapolis, MN
- 95 *Antinociceptive and motoric effects of i.c.v. THC in male vs. female rats*
A. A. Wakley, R. M. Craft, Psychology, Washington State University, Pullman, WA

PAIN

- 96 *Pain-elicited and -suppressed behaviors in CBI knockout mice and their wild-type littermates: Effects of morphine*
L. L. Miller, M. J. Picker, K. T. Schmidt, L. A. Dykstra, Psychology, University of North Carolina, Chapel Hill, NC
- 97 *Estrous cycle effects on physiological responses to pain in formalin- and carrageenan-induced inflammation*
N. J. Amador^{1,2}, K. Y. Shivers^{1,2}, D. Hunter^{1,2}, S. Jenab^{1,2}, V. Quinones-Jenab^{1,2}, ¹BioPsychology, CUNY Graduate School and University Center, New York, NY, ²Psychology, Hunter College, New York, NY
- 98 *Estrogen's antihyperalgesic effects in paw tissue of ovariectomized rats during carrageenan-induced inflammation*
K. Y. Shivers^{1,2}, L. C. Abrams^{1,2}, T. Mathew^{1,2}, D. Hunter^{1,2}, G. Barr^{1,2}, S. Jenab^{1,2}, V. Quinones-Jenab^{1,2}, ¹Psychology, The Graduate School and University Center, City University of New York, New York, NY, ²Biopsychology and Behavioral Neuroscience Subprogram, Hunter College City University of New York, New York, NY
- 99 *Estrogen increases behavioral responses to carrageenan-induced inflammation in ovariectomized mice*
L. Abrams^{1,2}, K. Y. Shivers^{1,2}, N. J. Amador^{1,2}, T. Mathew^{1,2}, D. Hunter^{1,2}, G. Barr^{1,2}, S. Jenab^{1,2}, V. Quiñones-Jenab^{1,2}, ¹Psychology, Hunter College, City University of New York, New York, NY, ²Psychology, The Graduate Center, City University of New York, New York, NY
- 100 *Mu/delta opioid agonist interactions in an assay of capsaicin-induced thermal allodynia in rhesus monkeys*
S. S. Negus¹, J. E. Folk², K. C. Rice², ¹Pharmacology and Toxicology, Virginia Commonwealth University, Richmond, VA, ²Chemical Biology Research Branch, NIDA/NIAAA, Rockville, MD
- 101 *A bivalent ligand (MDAN-21) containing μ -agonist and δ -antagonist pharmacophores is devoid of significant physical dependence capacity in rats*
M. D. Aceto¹, P. S. Portoghese², E. Akgun², L. S. Harris¹, ¹Pharmacology and Toxicology, Virginia Commonwealth University, Richmond, VA, ²Medicinal Chemistry, University of Minnesota, Minneapolis, MN
- 102 *Phase II study of the safety and tolerability of niacin combined with oxycodone HCl 5mg vs. oxycodone HCl 5mg alone in healthy adult subjects*
D. Freeland¹, R. Spivey², R. Colucci³, ¹Bee Caves Family Practice, Austin, TX, ²Acura Pharmaceuticals, Inc., Palatine, IL, ³Colucci and Assoc., LLC, Newtown, CT
- 103 *ACUROX[®] (Oxycodone HCl/Niacin) tablets for the treatment of acute, moderate to severe pain following bunionectomy surgery in adult patients*
S. Daniels¹, R. Spivey², R. Colucci³, ¹Premier Research Group Ltd, Austin, TX, ²Acura Pharmaceuticals, Inc., Palatine, IL, ³Colucci and Assoc., LLC, Newtown, CT
- 104 *Evaluation of plasma naltrexone concentrations resulting from use of ALO-01 (morphine sulfate extended-release with sequestered naltrexone hydrochloride) capsules for chronic pain*
F. Johnson¹, D. Manning¹, C. Wang¹, J. Stauffer^{1,2}, ¹Alpharma Pharmaceuticals LLC, Piscataway, NJ, ²Johns Hopkins University School of Medicine, Baltimore, MD
- 105 *Post surgery patient-controlled analgesia in smokers and non-smokers*
C. Diederichs¹, T. Roehrs^{1,2}, M. Hyde¹, M. Greenwald², T. Roth^{1,2}, ¹Sleep Disorders and Research Center, Henry Ford Health System, Detroit, MI, ²Psychiatry and Behavioral Neuroscience, School of Medicine, Wayne State University, Detroit, MI

- 106 *Pain assessment in patients on opioid maintenance therapy*
N. A. Authier^{1,2,3}, C. Auclair¹, C. Dubray², A. Eschaliere³, P. Y. Courty¹, ¹Pôle de Psychiatrie - CMP B, CHU G Monpied, Clermont Ferrand, France, ²Clinical Pharmacology, INSERM CIC 501, Clermont Ferrand, France, ³Pharmacology and Toxicology, UMR INSERM 766, Clermont Ferrand, France
- 107 *Prevalence of severe pain among methadone maintenance patients*
D. Perlman^{1,2}, C. L. Masson³, C. McKnight¹, N. Pepper³, L. Coffin¹, A. Morganstern³, A. Jordan¹, R. Seewald¹, D. C. Des Jarlais^{1,2}, R. Portenoy¹, ¹Beth Israel Medical Center, New York, NY, ²NDRI, Inc., New York, NY, ³University of California, San Francisco, San Francisco, CA
- 108 *Provider confidence recognizing opioid analgesic abuse in HIV care settings*
P. Lum¹, S. Little², D. Hersh², R. Thawley¹, J. Egan³, J. Mitty⁴, D. Fiellin⁵, ¹University of California, San Francisco, CA, ²San Francisco Department of Public Health, San Francisco, CA, ³New York Academy of Medicine, New York, NY, ⁴Brown University, Providence, RI, ⁵Yale University, New Haven, CT
- 109 *An integrated intervention for chronic pain and substance use reduces opioid medication misuse*
B. J. Morasco, A. Patterson, P. Benson, M. Dogra, M. P. Resnick, S. K. Dobscha, Portland VA Medical Center, Portland, OR

POLICY

- 110 *Medicaid reimbursement for screening and brief intervention of substance abuse*
H. E. Fussell, T. Rieckmann, M. Gilpin, J. Kohon, Oregon Health and Science University, Portland, OR
- 111 *Alcohol, press and public policies in Brazil: Content analysis of newspaper and magazine stories in 2006 compared to 2003 and 2000*
A. R. Noto, J. D. Silveira, F. C. Mastroianni, Psicobiologia, UNIFESP, São Paulo, Brazil
- 112 *Adolescent tobacco initiation, use and ongoing nicotine addiction: Perspectives on a reduced nicotine content policy*
S. J. Lo¹, C. Collins¹, J. Henningfield², E. Moolchan³, ¹NIDA/NIH, Baltimore, MD, ²Pinney Associates, Bethesda, MD, ³Alkermes, Inc., Cambridge, MA
- 113 *Smoking cessation services in drug abuse treatment: A national study*
H. K. Knudsen, J. L. Studts, Behavioral Science, University of Kentucky, Lexington, KY
- 114 *Addressing nicotine dependence in drug treatment settings: Organizational change*
J. Guydish¹, D. Ziedonis², B. Tajima¹, G. Brigham⁴, L. Zamarelli³, ¹University of California, San Francisco, San Francisco, CA, ²University of Massachusetts, Worcester, MA, ³Willamette Family, Inc, Eugene, OR, ⁴Maryhaven, Inc., Columbus, OH
- 115 *Heroin purchasing is income, price and arrest-rate sensitive*
J. K. Roddy¹, C. L. Steinmiller², M. K. Greenwald², ¹Social Sciences, University of Michigan Dearborn, Dearborn, MI, ²Psychiatry and Behavioral Neurosciences, Wayne State University, Detroit, MI
- 116 *Disaster preparedness for disruptions in methadone treatment*
D. Podus¹, J. C. Maxwell², ¹UCLA-ISAP, Los Angeles, CA, ²University of Texas, Austin, TX
- 117 *Adoption of medications in substance abuse treatment: Access, integration and workforce development*
T. Rieckmann, M. Gholson, D. McCarty, W. Nash, J. Kohon, H. Fussell, Public Health and Preventive Medicine, Oregon Health and Science University, Portland, OR

- 118 *New York drug policies and the lived experiences of African American women in distressed households*
L. C. Windsor¹, E. Dunlap², ¹School of Social Work, Rutgers: The State University of New Jersey, New Brunswick, NJ, ²National Development and Research Institutes, New York, NY
- 119 *Do organizational process improvement interventions significantly change motivational interviewing knowledge, attitudes, and use by substance abuse treatment counselors?*
S. Stevens Manser, D. Travis, E. Borah, R. Spence, Center for Social Work Research, Addiction Research Institute, University of Texas at Austin, Austin, TX
- 120 *Assessing participation in a randomized trial evaluating improvement strategies in addiction treatment*
A. Quanbeck¹, J. H. Ford¹, A. Pulvermacher¹, J. Robinson¹, A. Wheelock¹, J. McConnell², K. Hoffman², D. McCarty², D. Gustafson¹, V. Sviridova¹, J. Kadunc¹, ¹University of Wisconsin, Madison, WI, ²Oregon Health and Science University, Portland, OR
- 121 *Current drug-scheduling reviews reported by the Drug Enforcement Administration*
S. R. Tella, S. Ghosland, A. Sancho, C. Prioleau, S. Carr, C. Sannerud, Office of Diversion Control, Drug Enforcement Administration, Washington, DC
- 122 *Drug combinations seized by law enforcement, emerging trends and undetermined effects to the unsuspecting user*
T. L. Boos, L. L. Wong, S. M. Carr, C. A. Sannerud, Drug and Chemical Evaluation Section/ODE, Drug Enforcement Administration, Springfield, VA

TREATMENT OUTCOME

- 123 *The day treatment modality applied to patients with substance use disorders: Comparison with outpatient enhanced methadone service using a controlled, prospective matched pair-design*
R. R. Kowalewski, L. Bösch, M. Schaub, R. Stohler, Division of Substance Use Disorders, Psychiatric University Hospital Zurich, Zurich, Switzerland
- 124 *Characteristics and nine-month outcomes of discharged methadone maintenance clients*
D. M. Coviello¹, D. A. Zanis^{1,2}, S. A. Wesnoski¹, ¹Psychiatry/Addictions, University of Pennsylvania, Philadelphia, PA, ²Social Administration, Temple University, Philadelphia, PA
- 125 *Redefining retention: Three pathways for extending a treatment episode beyond a methadone program's boundaries*
S. G. Mitchell¹, R. P. Schwartz¹, H. S. Reisinger¹, J. A. Peterson¹, S. M. Kelly¹, S. Lotfi¹, M. H. Agar³, K. O'Grady², B. S. Brown⁴, ¹Friends Research Institute, Baltimore, MD, ²University of Maryland, College Park, MD, ³Ethknoworks, Santa Fe, NM, ⁴University of North Carolina, Wilmington, NC
- 126 *Preliminary outcomes of a behavioral treatment trial among opiate IDU in central Ukraine*
J. E. Schumacher¹, K. Dumchev², O. Zezyulin², P. Slobodyanyuk², S. Chandler¹, L. Moroz³, M. Wang⁴, ¹Division of Preventive Medicine, University of Alabama at Birmingham, Birmingham, AL, ²Vinnitsya Regional Narcological Dispensary, Vinnitsya, Ukraine, ³Vinnitsya National Medical University Pirogov, Vinnitsya, Ukraine, ⁴Expert Health Data Systems, Inc., Silver Spring, MD
- 127 *Preliminary functioning outcomes of a behavioral treatment trial in opiate IDU in Ukraine*
K. Dumchev¹, J. Schumacher², O. Zezyulin¹, P. Slobodyanyuk¹, S. Chandler², L. Moroz³, M. Wang⁴, ¹Vinnitsya Regional Narcological Dispensary, Vinnitsya, Ukraine, ²University of Alabama at Birmingham, Birmingham, AL, ³Vinnitsya National Medical University Pirogov, Vinnitsya, Ukraine, ⁴Expert Health Data Systems, Silver Spring, MD

- 128 *The effect of treatment setting on outcome in treating opioid dependence with buprenorphine*
S. Schroeder, K. Miotto, M. Hillhouse, C. Manneh, C. Domier, W. Ling, Integrated Substance Abuse Programs, University of California, Los Angeles, Los Angeles, CA
- 129 *Efficacy of the Manualized Cognitive-Behavioral Treatment Program CANDIS for cannabis use disorders*
A. Ruehlmann, E. Hoch, R. Noack, J. Henker, A. Pixa, H. Rohrbacher, M. Höfler, G. Bühringer, H. U. Wittchen, Institut fuer Klinische Psychologie und Psychotherapie, Technische Universitaet Dresden, Germany, Dresden, Germany
- 130 *Effects of psychosocial treatment dose on outcomes in stimulant-dependent adults*
S. Glasner-Edwards, D. Farabee, L. Brecht, R. A. Rawson, Integrated Substance Abuse Programs, University of California, Los Angeles, CA
- 131 *The impact of directive and non-directive drug counseling approaches as a function of patient trait reactance*
D. J. Farabee, R. Rawson, V. J. Pearce, S. J. Cousins, A. Bellows, J. Hemberg, University of California, Los Angeles, CA
- 132 *Medical outcomes in methamphetamine-dependent adults 3 years after treatment*
L. Mooney¹, S. Glasner-Edwards¹, P. Marinelli-Casey¹, M. Hillhouse¹, A. Ang¹, J. Hunter¹, W. Haning², P. Colescott², W. Ling¹, R. Rawson¹, ¹University of California, Los Angeles, CA, ²University of Hawaii, Honolulu, HI
- 133 *An analysis of substance abuse treatment outcomes between a sample of American Indians/Alaska Natives and a comparison group*
D. L. Dickerson, S. E. Spear, MS, P. Marinelli-Casey, R. A. Rawson, Ph.D., Y. Hser, Integrated Substance Abuse Program, University of California, Los Angeles, CA
- 134 *Emotional abuse as a risk factor for poor treatment outcome in residential substance abuse treatment*
S. M. Gorka¹, M. A. Bornovalova², K. Kochanska¹, S. B. Daughters¹, ¹School of Public Health, University of Maryland, College Park, MD, ²Psychology, University of Minnesota, Minneapolis, MN
- 135 *Outcomes of substance abuse treatment adjusting for selection bias*
M. Brecht, R. Gonzales, R. Rawson, Integrated Substance Abuse Programs, University of California, Los Angeles, CA
- 136 *The risk and responsivity principles as moderators of drug abuse treatment outcomes: A meta-analysis*
F. S. Pearson¹, M. Prendergast², D. Podus², L. Greenwell², ¹National Development and Research Institutes, New York, NY, ²UCLA Integrated Substance Abuse Programs, Los Angeles, CA

Symposium VI

**Rose Ballroom A
2:00 - 4:00 PM**

PRECLINICAL STUDIES OF SEX DIFFERENCES IN RESPONSE TO COCAINE IN ADOLESCENTS: ARE THEY DIFFERENT FROM ADULTS?

Chairs: Cora Lee Wetherington and Jill Becker

- 2:00 *Aquisition and maintenance of cocaine self-administration in adolescent rats: Effects of sex and gonadal hormones*
Wendy Lynch, University of Virginia, Charlottesville, VA

- 2:25 *Adolescence and sex differences in reinstatement of drug-seeking and impulsivity for drug and non-drug rewards*
Marilyn Carroll, University of Minnesota, Minneapolis, MN
- 2:50 *Environmental effects on cocaine reward: Sex and age matter*
Sari Izenwasser, University of Miami Miller School of Medicine, Miami, FL
- 3:15 *Emergence of sex differences in dopamine function in adolescence*
Cynthia Kuhn, Duke University Medical Center, Durham, NC
- 3:40 *Adolescence and sex differences in drug abuse: A synthesis*
Jill Becker, University of Michigan, Ann Arbor, MI

Symposium VII

Ponderosa B
2:00 - 4:00 PM

INTERNATIONAL RESEARCH PRIORITIES FOR SCALING UP EFFECTIVE INTERVENTIONS FOR DRUG USE AND DEPENDENCE

Chairs: Vladimir Poznyak (WHO) and Sharon L. Walsh

- 2:00 *The global epidemiology of injecting drug use and HIV among people who inject drugs: What do we know?*
Louisa Degenhardt, National Drug and Alcohol Research Center, University of New South Wales, Sydney, NSW, Australia
- 2:25 *The potential impact of scaling up effective substance abuse treatment in HIV/AIDS prevention and care*
George E. Woody, University of Pennsylvania and Treatment Research Institute, Philadelphia, PA
- 2:50 *Pharmacotherapy for opioid dependence: Gaps in the evidence and priorities for future research*
Nicholas Clark, Management of Substance Abuse, World Health Organization (WHO), Geneva, Switzerland
- 3:15 *Effectiveness of interventions based on WHO ASSIST package in different cultural contexts: Implications for future research*
R. Ali, School of Medical Sciences, University of Adelaide, Adelaide, SA, Australia
- 3:40 *Discussant*
Thomas Babor, Community Medicine and Healthcare, University of Connecticut Health Center, Farmington, CT

Oral Communications 8

Rose Ballroom B
2:00 - 4:00 PM

NEUROPATHIC CONSEQUENCES OF ACUTE AND CHRONIC EXPOSURE

Chairs: Ratna Sircar and Shane A. Perrine

- 2:00 *Long-term alterations of stress responsive and opioid systems in rat hypothalamus and amygdala during chronic heroin withdrawal*
Y. Zhou, J. Choi, J. Huynh, A. Ho, M. J. Kreek, Rockefeller University, New York, NY

- 2:15 *Gamma-hydroxybutyric acid impairs spatial memory and alters NMDA receptor subunits in adolescent female rats*
R. Sircar^{1,2}, A. Basak¹, L. Wu¹, K. Reddy¹, ¹Feinstein Institute for Medical Research, Manhasset, NY, ²Psychiatry and Behavioral Sciences, Albert Einstein College of Medicine, Bronx, NY
- 2:30 *Chronic toluene exposure differentially regulates amino acid neurotransmitters in the adolescent rat brain following acute or prolonged drug abstinence*
S. A. Perrine¹, S. K. O'Leary-Moore^{1,2}, M. P. Galloway¹, J. H. Hannigan², S. E. Bowen², ¹Psychiatry and Behavioral Neurosciences, Wayne State University School of Medicine, Detroit, MI, ²Psychology and OB/GYN, Wayne State University, Detroit, MI
- 2:45 *MDMA use is associated with increased basal ganglia-thalamocortical circuit activation during motor task performance in humans: An fMRI study*
J. Karageorgiou, M. S. Dietrich, E. J. Charboneau, N. D. Woodward, J. U. Blackford, R. M. Salomon, R. L. Cowan, Psychiatry, Vanderbilt University, Nashville, TN
- 3:00 *Cortisol secretion profile is associated with drop-out and more persistent cocaine craving during a trial of mirtazapine for the treatment of depressed cocaine abusers*
L. C. Sanfilippo, W. N. Raby, E. V. Nunes, Psychiatry, New York Psychiatric Institute, New York, NY
- 3:15 *Chronic marijuana users have decreased responsiveness to emotionally charged visual stimuli*
M. J. Wesley, C. A. Hanlon, L. J. Porrino, Physiology and Pharmacology, Wake Forest University School of Medicine, Winston Salem, NC
- 3:30 *Alterations in microstructure of the isthmus in midsagittal corpus callosum is associated with duration of cocaine use in the cocaine-dependent subjects*
L. Ma¹, K. M. Hasan², J. L. Steinberg¹, P. A. Narayana², S. D. Lane¹, E. A. Zuniga¹, L. A. Kramer², F. G. Moeller¹, ¹Psychiatry and Behavioral Sciences, University of Texas Health Science Center, Houston, TX, ²Diagnostic and Interventional Imaging, University of Texas Health Science Center, Houston, TX
- 3:45 *Are there cognitive sequelae to callosal damage in chronic cocaine users?*
C. A. Hanlon, M. J. Wesley, M. C. Torrence, A. Liguori, L. J. Porrino, Physiology and Pharmacology, Wake Forest University, Winston-Salem, NC

Oral Communications 9

Bonanza
2:00 - 4:00 PM

MUSING ABOUT MU: PRECLINICAL STUDIES WITH OPIOIDS

Chairs: Jean M. Bidlack and Pouya Tahsili-Fahadan

- 2:00 *Anatomical and functional interactions between chemokine and μ -opioid receptors in periaqueductal grey neurons*
L. G. Kirby, J. Palma, S. Heinisch, Anatomy and Cell Biology and Center for Substance Abuse Research, Temple University School of Medicine, Philadelphia, PA
- 2:15 *Inhibition of G $\beta\gamma$ signaling to phospholipase β 3 enhances antinociception mediated by the μ opioid receptor but does not affect respiration or locomotion*
J. M. Bidlack¹, J. P. McLaughlin², ¹Pharmacology and Physiology, University of Rochester, Rochester, NY, ²Psychology, Northeastern University, Boston, MA

- 2:30 *Opioid receptor mediation of morphine's discriminative stimulus effects in the inbred Fischer 344 and Lewis rat strains*
C. M. Davis¹, K. C. Rice², A. L. Riley¹, ¹Psychology, American University, Washington, DC, ²Drug Design and Synthesis Section, Chemical Biology Research Branch, National Institute on Drug Abuse and National Institute on Alcoholism and Alcohol Abuse, Rockville, MD
- 2:45 *Morphine antinociception in combination with metabotropic glutamate receptor (mGluR) antagonists*
D. E. Daugherty¹, L. L. Miller¹, M. J. Picker¹, L. A. Dykstra^{1,2}, ¹Psychology, University of North Carolina at Chapel Hill, Chapel Hill, NC, ²Pharmacology, University of North Carolina at Chapel Hill, Chapel Hill, NC
- 3:00 *Changes in mGluR5 surface expression: Comparison between repeated morphine and methamphetamine*
A. A. Herrold^{1,2,4}, A. L. Mickiewicz^{1,3,4}, T. C. Napier^{1,4}, ¹Pharmacology, Rush University Chicago, Chicago, IL, ²Neuroscience, Loyola University Chicago, Maywood, IL, ³Pharmacology, Loyola University Chicago, Maywood, IL, ⁴Center for Compulsive Behavior and Addiction, Rush University Chicago, Chicago, IL
- 3:15 *Modafinil blocks morphine-primed reinstatement of conditioned place preference*
P. Tahsili-Fahadan¹, G. V. Carr², G. C. Harris², G. Aston-Jones¹, ¹Medical University of South Carolina, Charleston, SC, ²University of Pennsylvania, Philadelphia, PA
- 3:30 *Assessment of individual differences in the aversive and rewarding effects of morphine*
A. Verendeev, A. L. Riley, Psychopharmacology Laboratory, Psychology, American University, Washington, DC
- 3:45 *Differential modification of the antinociceptive and discriminative stimulus effects of morphine by 5-HT1A and 5-HT2A receptor agonists in rhesus monkeys*
J. Li¹, K. C. Rice³, W. Koek^{1,2}, C. P. France^{1,2}, ¹Pharmacology, University of Texas Health Science Center, San Antonio, TX, ²Psychiatry, University of Texas Health Science Center, San Antonio, TX, ³Chemical Biology Research Branch, NIDA and NIAAA, National Institutes of Health, Rockville, MD

Marian W. Fischman Memorial Award Lecture

**Rose Ballroom A
4:15 - 5:15 PM**

*Presentation of the Marian W. Fischman Memorial Award to
Harriet de Wit*

Introduction by Chris-Ellyn Johanson

Lecture: Determinants of drug preference in humans
Harriet de Wit

BADGES MUST BE WORN IN ALL SCIENTIFIC SESSIONS

NIDA/CPDD Pre- and Post-Doc Mixer

**Genoa
5:30 - 7:00 PM**

**NETWORKING GET-TOGETHER FOR ALL STUDENTS,
TRAINEES, AND MENTORS**

Workshop V

**Bonanza
8:00 - 10:00 PM**

15TH ANNUAL CONTINGENCY MANAGEMENT WORKING GROUP

Chairs: Stacey C. Sigmon and Kelly Dunn

Workshop VI

**Rose Ballroom A
8:00 - 10:00 PM**

**EVALUATING THE ABUSE POTENTIAL OF NOVEL
COMPOUNDS AND ABUSE-RESISTANT FORMULATIONS**

Chair: Michael A. Nader

Emerging drugs of abuse as identified by the DEA

Srihari R. Tella, Drug and Chemical Evaluation Section, Arlington, VA

The role of NIDA in the evaluation of emerging drugs of abuse

Jane B. Acri, National Institute on Drug Abuse, Bethesda, MD

Limitations of current preclinical abuse assessment strategies and possible future approaches

Patrick Beardsley, Virginia Commonwealth, Richmond, VA

Clinical research issues in the evaluation of novel compounds and formulations

John D. Roache, University of Texas Health Science Center at San Antonio, San Antonio, TX

Workshop VII

**Ponderosa B
8:00 - 10:00 PM**

**SUBSTANCE USE DISORDERS IN DSM-V:
A PROGRESS REPORT**

Chairs: Thomas J. Crowley and Charles O'Brien

Combining abuse with dependence

Thomas J. Crowley, University of Colorado Denver, School of Medicine, Aurora, CO

Inclusion of cannabis withdrawal and related issues

Alan Budney, University of Arkansas for Medical Sciences, Little Rock, AR

Addiction vs dependence for DSM V

Charles O'Brien, University of Pennsylvania School of Medicine, Philadelphia, PA

Consumption level as a diagnostic criterion?

Guilherme Borges, Instituto Nacional de Psiquiatria and Universidad Autonoma Metropolitana, San Lorenzo Huipulco, Mexico

Workshop VIII

**Rose Ballroom B
8:00 - 10:00 PM**

FOUR PRACTICAL INTERVENTIONS TO MAKE OUTPATIENT TREATMENT ATTRACTIVE AND ACCOUNTABLE - TRANSLATIONAL RESEARCH IN THE REAL WORLD

Chair: A. Thomas McLellan and David Festinger

Concurrent recovery monitoring as a clinical activity

John Cacciola, University of Pennsylvania School of Medicine, Philadelphia, PA

Telephone counseling to support recovery following residential treatment

Deni Carise, Treatment Research Institute and University of Pennsylvania, Philadelphia, PA

Improving monitoring and evaluation in drug courts: TRI Court Evaluation Program

David Festinger, Treatment Research Institute and University of Pennsylvania,
Philadelphia, PA

CRAFT: Helping families motivate loved ones to enter treatment

Kimberly C. Kirby, Treatment Research Institute and University of Pennsylvania,
Philadelphia, PA

NIDA International Meeting Poster Session

**Rose Foyer
8:00 - 10:00 PM**

Chair: Steven W. Gust

POSTER SESSION II (Breakfast)

**Pavilion
8:00 - 10:00 AM**

**Odd-numbered posters manned first hour;
Even-numbered, second hour**

**Set-up time begins Monday no earlier than 3:00 PM
Must be removed by Tuesday no later than 3:00 PM**

NICOTINE: ANIMALS

- 1 *Sex differences in nicotine self-administration and reinstatement in rats*
M. W. Feltenstein, R. E. See, Neurosciences, Medical University of South Carolina, Charleston, SC
- 2 *Enrichment-induced differences in nicotine drug discrimination in rats is nicotinic receptor-mediated*
D. J. Stairs¹, C. S. Bockman², J. Fosdick¹, B. Mittelstet¹, L. Schwarzkopf¹, ¹Psychology, Creighton University, Omaha, NE, ²Pharmacology, Creighton University, Omaha, NE
- 3 *Effects of acute nicotine on delay discounting in rats*
J. L. Perry, M. G. LeSage, Minneapolis Medical Research Foundation, Minneapolis, MN
- 4 *Nicotine conditioned place preference in adolescence differs as a function of sex*
M. Lenoir, E. Zakharova, J. Ledon, A. Rhodes, C. Booth, S. Izenwasser, Psychiatry and Behavioral Sciences, University of Miami Miller School of Medicine, Miami, FL
- 5 *Preweanling rats exhibit deficits in prepulse inhibition of the startle reflex when gestationally exposed to nicotine*
R. T. Lacy, C. F. Mactutus, S. B. Harrod, Psychology, University of South Carolina, Columbia, SC
- 6 *Transfer of extinction learning for the conditioned stimulus of nicotine by nicotinic receptor agonists*
C. Reichel, J. Murray, J. Barr, S. Sanderson, M. Tracy, R. Bevins, Psychology, University of Nebraska-Lincoln, Lincoln, NE
- 7 *Behavioral characterization of novel nicotinic receptor compounds based on the structure of cytisine*
E. M. Jutkiewicz¹, F. Sparatore², B. Tasso², J. H. Woods¹, ¹Pharmacology, University of Michigan, Ann Arbor, MI, ²Pharmaceutical Sciences, University of Genoa, Genoa, Italy
- 8 *The effects of nicotine preexposure during periadolescence on the aversive and physiological effects of alcohol in adulthood*
J. A. Rinker¹, M. A. Hutchison¹, S. A. Chen², E. D. Singley², M. A. Heilig², A. L. Riley¹, ¹Psychology, American University, Washington, DC, ²NIAAA, NIH, Bethesda, MD
- 9 *Involvement of the hypocretin system in the reinforcing effects of nicotine in rats*
W. A. Corrigan^{1,3}, C. M. Kotz², J. L. Perry¹, J. A. Teske², M. G. LeSage^{1,3}, ¹Minneapolis Medical Research Foundation, Minneapolis, MN, ²VA Medical Center, Minneapolis, MN, ³University of Minnesota, Minneapolis, MN
- 10 *Nicotine and learning, from changes in behavior to cell signaling: Implications for nicotine addiction*
T. J. Gould, ¹Psychology, Temple University, Philadelphia, PA, ²Center for Substance Abuse Research, Temple University, Philadelphia, PA

IMAGING

- 11 *Differences in brain activation between marijuana smokers and non-smoking controls during a spatial navigation fMRI task*
J. T. Sneider^{1,2}, J. Rogowska^{1,2}, S. A. Gruber^{1,2}, D. Yurgelun-Todd^{1,2,3}, ¹Neuroimaging Center, McLean Hospital, Belmont, MA, ²Psychiatry, Harvard Medical School, Boston, MA, ³University Utah Medical School, Salt Lake City, UT
- 12 *Dronabinol blunts drug cue reactivity in marijuana-dependent patients*
M. Goldman¹, R. Ehrman^{1,2}, Z. Wang¹, Y. Li¹, W. Jens¹, J. Hakun¹, J. Suh^{1,2}, C. P. O'Brien^{1,2}, J. Detre¹, A. R. Childress^{1,2}, K. Kampman¹, A. V. Hole¹, ¹Psychiatry, University of Pennsylvania, Philadelphia, PA, ²VA Medical Center, Philadelphia, PA
- 13 *Cocaine rewards segregate neural processing underlying performance of cognitive tasks in nonhuman primates*
S. Deadwyler, I. Opris, R. Hampson, Physiology and Pharmacology, Wake Forest University Health Sciences, Winston Salem, NC
- 14 *Sex differences in the interactions between social rank and cocaine reinforcement in cynomolgus monkeys*
M. A. Nader^{1,2}, P. W. Czoty¹, N. V. Riddick¹, H. D. Gage², J. R. Kaplan³, ¹Physiology and Pharmacology, Wake Forest University School of Medicine, Winston-Salem, NC, ²Radiology, Wake Forest, Winston-Salem, NC, ³Pathology, Wake Forest University School of Medicine, Winston-Salem, NC
- 15 *Does prior trauma modulate limbic brain response to aversive cues in cocaine-dependent patients?*
C. A. Rudoy¹, J. Suh^{1,2}, R. Ehrman^{1,2}, Y. Li¹, Z. Wang¹, W. Jens¹, J. Hakun¹, T. Franklin¹, M. Goldman¹, C. P. O'Brien^{1,2}, A. R. Childress^{1,2}, ¹Psychiatry, University of Pennsylvania School of Medicine, Philadelphia, PA, ²VA VISN 4 MIRECC, Philadelphia, PA
- 16 *Brain MR spectroscopy in the frontal white matter of prenatally cocaine-exposed adolescents*
E. S. Bandstra¹, V. Govindaraju², G. R. Simpson¹, B. C. Bowen², V. H. Accornero¹, E. Romano¹, L. Xue¹, C. E. Morrow¹, A. Maudsley², ¹Pediatrics, University of Miami Miller School of Medicine, Miami, FL, ²Radiology, University of Miami Miller School of Medicine, Miami, FL
- 17 *Increased neural response to lidocaine relative to procaine in healthy subjects*
B. Adinoff^{1,2}, M. D. Devous¹, D. C. Cooper¹, S. E. Best^{1,2}, T. S. Harris¹, M. J. Williams¹, ¹University of Texas Southwestern Medical Center, Dallas, TX, ²VA North Texas Health Care System, Dallas, TX
- 18 *Neurochemical effects of citicoline treatment in methamphetamine-dependent patients: A longitudinal proton magnetic resonance spectroscopy study*
I. Lyoo², S. J. Yoon¹, H. J. Kim², J. Hwang², Y. Sung³, N. Kim³, S. E. Lukas⁴, P. F. Renshaw³, ¹Psychiatry, Catholic University College of Medicine, Seoul, Korea, South, ²Psychiatry, Seoul National University Hospital, Seoul, Korea, South, ³Psychiatry, University of Utah, Salt Lake City, UT, ⁴Behavioral Psychopharmacology Research Laboratory and Sleep Research Program, McLean Hospital, Belmont, MA
- 19 *Neural correlates of impaired number processing in young adults with prenatal alcohol exposure*
M. J. Avison⁴, R. L. Cowan¹, E. E. Garcia⁴, J. Pryweller⁴, N. C. Dodge³, M. J. Burden³, R. Klorman², S. W. Jacobson³, J. L. Jacobson³, ¹Psychiatry, Vanderbilt University, Nashville, TN, ²Psychology, University of Rochester, Rochester, NY, ³Psychiatry and Behavioral Neurosciences, Wayne State University, Detroit, MI, ⁴Radiology, Vanderbilt University, Nashville, TN

- 20 *Reduced fractional anisotropy in human MDMA users is consistent with cortical axon loss: A 3 Tesla diffusion tensor MRI study*
A. Cao, M. S. Dietrich, R. L. Cowan, Psychiatry and Radiology and Radiological Sciences, Vanderbilt University, Nashville, TN

CHEMISTRY/PHARMACOKINETICS

- 21 *Evaluation of [³H]-SN56, a novel sigma-1 receptor radioligand*
J. A. Fishback¹, C. R. McCurdy², R. R. Matsumoto¹, ¹Basic Pharmaceutical Sciences, West Virginia University, Morgantown, WV, ²Medicinal Chemistry, University of Mississippi, University, MS
- 22 *Development of biaryl urea analogs of SB-334867 as orexin-1 receptor antagonists*
Y. Zhang, S. P. Runyon, B. P. Gilmour, H. A. Navarro, B. F. Thomas, Research Triangle Institute, Research Triangle Park, NC
- 23 *Pharmacokinetics of lisdexamfetamine dimesylate following intranasal administration*
J. Ermer¹, K. Dennis¹, M. Haffey¹, W. Doll², E. Sandefer², M. Buckwalter¹, R. Page², B. Diehl¹, P. Martin¹, ¹Shire Development Inc., Wayne, PA, ²Scintipharma, Inc, Lexington, KY
- 24 *Pharmacokinetic profile of lisdexamfetamine dimesylate after 14-day intranasal administration in dogs*
M. Pennick, R. Secker, Shire Pharmaceutical Development Ltd, Basingstoke, United Kingdom
- 25 *Pharmacokinetics of crushed intranasal Oxycontin® in non-dependent prescription opioid users*
M. Lofwall^{1,2}, D. Moody³, P. Nuzzo², W. Fang³, S. L. Walsh^{2,1}, ¹Psychiatry, University of Kentucky, Lexington, KY, ²Behavioral Science, Center for Drug and Alcohol Research, University of Kentucky, Lexington, KY, ³Center for Human Toxicology, University of Utah, Salt Lake City, UT
- 26 *Effect of cocaine use on buprenorphine pharmacokinetics in humans*
E. F. McCance-Katz¹, P. M. Rainey², D. E. Moody³, ¹Psychiatry, University of California San Francisco, San Francisco, CA, ²Laboratory Medicine, University of Washington, Seattle, WA, ³Center for Human Toxicology, University of Utah, Salt Lake City, UT
- 27 *Stereospecificity, or lack thereof, in human methamphetamine metabolic pathways*
L. Li¹, E. Everhart², E. Fernandez², P. Jacob III², R. T. Jones², J. Mendelson¹, ¹Addiction Pharmacology, California Pacific Medical Center Research Institute, San Francisco, CA, ²Psychiatry, University of California, San Francisco, CA

AMPHETAMINE/METHAMPHETAMINE: HUMAN STUDIES

- 28 *Predictors of cue-induced craving for methamphetamine in subjects with recent methamphetamine abuse or dependence*
B. Tolliver, A. L. McRae-Clark, M. Saladin, K. L. Price, E. Chapman, K. T. Brady, Psychiatry, Medical University of South Carolina, Charleston, SC
- 29 *Relationship between the subjective and discriminative effects of d-amphetamine: A retrospective analysis*
M. M. Poole^{1,2}, A. R. Reynolds¹, A. R. Vansickel^{1,2}, C. R. Rush^{2,1,3}, ¹Psychology, University of Kentucky, Lexington, KY, ²Behavioral Science, University of Kentucky, Lexington, KY, ³Psychiatry, University of Kentucky, Lexington, KY
- 30 *The effects of progesterone pretreatment on the response to oral d-amphetamine: Impulsivity, mood and performance*
S. C. Reed, F. R. Levin, S. M. Evans, Psychiatry, Columbia University, New York, NY
- 31 *Cocaine choice in humans during d-amphetamine maintenance*
C. R. Rush, W. W. Stoops, R. J. Sevak, L. R. Hays, University of Kentucky, Lexington, KY

- 32 *Sustained release d-amphetamine maintenance decreases cocaine seeking in COC/heroin-dependent, buprenorphine-stabilized volunteers*
M. Greenwald, C. Steinmiller, L. Lundahl, Psychiatry, Wayne State University, Detroit, MI
- 33 *Route of administration of methamphetamine: How impaired are swallowers?*
J. C. Maxwell¹, J. K. Cunningham², ¹Addiction Research Institute, University of Texas at Austin, Austin, TX, ²College of Medicine, University of Arizona, Tucson, AZ
- 34 *Cognitive distinctions between currently using and abstaining methamphetamine-dependent individuals*
C. Domier, M. Hillhouse, P. Marinelli-Casey, R. Rawson, Integrated Substance Abuse Programs, University of California, Los Angeles, Los Angeles, CA
- 35 *Randomized, double-blind trial of modafinil vs placebo for methamphetamine dependence*
K. G. Heinzerling¹, S. Shoptaw^{1,2}, A. Swanson¹, W. Ling², ¹Family Medicine, UCLA, Los Angeles, CA, ²Integrated Substance Abuse Programs, University of California, Los Angeles, CA
- 36 *Predicting adherence to treatment for methamphetamine dependence from neuropsychological and drug use variables*
A. C. Dean¹, E. D. London^{1,2}, C. A. Sugar³, C. M. Kitchen³, A. N. Swanson⁴, K. G. Heinzerling⁴, A. D. Kalechstein¹, S. Shoptaw⁴, ¹Psychiatry and Biobehavior Science, UCLA, Los Angeles, CA, ²Molecular and Medical Pharmacology and Brain Research Institute, UCLA, Los Angeles, CA, ³Biostatistics, UCLA, Los Angeles, CA, ⁴Family Medicine and Psychiatry, University of California, Los Angeles, CA
- 37 *Actively using, non-treatment-seeking men who have sex with men can be successfully enrolled and retained in pharmacologic studies for methamphetamine dependence*
M. Das-Douglas^{1,2}, D. Santos², G. Santos², P. Chu², E. Vittinghoff¹, S. Shoptaw³, G. Colfax^{1,2}, ¹University of California, San Francisco, CA, ²San Francisco Department of Public Health, San Francisco, CA, ³University of California, Los Angeles, CA
- 38 *Treatment impact on health-related quality of life among methamphetamine-dependent individuals*
R. Gonzales, P. Marinelli-Casey, R. A. Rawson, University of California, Los Angeles, CA
- 39 *Methamphetamine-related violence among women users*
A. Hamilton¹, R. A. Rawson¹, N. E. Goeders², ¹Psychiatry, University of California, Los Angeles, CA, ²Pharmacology, Toxicology, and Neuroscience, Louisiana State Health Sciences Center, Shreveport, LA
- 40 *Service needs, treatment utilization, and outcomes of Asian Americans in drug treatment*
E. Evans, P. Marinelli-Casey, L. Li, Y. Hser, R. Rawson, Integrated Substance Abuse Programs, University of California, Los Angeles, CA
- 41 *Rise in meth use in the Latino community*
D. A. Crevecoeur-MacPhail, NPI, University of California, Integrated Substance Abuse Program, Los Angeles, CA

STRESS

- 42 *Role of adrenergic receptors in the reinstatement of extinguished cocaine-induced conditioned place preference by cocaine, forced swim stress, and yohimbine in mice*
H. Caretta, A. Weyer, J. R. Mantsch, Biomedical Sciences, Marquette University, Milwaukee, WI
- 43 *The effects of weight loss and methamphetamine administration on hormone levels*
M. D. Garcia-Villarreal, D. Alford, G. Guerin, N. E. Goeders, Pharmacology, Toxicology and Neuroscience, Louisiana University Health Sciences Center, Shreveport, LA

- 44 *Both imagery scripts and mental arithmetic induce stress in methamphetamine users*
K. J. Garrison, G. P. Galloway, J. R. Coyle, M. J. Baggott, J. Mendelson, Addiction Pharmacology, California Pacific Medical Center Research Institute, San Francisco, CA
- 45 *Ovarian hormones and subjective responding to stress and cues in cocaine-dependent females*
M. Moran-Santa Maria, M. W. Feltenstein, A. L. McRae, S. E. Back, S. M. DeSantis, K. L. Price, L. M. Jenkins, K. T. Brady, Psychiatry and Behavioral Sciences, Medical University of South Carolina, Charleston, SC
- 46 *Social support moderates biological and subjective responses to stress and drug cues in cocaine-dependent inpatients*
S. M. Hyman¹, H. Fox¹, M. J. Kreek², R. Sinha¹, ¹Psychiatry, Yale University School of Medicine, New Haven, CT, ²Laboratory on the Biology of Addictive Diseases, Rockefeller University, New York, NY
- 47 *The relationship between response to laboratory stress provocation and relapse to cocaine*
K. Hartwell, S. E. Back, S. M. DeSantis, K. T. Brady, Psychiatry and Behavioral Sciences, Medical University of South Carolina, Charleston, SC
- 48 *HPA axis response to psychological stress is predictive of treatment retention in residential substance abuse treatment*
S. B. Daughters^{1,2}, J. M. Richards², S. M. Gorka^{1,2}, R. Sinha³, ¹School of Public Health, University of Maryland, College Park, MD, ²Center for Addictions, Personality, and Emotion Research, Psychology, University of Maryland, College Park, MD, ³Psychiatry, Yale University School of Medicine, New Haven, CT
- 49 *A mental arithmetic stressor increases anxiety and heart rate but not craving in methamphetamine-dependent subjects*
J. D. Siegrist, J. Mendelson, M. J. Baggott, G. P. Galloway, Addiction Pharmacology, California Pacific Medical Center Research Institute, San Francisco, CA
- 50 *Effect of individual vs dyadic relapse prevention on stress levels of caregivers of alcohol-dependent subjects: Correlates of caregiver stress*
P. Nattala¹, A. Nagarajaiah², P. Murthy², ¹Psychiatry, Washington University, St. Louis, MO, ²National Institute of Mental Health and Neurosciences, Bangalore, India

GAMBLING

- 51 *Gender differences in psychosocial stress and in its relationship to gambling urges in individuals with pathological gambling*
E. Tschibelu, K. Lindsey, I. Elman, McLean Hospital, Belmont, MA
- 52 *The impact of a curriculum infusion on college students' knowledge and attitudes toward problem gambling*
M. L. Shadley¹, M. C. Leone¹, J. A. Hartje¹, D. F. Quick², A. D. Broadus¹, N. A. Roget¹, ¹Center for the Application of Substance Abuse Technologies, University of Nevada, Reno, Reno, NV, ²Reno Problem Gambling Center, Reno, NV
- 53 *Problem gambling and risk behavior: Results from a baseline study at the University of Iowa*
A. H. Skinstad^{2,1}, S. Hansen³, T. Bergthold^{2,1}, K. Summers^{2,1}, ¹Community and Behavioral Health, University of Iowa, College of Public Health, Iowa City, IA, ²PrairieLands Addiction Technology Transfer Center, Iowa City, IA, ³Student Health, University of Iowa, Iowa City, IA
- 54 *Validity of the gambling section for the French adaptation of the Addiction Severity Index*
C. Denis¹, G. Bouju², M. Bronnec², M. Fatseas¹, M. Guillou², J. Venisse², M. Auriacombe¹, ¹Addiction Psychiatry EA4139/INSERM-IFR99, Université Victor Segalen Bordeaux 2, Bordeaux, France, ²Centre de Référence sur le Jeu Excessif, CHU de Nantes, Nantes, France

- 55 *Describing the gambling treatment workforce: A survey to explore an unexamined population*
T. L. Bergthold^{1,2}, A. H. Skinstad^{1,2}, K. M. Summers^{1,2}, ¹Community and Behavioral Health, University of Iowa, College of Public Health, Iowa City, IA, ²Prairieland Addictions Technology Transfer Center, Iowa City, IA

PSYCHIATRIC COMORBIDITY

- 56 *An exploratory qualitative study on disease models and perceptions towards cannabis use among patients with schizophrenia*
M. Liebrecht, A. Buadze, R. Stohler, Research Group on Substance Use Disorders, Psychiatric University Clinic, Zurich, Switzerland
- 57 *Depressed cocaine-dependent and cannabis-dependent individuals seeking treatment: Comparison of psychiatric symptomatology*
B. J. Wyman, L. C. Sanfilippo, D. J. Brooks, W. N. Raby, E. V. Nunes, J. J. Mariani, F. R. Levin, Psychiatry, New York State Psychiatric Institute, New York, NY
- 58 *Mental health outcomes and drug use trajectories among adults in the general population (the CARDIA study)*
Y. Khodneva¹, M. Pletcher², B. Jones³, J. Tucker¹, S. Kertesz^{1,4}, ¹University of Alabama Birmingham, Birmingham, AL, ²University of California, San Francisco, CA, ³Carnegie-Mellon University, Pittsburgh, PA, ⁴VA Medical Center, Birmingham, AL
- 59 *Psychological symptom severity in a residential sample of women with substance use disorders*
H. Lee, S. Meshberg-Cohen, D. Svikis, Psychology, Virginia Commonwealth University, Richmond, VA
- 60 *Expressive writing as a therapeutic adjunct to treatment for drug-dependent women: Short-term outcomes from a randomized clinical trial*
S. Meshberg-Cohen, D. Nilson, K. Suwal, H. Lee, D. Svikis, Psychology, Virginia Commonwealth University, Richmond, VA
- 61 *Concurrent treatment of substance use disorder and Post Traumatic Stress Disorder: A treatment that works for both genders?*
S. Merz¹, K. L. Mills¹, J. Rosenfeld¹, E. Barrett¹, M. Teesson¹, S. Back², C. Sannibale¹, A. Baker³, S. Hopwood⁴, K. Brady², ¹National Drug and Alcohol Research Centre, University of New South Wales, Sydney, NSW, Australia, ²Psychiatry, Medical University of South Carolina, Charleston, SC, ³Centre for Brain and Mental Health Research, University of Newcastle, Newcastle, NSW, Australia, ⁴Centre for Traumatic Stress, Westmead Hospital, Westmead, NSW, Australia
- 62 *Alcohol dependence and Post Traumatic Stress Disorder: Craving and alcohol-related physiological reactivity to trauma and alcohol cues*
S. F. Coffey¹, J. A. Schumacher¹, A. M. Henslee¹, P. R. Stasiewicz², ¹Psychiatry and Human Behavior, The University of Mississippi Medical Center, Jackson, MS, ²Research Institute on Addictions, University at Buffalo, Buffalo, NY
- 63 *Effect of traumatic event re-exposure and Post Traumatic Stress Disorder on Substance Use Disorder treatment outcomes*
J. M. Peirce, K. B. Stoller, V. L. King, R. K. Brooner, Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD
- 64 *Trauma exposure, distress and self-reported drug use*
A. Umbricht¹, D. A. Tompkins¹, E. L. Winstanley², E. C. Strain¹, M. Z. Mintzer¹, J. M. Peirce¹, G. E. Bigelow¹, ¹Psychiatry, Johns Hopkins University, Baltimore, MD, ²Psychiatry, Lindner Center Of Hope, Mason, OH

- 65 *Substance use and risky sexual partners in women with borderline personality disorder*
U. Feske, N. De Genna, T. Angiolieri, M. Gold, M. Cornelius, University of Pittsburgh, Pittsburgh, PA
- 66 *Attachment and alexithymia in alcohol-misusing outpatients*
F. A. Thorberg^{1,2}, R. M. Young^{1,5}, K. A. Sullivan^{1,2}, M. Lyvers³, J. P. Connor^{4,5}, G. Feeney⁵, ¹Inst Hlth & Biomed Innovat, Qld Univ of Technol, Brisbane, QLD, Australia, ²School of Psych and Counselling, Qld Univ of Technol, Brisbane, QLD, Australia, ³Dep Psych, Bond Univ, Gold Coast, QLD, Australia, ⁴Discipline of Psychiatry, Univ of Qld, Brisbane, QLD, Australia, ⁵Alcohol & Drug Assessment Unit, Princess Alexandra Hosp, Brisbane, QLD, Australia
- 67 *Exploring NEO personality factors in methadone maintenance treatment patients*
G. Staios^{1,2}, A. K. Elkader^{1,2}, B. Brands^{1,2,3}, M. Zack^{1,2}, R. Callaghan^{1,2}, B. A. Sproule^{1,2}, ¹Centre for Addiction and Mental Health, Toronto, ON, Canada, ²University of Toronto, Toronto, ON, Canada, ³Health Canada, Ottawa, ON, Canada
- 68 *Psychopathy, vulnerable attachment styles, drug abuse and their relations to patients' outcome in methadone maintenance treatment*
D. Potik^{1,2}, Y. Abramsohn¹, E. Peles¹, S. Schreiber^{2,1}, M. Adelson¹, ¹Dr. Miriam & Sheldon G. Adelson Clinic for Drug Abuse, Treatment and Research, Tel Aviv, Israel, ²Psychiatry, Tel Aviv Sourasky Medical Center, Tel-Aviv, Israel
- 69 *A preliminary investigation into the role of family environment, personality, and positive schizotypy in predicting substance use disorders in social anhedonics and controls*
M. N. Sargeant, J. Blanchard, Psychology, University of Maryland, College Park, College Park, MD
- 70 *Cessation treatment for smokers with serious mental illness*
L. A. Zawertailo^{1,2}, S. Voci¹, B. Brands², P. Selby^{1,3,4}, ¹Addictions Program, Centre for Addiction and Mental Health, Toronto, ON, Canada, ²Pharmacology and Toxicology, University of Toronto, Toronto, ON, Canada, ³Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada, ⁴Family and Community Medicine, University of Toronto, Toronto, ON, Canada
- 71 *Psychiatric comorbidity, severity of addiction and quality of life in opiate-dependent treated patients: A one-year prospective study*
E. Lavie¹, C. Denis¹, M. Fatseas¹, J. Daulouede^{2,1}, M. Auriacombe^{1,2}, ¹Addiction Psychiatry EA4139/INSERM-IFR99, Universite Victor Segalen Bordeaux 2, Bordeaux, France, ²Bizia, Bayonne, France
- 72 *Comorbid patients improve on substance use and psychological symptoms in psychiatric day treatment*
A. Rosenblum¹, S. Magura², ¹National Development and Research Institutes, New York, NY, ²Western Michigan University, Kalamazoo, MI
- 73 *Effects of Motivational Interviewing and Cognitive Behavioral Therapy on people with co-occurring disorders*
E. Schoener, C. Madeja, J. Janisse, Psychiatry, Wayne State University, Detroit, MI
- 74 *Neighborhood factors predicting treatment compliance and rehospitalization for dually diagnosed patients*
G. Stahler¹, J. Mennis¹, R. Cotlar¹, D. A. Baron², ¹Geography and Urban Studies, Temple University, Philadelphia, PA, ²Psychiatry and Behavioral Sciences, Temple University, Philadelphia, PA

PRESCRIPTION DRUG ABUSE

- 75 *Feeling and performing better following placebo methylphenidate: The role of expectancy*
A. Looby, M. Earleywine, Psychology, University at Albany, Albany, NY
- 76 *Phase II, randomized, double-blind study in fasted and fed healthy subjects to evaluate the dose-response for flushing, tolerability, and safety of escalating doses of niacin*
R. Wood¹, R. Spivey², R. Colucci³, ¹i3 Statprobe, Chapel Hill, NC, ²Acura Pharmaceuticals, Inc., Palatine, IL, ³Colucci & Assoc., LLC, Newtown, CT
- 77 *Abuse liability of IV buprenorphine vs buprenorphine-naloxone in buprenorphine-dependent individuals*
S. D. Comer^{1,2}, M. A. Sullivan^{1,2}, S. K. Vosburg², J. M. Manubay^{1,2}, Z. D. Cooper^{1,2}, P. A. Saccone², ¹Psychiatry, Columbia University, New York, NY, ²New York State Psychiatric Institute, New York, NY
- 78 *Relative reinforcing effects of oxycodone and morphine in heroin-dependent volunteers*
Z. D. Cooper^{1,2}, M. A. Sullivan^{1,2}, S. K. Vosburg^{1,2}, J. M. Manubay^{1,2}, W. J. Kowalczyk^{1,2}, P. A. Saccone^{1,2}, S. D. Comer^{1,2}, ¹Psychiatry, Columbia University, New York, NY, ²New York State Psychiatric Institute, New York, NY
- 79 *ACCESS 2008: Preliminary results from a clinical trial to assess, stratify, and monitor the risk of prescription opioid abuse and misuse in the primary care setting*
S. Siegel¹, B. Setnik¹, C. Roland¹, J. Cleveland¹, R. Colucci², L. Wase¹, ¹King Pharmaceuticals®, Inc., Bridgewater, NJ, ²Colucci & Associates, LLC, Newtown, CT
- 80 *Characterization of adolescent prescription drug abuse as reported in RADARS System Poison Center data*
A. E. Zosel^{1,2}, M. Kirtland¹, J. E. Bailey¹, R. Dart^{1,2}, ¹Rocky Mountain Poison and Drug Center, Denver, CO, ²University of Colorado Health Sciences Center, Denver, CO
- 81 *Urban-rural differences in risk and protective factors for youth abuse of opioid analgesics*
M. Smith¹, R. Jain¹, B. Hosmane², A. Best¹, ¹Risk Management, Pain Care, General Practice Research Database, Abbott Laboratories, Abbott Park, IL, ²Biostatistics, Northern Illinois University, Dekalb, IL
- 82 *Cohort differences in nonmedical prescription drug use in adolescence*
S. S. Martins¹, S. G. Severtson¹, G. P. Lee¹, C. L. Storr^{2,1}, ¹Mental Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, ²Family and Community Health, University of Maryland School of Nursing, Baltimore, MD
- 83 *Patterns of prescription drug misuse among high-risk youth*
S. Lankenau^{1,2}, A. Harocopos³, M. Treese², J. Jackson Bloom², C. Shin², L. Goldsamt³, M. Clatts³, ¹Pediatrics, University of Southern California, Los Angeles, CA, ²Community Health Outcomes and Intervention Research, Childrens Hospital Los Angeles, Hollywood, CA, ³National Development and Research Institutes, New York, NY
- 84 *Does prescription drug abuse take a holiday?*
H. A. Spiller¹, S. S. Spiller¹, J. E. Bailey², R. C. Dart^{2,3}, ¹Kentucky Regional Poison Center, Louisville, KY, ²Rocky Mountain Poison and Drug Center, Denver, CO, ³University of Colorado Health Sciences, Denver, CO
- 85 *Factors associated with nonmedical use of prescription drugs*
G. G. Homish^{1,2}, K. E. Leonard^{2,3}, J. R. Cornelius⁴, ¹Health Behavior, The State University of New York at Buffalo, Buffalo, NY, ²Research Institute on Addictions, The State University of New York at Buffalo, Buffalo, NY, ³Psychiatry, The State University of New York at Buffalo, Buffalo, NY, ⁴Psychiatry, University of Pittsburgh, Pittsburgh, PA

- 86 *Gender differences in the prevalence of prescription opioid use among inpatients with substance use disorders*
R. Payne¹, S. E. Back¹, A. E. Waldrop², K. T. Brady¹, ¹Psychiatry and Behavioral Science, Medical University of South Carolina, Charleston, SC, ²Psychiatry, University of California, San Francisco, CA
- 87 *Does day of week impact prevalence of prescription drug abuse?*
J. E. Bailey¹, H. A. Spiller², S. S. Spiller², R. C. Dart^{1,3}, ¹Rocky Mountain Poison and Drug Center, Denver, CO, ²Kentucky Regional Poison Center, Louisville, KY, ³University of Colorado Health Sciences Center, Denver, CO
- 88 **WITHDRAWN**
- 89 *Non-medical use of prescription opioids among veterans with and without HIV: Pain, psychiatric, medical and substance use correlates*
D. Barry¹, J. Goulet², A. Heapy², R. Kerns², A. Justice², D. Fiellin¹, ¹Yale University School of Medicine, New Haven, CT, ²West Haven VA, West Haven, CT

HIV/HCV

- 90 *HIV prevention using a dyadic and network intervention: The STEP study*
C. A. Latkin, K. Tobin, S. J. Kuramoto, Health Behavior and Society, Johns Hopkins University, Baltimore, MD
- 91 *Social network factors influencing recent HIV testing in drug users*
A. E. Rudolph^{1,2}, K. Jones¹, C. Fuller¹, ¹Johns Hopkins School of Public Health, Baltimore, MD, ²New York Academy of Medicine, New York City, NY
- 92 *Prescription opiate use as a protective factor for other drug and alcohol use in HIV-positive methadone patients*
S. E. Larios, V. Gruber, E. Powelson, J. L. Sorensen, Psychiatry, University of California San Francisco, San Francisco, CA
- 93 *Modified Therapeutic Community for persons with HIV/AIDS and co-occurring disorders*
J. Sacks, K. McKendrick, Center for the Integration of Research and Practice, National Development and Research Institutes, Inc., New York, NY
- 94 *Effect of mixed drug use on HIV serostatus and life functioning in Ukrainian injection drug users*
O. Zezyulin¹, J. Schumacher², K. Dumchev², S. Chandler¹, P. Slobodyanyuk², L. Moroz³, ¹Vinnitsa Regional Narcological Dispensary, Vinnitsya, Ukraine, ²University of Alabama at Birmingham, Birmingham, AL, ³Vinnitsya National Medical University Pirogov, Vinnitsya, Ukraine
- 95 *Substance use and the quality of patient-provider communication in HIV clinics*
P. T. Korthuis¹, M. C. Beach², S. Saha¹, R. D. Moore², J. Cohn³, V. Sharp⁴, D. McCarty¹, ¹Oregon Health and Science University, Portland, OR, ²Johns Hopkins University, Baltimore, MD, ³St. Luke's Roosevelt Hospital, New York, NY, ⁴Wayne State University, Detroit, MI
- 96 *Impact of the drug use and substitution treatments on the antiviral treatment of chronic hepatitis C analysis of adherence, virological response and quality of life (CHEOBS)*
P. Melin^{1,3}, J. Lang^{2,3}, D. Ouzan³, M. Choustermann³, M. Varastet³, M. Rotily³, T. Fontanges³, P. Marcellin³, P. Cacoub³, ¹General Hospital, Saint dizier, France, ²Hopital, Erstein, France, ³Cheobs Group, Paris, France

- 97 *Antiretroviral use among HIV+ injection drug users: The role of methadone maintenance and provider engagement*
A. R. Knowlton¹, J. Arnsten², J. Wilkinson³, S. Shade⁴, D. Purcell⁵, ¹Johns Hopkins University, Baltimore, MD, ²Albert Einstein College of Medicine, Bronx, NY, ³University of Miami, Miami, FL, ⁴University of California, San Francisco, CA, ⁵CDC, Atlanta, GA
- 98 *Characteristics of heroin users in methadone maintenance treatment clinics in Wuhan, China*
W. Zhou¹, P. Liu¹, L. Luo¹, R. S. Schottenfeld², M. C. Chawarski², ¹Division of HIV/AIDS Prevention, Wuhan Center for Disease Control and Prevention, Wuhan, China, ²Psychiatry, Yale University School of Medicine, New Haven, CT
- 99 *Patterns of cognitive impairments among heroin and cocaine users and the association with preexisting developmental conditions and hepatitis status*
S. G. Severtson, S. L. Hedden, D. Whitaker, W. W. Latimer, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD
- 100 *An investigation of sexual partnerships and HCV prevalence among regular users of cocaine and heroin*
D. Whitaker, B. Mancha, L. Floyd, S. L. Hedden, W. W. Latimer, Mental Health, Johns Hopkins School of Public Health, Baltimore, MD
- 101 *Relapse and recovery among hepatitis C-infected patients with a history of cocaine or heroin use*
A. Y. Walley¹, T. Heeren², C. Bliss², P. R. Skolnik¹, S. Stuver², D. Nunes¹, D. Cotton¹, ¹Boston University School of Medicine, Boston, MA, ²Boston University School of Public Health, Boston, MA
- 102 *Hepatitis C Virus knowledge, attitudes, beliefs, and experiences in methadone treatment patients with HCV infection*
K. M. Canfield¹, S. L. Batki^{2,3,1}, E. Smyth¹, R. Ploutz-Snyder⁴, ¹Psychiatry, State University of New York Upstate Medical University, Syracuse, NY, ²Psychiatry, University of California, San Francisco, CA, ³San Francisco VA Medical Center, San Francisco, CA, ⁴NASA, Houston, TX
- 103 *Medical comorbidity and HCV treatment eligibility in Methadone Maintenance Treatment vs non-Methadone Maintenance Treatment patients seeking treatment for HCV infection*
S. L. Batki^{1,2,3}, K. M. Canfield³, E. Smyth³, R. J. Ploutz-Snyder⁴, ¹Psychiatry, University of California, San Francisco, San Francisco, CA, ²San Francisco VA Medical Center, San Francisco, CA, ³Psychiatry, State University of New York Upstate Medical University, Syracuse, NY, ⁴NASA, Houston, TX
- 104 *Illicit drug use and dependence among patients referred to a hepatology clinic in an urban academic medical center*
C. Jackson¹, J. Varon¹, A. Ho¹, A. Talal², M. J. Kreek¹, ¹The Laboratory of the Biology of Addictive Diseases, Rockefeller University, New York, NY, ²Center for the Study of Hepatitis C, Weill Cornell Medical College, New York, NY
- 105 *Prevalence and factors associated with HCV-positive saliva test in injecting drug users in North and East France*
J. Harbonnier^{1,2}, E. Lavie³, M. Auriacombe³, ¹Centre Boris Vian, Lille, France, ²North and East IVDU HCV Study Group, Lille, France, ³Addiction Psychiatry, Universite de Bordeaux, Bordeaux, France

TREATMENT PROVIDERS AND PROGRAMS

- 106 *Staff reports of program structure in relation to client retention, alliance, and drug/alcohol outcomes*
B. McClure¹, A. Kulaga¹, J. Rotrosen¹, R. Forman³, C. Temes², S. Ring-Kurtz², R. Gallop², P. Crits-Christoph², ¹New York University School of Medicine, New York, NY, ²University of Pennsylvania, Philadelphia, PA, ³Alkermes, Inc., Boston, MA
- 107 *The impact of a three-hour curriculum infusion on university students' knowledge and attitudes about the neuroscience of addiction: Results from the two-year NIDA Enters College Project*
N. A. Roget¹, J. A. Hartje¹, M. S. Berry¹, W. L. Woods¹, A. D. Broadus¹, P. Riggs², ¹Center for the Application of Substance Abuse Technologies, University of Nevada, Reno, NV, ²University of Colorado Health Sciences Center, Denver, CO
- 108 *A comparison of three methods for training South African substance abuse counselors in Cognitive Behavioral Therapy*
R. Sodano¹, D. Watson², S. Rataemane³, L. Rataemane⁴, R. Rawson¹, ¹University of California & Integrated Substance Abuse Program, Los Angeles, CA, ²FRI, Los Angeles, CA, ³University of Limpopo, Sovenga, South Africa, ⁴MEHADIC, Pretoria, South Africa
- 109 *Outcomes of a Swiss practitioner network survey on the current use of U.S. treatment approaches to cocaine addiction*
R. Stohler¹, M. P. Schaub^{1,2}, T. Berthel¹, ¹Psychiatric University Hospital, Zurich, Switzerland, ²Research Institute for Public Health and Addiction, Zurich, Switzerland
- 110 *Treatment vs non-treatment groups: Validation of the Addiction Belief Inventory*
A. D. Broadus¹, J. A. Hartje¹, N. A. Roget¹, S. S. Clinkinbeard², ¹Center for the Application of Substance Abuse Technologies, University of Nevada, Reno, NV, ²University of Nebraska, Omaha, NE
- 111 *Attitudes toward 12-step groups and referral practices in a culture naive to 12-step ideology*
J. Vederhus¹, T. Clausen^{1,2}, A. Laudet³, O. Kristensen¹, ¹Addiction Unit, Sørlandet Hospital, Kristiansand, Norway, ²Norwegian Centre for Addiction Research (SERAF), Institute of Psychiatry, University of Oslo, Oslo, Norway, ³C-STAR Studies on Recovery, National Development and Research Institutes, Inc., New York, NY
- 112 *Field clinician reports of implementation of evidence-based practice*
C. Barrick¹, G. Homish², ¹Research Institute on Addictions, University at Buffalo, Buffalo, NY, ²University at Buffalo, Buffalo, NY
- 113 *Substance abuse treatment needs, service utilization, and the role of culture among American Indians/Alaska Natives in recovery: Perspectives of clients and service providers*
C. Teruya, D. Dickerson, F. Wu, Y. Hser, University of California Integrated Substance Abuse Programs, Los Angeles, CA
- 114 *Problem severity and treatment needs among Native American/Alaska Native and Asian American/Pacific Islander drug abusers*
F. Wu¹, Y. Hser², P. Marinelli-Casey², R. Rawson², ¹Social Welfare, UCLA, Los Angeles, CA, ²Integrated Substance Abuse Programs, University of California, Los Angeles, CA
- 115 *Racial disparities in residential substance abuse treatment programs*
A. Duncan¹, G. Melnick², ¹Behavioral Science Training in Drug Abuse Research, Public Health Solutions, New York, NY, ²Center for the Integration of Research and Practice, National Development and Research Institutes, Inc., New York, NY
- 116 *Experiential avoidance predicts substance abuse treatment entry*
K. L. Williams^{1,2}, K. M. Carpenter^{1,2}, F. R. Levin^{1,2}, E. V. Nunes^{1,2}, ¹Psychiatry, Columbia University, New York, NY, ²Substance Abuse, New York State Psychiatric Institute, New York, NY

- 117 *Predictors of treatment retention in a community substance abuse clinic*
R. Vandrey¹, J. Fry¹, P. Stabile², M. Stitzer¹, ¹Johns Hopkins University, Baltimore, MD,
²Harbel Treatment and Recovery Center, Baltimore, MD

EPIDEMIOLOGY I

- 118 *Five-year follow-up of a group of Brazilian ecstasy users: Is MDMA use a transient phenomenon?*
M. C. Battisti, A. R. Noto, Psychobiology, UNIFESP, Sao Paulo, Brazil
- 119 *Brazilian roadside survey for alcohol and other drugs – interim analysis*
F. Pechansky¹, R. DeBoni¹, D. Benzano¹, C. G. Leukefeld², ¹Psychiatry, Center for Drug and Alcohol Research, UFRGS, Porto Alegre, Brazil, ²Behavioral Sciences, Center for Drug and Alcohol Research, University of Kentucky, Lexington, KY
- 120 *Influences of medicines, stress events, and narcissistic personality on relapse risk in Japanese alcohol-dependent inpatients*
Y. Ogai¹, Y. Kakibuchi², E. Senoo¹, K. Ikeda¹, ¹Tokyo Institute of Psychiatry, Tokyo, Japan,
²Narimasu Kosei Hospital, Tokyo, Japan
- 121 *Epidemiology of substance use disorders in Australia: Findings from the 2007 National Survey of Mental Health and Wellbeing*
T. Slade, M. Teesson, A. Johnston, K. Mills, National Drug and Alcohol Research Centre,
University of New South Wales, Sydney, NSW, Australia
- 122 *The prevalence and onset of alcohol use disorders during older adulthood: Findings from a 3-year national study in the United States*
S. Novak¹, E. Johnson¹, L. Simoni-Wastila², ¹Behavioral Epidemiology, RTI International,
Research Triangle Park, NC, ²School of Pharmacy, University of Maryland, Baltimore, MD
- 123 *Leisure time activities that predict initiation, persistence, progression, and reduction of cannabis use: A prospective, population-based panel survey*
M. P. Schaub¹, B. Annaheim², M. Mueller³, D. Schwappach¹, G. Gmel², ¹Research Institute for Public Health and Addiction, Zurich, Switzerland, ²Swiss Institute for the Prevention of Alcohol and Drug Problems, Lausanne, Switzerland, ³Social and Market Research Institute, Zurich, Switzerland
- 124 *Drug use in individuals screened for participation in human behavioral pharmacology laboratory studies*
F. Wagner¹, W. W. Stoops¹, C. R. Rush^{1,2,3}, ¹Behavioral Science, University of Kentucky,
Lexington, KY, ²Psychiatry, University of Kentucky, Lexington, KY, ³Psychology, University of Kentucky, Lexington, KY
- 125 *Validating self-reports of illegal drug use to evaluate National Drug Control Policy*
S. Magura, Evaluation Center, Western Michigan University, Kalamazoo, MI
- 126 *Characteristics of opiate injection drug users with and without amphetamine type stimulant abuse in Kuala Lumpur, Malaysia*
M. Mazlan¹, V. Balasingam Kasinather², M. C. Chawarski³, R. S. Schottenfeld³, ¹Substance Abuse Center, Muar, Malaysia, ²University Sains Malaysia, Penang, Malaysia, ³Psychiatry, Yale University School of Medicine, New Haven, CT
- 127 *Regional variations and factors associated with late injection drug use initiation in California*
R. Bluthenthal¹, L. Wenger², P. Bourgois³, M. Iguchi⁴, A. Kral², ¹RAND Corporation, Santa Monica, CA, ²RTI International, San Francisco, CA, ³University of Pennsylvania, Philadelphia, PA, ⁴University of California, Los Angeles, CA
- 128 *Spatial analysis of injection drug use, drug treatment, and HIV in Baltimore City*
M. Smart, A. Milam, D. Whitaker, C. Furr-Holden, Mental Health, Johns Hopkins School of Public Health, Baltimore, MD

- 129 *Disaggregating a neighborhood perception scale by heroin dependence*
J. Gass, D. C. Ompad, V. Nandi, D. Vlahov, Center for Urban Epidemiologic Studies, New York Academy of Medicine, New York, NY
- 130 *Reductions in heroin use frequency following Hurricane Katrina*
B. D. Johnson¹, E. Dunlap¹, N. Tiburcio¹, R. Twiggs², ¹Special Populations Research, National Development and Research Institutes, New York, NY, ²School of Social Work, Fordham University, New York, NY
- 131 *Motivators of change among drug-using New Orleans evacuees*
R. Twiggs², N. Tiburcio¹, B. D. Johnson¹, E. Dunlap¹, ¹Special Populations Research, National Development and Research Institutes, New York, NY, ²Social Work, Fordham University, New York, NY
- 132 *Methamphetamine-related vs cocaine-related emergency department visits in urban vs rural counties in California*
T. J. Florence², K. G. Heinzerling¹, A. Swanson¹, S. Shoptaw¹, ¹Family Medicine, University of California, Los Angeles, CA, ²University of Southern California, Los Angeles, CA
- 133 **WITHDRAWN**
R. Falck, R. Carlson, J. Wang, Community Health, Wright State University School of Medicine, Dayton, OH
- 134 *Quality of life and severity of problems related to alcohol misuse*
S. Faller, F. Kessler, N. S. Rocha, D. Benzano, M. P. Santos, F. Pechansky, Center for Drug and Alcohol Research - Federal University of Rio Grande do Sul, Porto Alegre, Brazil
- 135 *Higher psychiatric comorbidity and severity of problems among substance abusers with ADHD*
F. H. Kessler, S. Faller, D. B. Benzano, H. Moura, C. Szobot, L. V. Diemen, M. P. Santos, F. Pechansky, Psychiatry, Federal University of Rio Grande do Sul, Porto Alegre, Brazil

Symposium VIII

Rose Ballroom A
10:00 AM - 12:00 PM

THIS IS YOUR BRAIN ON GAMBLING (AND DRUGS)... PARSING DRUG AND ADDICTION INFLUENCES BY CONTRASTING "BEHAVIORAL" AND DRUG ADDICTIONS

Chairs: Marc N. Potenza and Robert Rogers

- 10:00 *The clinical features and neurobiological substrates of casino gambling*
Robert Rogers, Oxford University and Warneford Hospital, Oxford, United Kingdom
- 10:25 *Neural correlates of decision-making in substance-dependent subjects with and without pathological gambling*
Jody Tanabe, University of Colorado at Denver Health Sciences, Aurora, CO
- 10:50 *Pathological gambling and substance use disorders: Similarities and differences in neurocognitive and neuroimaging parameters*
Wim van den Brink, Academic Medical Center University of Amsterdam, Amsterdam, Netherlands
- 11:15 *Problem gamblers share deficits in impulsive decision-making with substance-dependent subjects*
Luke Clark, University of Cambridge, Cambridge, United Kingdom
- 11:40 *Discussant*
Marc N. Potenza, Yale School of Medicine, New Haven, CT

Symposium IX

Bonanza

10:00 AM - 12:00 PM

THE ACETYLCHOLINE SYSTEM AS THERAPEUTIC TARGET IN DRUG DEPENDENCE: MOLECULAR BIOLOGY, NEUROCHEMISTRY, ANIMAL AND HUMAN BEHAVIORAL PHARMACOLOGY

Chairs: Gerald Zernig and Richard De La Garza, II

- 10:00 *Acetylcholinergic receptors and cocaine addiction: Neuroanatomical, genomic and proteomic perspectives*
Scott E. Hemby, Wake Forest University School of Medicine, Winston-Salem, NC
- 10:25 *Activation of nicotinic and muscarinic acetylcholine receptors in nucleus accumbens core are necessary for the acquisition of drug seeking but not food reinforcement*
Gerald Zernig, Experimental Psychiatry Unit, Medical University Innsbruck, Innsbruck, ACT, Australia
- 10:50 *Sustained decreases in cocaine self-administration following chronically administered acetylcholinesterase inhibitors*
Kenneth Grasing, Substance Abuse Research Laboratory, Kansas City VA Medical Center, Kansas City, MO
- 11:15 *Laboratory-based clinical evaluation of the safety and preliminary efficacy of acetylcholinesterase inhibitors as a treatment for methamphetamine dependence*
Richard De La Garza, II, Baylor College of Medicine, Houston, TX
- 11:40 *Limbic disruptions identified by cholinergic probes in cocaine-addicted subjects*
Bryon Adinoff, University of Texas Southwestern Medical Center, VA North Texas Health Care System, Dallas, TX

Oral Communications 10

Ponderosa B

10:00 AM - 12:00 PM

TAKING THE POT: CANNABINOIDS

Chairs: Sandra P. Welch and Prashanthi N. Mainampally

- 10:00 *A BOLD fMRI study of cannabinoid action in rat brain*
A. S. Bloom¹, H. Cios¹, W. Collier¹, K. Douville¹, S. Durgerian¹, S. J. Li¹, L. Chang², ¹Medical College of Wisconsin, Milwaukee, WI, ²University of Hawaii, Honolulu, HI
- 10:15 *Endocannabinoid alterations in the hippocampus and nucleus accumbens following chronic cocaine treatment, during withdrawal and following cocaine challenge*
S. L. Amen, C. J. Hillard, Pharmacology and Toxicology, Medical College of Wisconsin, Milwaukee, WI
- 10:30 *Forced Swim Test and the endogenous cannabinoid receptor system: Effects of an anandamide reuptake inhibitor and a fatty acid amide hydrolase metabolism inhibitor*
T. Culmer¹, L. Miller², L. Dykstra^{1,2}, ¹Pharmacology, UNC-Chapel Hill, Chapel Hill, NC, ²Psychology, UNC-Chapel Hill, Chapel Hill, NC
- 10:45 *Interaction of SIP and FTY720 with opioid systems in the production of antinociception and opioid tolerance*
S. P. Welch, D. E. Selley, L. J. Sim-Selley, Pharmacology and Toxicology, Virginia Commonwealth University, Richmond, VA

- 11:00 *Abuse potential of taranabant, a cannabinoid 1 receptor inverse agonist: A randomized, double-blind, crossover study in recreational polydrug users*
K. A. Schoedel¹, B. Chakraborty¹, C. Addy², K. Rosko², A. Maes², N. Chen¹, E. Sellers¹,
¹Clinical Pharmacology, Kendle Early Phase, Toronto, ON, Canada, ²Merck & Co, Inc, Whitehouse Station, NJ
- 11:15 *Persistence of cannabis use once it starts: Initial findings from epidemiological research*
P. N. Mainampally, J. C. Anthony, Michigan State University, East Lansing, MI
- 11:30 *Is early alcohol and nicotine use associated with the risk of cannabis use and transition to cannabis use disorders in adolescence?*
S. Behrendt¹, H. U. Wittchen^{1,2}, M. Höfler¹, R. Lieb^{2,3}, K. Beesdo¹, ¹Institute of Clinical Psychology and Psychotherapy, Technische Universität Dresden, Dresden, Germany, ²Max Planck Institute of Psychiatry, Munich, Germany, ³Institute of Psychology, University of Basel, Basel, Switzerland
- 11:45 *The role of temperament in the relationship between early onset of cigarette smoking and cannabis use. The TRAILS study*
H. E. Creemers¹, T. Korhonen^{2,3}, J. Kaprio^{2,3}, W. Vollebergh^{4,5}, J. Ormel⁶, F. Verhulst¹, A. Huizink^{1,6}, ¹Child and Adolescent Psychiatry, Erasmus Medical Center/Sophia Children's Hospital, Rotterdam, Netherlands, ²Public Health, University of Helsinki, Helsinki, Finland, ³Mental Health and Alcohol Research, National Public Health Institute, Helsinki, Finland, ⁴Netherlands Institute of Mental Health and Addiction, Utrecht, Netherlands, ⁵Social Sciences, Utrecht University, Utrecht, Netherlands, ⁶University Medical Center Groningen, University of Groningen, Groningen, Netherlands

Symposium X

Rose Ballroom B
10:00 - 11:00 AM

RACIAL AND ETHNIC DISPARITIES IN SUBSTANCE ABUSE AND ADDICTION: NATIVE AMERICANS AND NATIVE HAWAIIANS

Chairs: Lula A. Beatty and Rumi Price

- 10:00 *Racial/ethnic health disparities in drug addiction: Highlights on Native Americans and Native Hawaiians*
Rumi Price, Washington University in St. Louis, School of Medicine, St. Louis, MO
- 10:20 *Can religious use of psychoactive substances reduce disparities in illicit and licit substance abuse among Native Americans?*
John H. Halpern, Harvard Medical School, McLean Hospital, Belmont, MA
- 10:40 *Physiological and neuroimaging abnormalities in Native Hawaiians exposed to methamphetamine*
William Haning, John A. Burns School of Medicine, University of Hawaii, Honolulu, HI

BADGES MUST BE WORN IN ALL SCIENTIFIC SESSIONS

Symposium XI

**Rose Ballroom B
11:15 AM - 12:15 PM**

HIV RISK PREVENTION IN THE NIDA CLINICAL TRIALS NETWORK

Chair: Raul Mandler

- 11:15 *Comparative HIV prevention effects between methadone maintenance and psychosocial outpatient programs for male drug users*
Donald A. Calsyn, Alcohol and Drug Abuse Institute, University of Washington, Seattle, WA
- 11:35 *Comparative HIV prevention intervention effects between methadone maintenance and psychosocial outpatient programs for female drug users*
Susan Tross, Columbia University, New York State Psychiatric Institute, New York, NY
- 11:55 *Discussant: Implications of the results of CTN protocols 0018 and 0019 for future HIV prevention interventions in drug abuse treatment protocols*
Lisa Metsch, University of Miami Miller School of Medicine, Miami, FL

Late-Breaking Research News

**Rose Ballroom A
12:15 - 1:35 PM**

Chair: Sari Izenwasser

- 12:15 *$\alpha 6\beta 2$ *nAChRs regulate progressive ratio responding for nicotine*
D. H. Brunzell, K. Boschen, E. S. Hendrick, P. Taylor, P. M. Beardsley, and J. M. McIntosh, Virginia Commonwealth University, Richmond, Virginia; University of Utah, Salt Lake City, Utah
- 12:20 *Smoking-associated cues decrease dopamine D2/3 binding potential in tobacco-dependent individuals: A preliminary [11C]-(+)-PHNO PET study*
L. Chiucciariello, I. Boileau, P. Rusjan, A. Wilson, S. Houle, L. Zawertailo, B. Busto, and B. Le Foll, Centre for Addiction and Mental Health, Pharmacology and Toxicology, University of Toronto, Pharmaceutical Sciences, University of Toronto, Canada
- 12:25 *Responses to smoking cues increase with duration of abstinence*
H. de Wit, G. Bedi, A.C. King, D.H. Epstein, S.J. Heishman, G. Marrone, and K.L. Preston, University of Chicago, IL, Columbia University, NY, NIDA Intramural Research Program, Baltimore, MD
- 12:30 *Cigarette smokers and non-smokers with serious mental illness: A cross-sectional comparison of neurocognitive function by diagnosis and smoking status*
D. Morisano, K.A. Sacco, and T.P. George, Division of Addiction Psychiatry, Psychiatry, University of Toronto, Canada, Schizophrenia Program, Centre for Addiction and Mental Health, Program for Research in Smokers with Mental Illness (PRISM), Psychiatry, Yale University
- 12:35 *(R)-cis-N-(2,3)-Dihydroxypropyl)-2,6-di-(4-methoxyphenylethyl)piperidine hemisulfate (UK-793A) selectively blocks methamphetamine reinforcement without producing tolerance in rats*
J. Beckmann, D. Horton, K. Siripurapu, E. Denehy, G. Zheng, P. Crooks, L. Dwoskin, and M. Bardo, University of Kentucky, KY
- 12:40 *Self-administered cocaine causes lasting increases in impulsive choice in a delay discounting task*
I.A. Mendez, N.W. Simon, N. Hart, M.R. Mitchell, J.R. Nation, P.J. Wellman, and B. Setlow, Psychology, Texas A&M University, TX

- 12:45 *Neural correlates of spatial learning in chronic cocaine users*
G. Tau, R. Marsh, F. Garcia, X. Hao, D. Xu, S. Yu, M. Packard, Z. Wang, Y. Duan, A. Kangarlu, F. Levin, D. Martinez, and B. Peterson, Division of Child and Adolescent Psychiatry, Division on Substance Abuse, Psychiatry, Columbia University and The New York State Psychiatric Institute, New York, NY, Psychology, Texas A&M University, College Station, TX
- 12:50 *Neurobehavioral plasticity in stimulant addiction: Initial results of executive function therapy*
W.K. Bickel and R. Yi, University of Arkansas for Medical Science, AK
- 12:55 *Third outpatient pharmacogenetic clinical trial of disulfiram (DS) for cocaine*
T.R. Kosten, X. Zhang, D. Nielsen, G. Wu, N. Rubio, W. Huang, G. Gonzalez, and J. Poling, Baylor College of Medicine, Psychiatry, ME DeBakey VA Medical Center, Houston, TX
- 1:00 *Abuse potential of nabiximols oromucosal spray in recreational marijuana users*
K. Schoedel, N. Chen, and E. Sellers, Kendle Early Phase, Toronto, Canada
- 1:05 *Sleep dysfunction during cannabis withdrawal*
R. Vandrey, U. McCann, M. Smith, and A. Budney, Johns Hopkins University School of Medicine, Baltimore, MD, and University of Arkansas for Medical Sciences, Little Rock, AR
- 1:10 *Cue reactivity in response to alcohol odors is associated with a reduction in brain activation in treatment-seeking chronic alcohol-dependent individuals: An fMRI study*
S.E. Lukas, S.B. Lowen, D. Penetar, K.P. Lindsey, J. Rodolico, W. Tartarini, R. MacLean, N. Conn, C. Palmer, and G. Mallya, Brain Imaging Center, McLean Hospital, Harvard Medical School, Belmont, MA
- 1:15 *Personality and alcohol dependence: A community-based study on older adults*
G. Narayanan, T. Oltmanns, and L.B. Cottler, Washington University, St. Louis, MO
- 1:20 *Gabapentin improves cold-pressor pain tolerance in methadone-maintained patients*
W. Ling, P.A. Compton, and P. Kehoe, Integrated Substance Abuse Programs, University of California, Los Angeles, CA, School of Nursing, University of California, Los Angeles, CA
- 1:25 *Pharmacy willingness to conduct random buprenorphine pill counts for office-based opioid dependence treatment practices*
M.R. Lofwall, M. J. Wunsch, and S.L. Walsh, Psychiatry, University of Kentucky, Lexington, KY, Behavioral Science, Center on Drug and Alcohol Research, University of Kentucky, Lexington, KY
- 1:30 *Delivering substance abuse treatment services in frontier states: Examining treatment costs and reimbursement structures*
J.A. Hartje, M. Zagidullin, N.A. Roget, W. Wendt, and A.H. Skinstad, University of Nevada, Reno; Signal Behavioral Health; University of Iowa, IA

Grant-Writing Workshop
(Pre-Registrants Only)

Genoa
1:30 - 4:00 PM

BADGES MUST BE WORN IN ALL SCIENTIFIC SESSIONS

FILM NIGHT

FIGHTING THE DRAGON WITH LUCK

**Celebrity Showroom
6:30 - 8:00 PM**

*A documentary about treatment of heroin addiction in Australia
Screening followed by discussion with Angelo Pricolo*

CLEAN AND SOBER (1988)

**Celebrity Showroom
8:00 - 10:00 PM**

Michael Keaton, Kathy Baker, Morgan Freeman

Workshop IX

**Rose Ballroom A
8:00 - 10:00 PM**

CAREER DEVELOPMENT: A PERSPECTIVE FROM JUNIOR AND SENIOR RESEACHERS

Chairs: Gerald McLaughlin, Scott Chen, Jose Ruiz and Elaine Lazar-Wesley
Speakers: Mary Jeanne Kreek, Hendree Jones, and David Herin

Workshop X

**Ponderosa B
8:00 - 10:00 PM**

MATHEMATICAL AND SIMULATION MODELING IN BIOLOGICAL AND EPIDEMIOLOGICAL STUDIES OF DRUG ADDICTION

Chairs: Georgiy Bobashev and Boris Gutkin

*A synthetic model of addiction and control theory
David Newlin, RTI International, Baltimore, MD*

*Computational models of nicotine addiction: From circuit dynamics to behavior
Boris Gutkin, Group for Neural Theory, DEC, ENS, Paris, France*

*Projecting risk factors into the future with agent-based modeling
Georgiy Bobashev, RTI International, Research Triangle Park, NC*

*Measuring levels of proteins by PET and other technologies: Is that the whole story?
Michael Kuhar, Emory University, Atlanta, GA*

*Physiologically based pharmacokinetic modeling of cocaine and other psychostimulants
Vladimir Tsibulsky, University of Cincinnati, Cincinnati, OH*

*Baseline differences in cortico-striatal-thalamic network coherence in chronic cocaine users
Colleen A. Hanlon, Wake Forest University School of Medicine, Winston Salem, NC*

Workshop XI

**Rose Ballroom B
8:00 - 10:00 PM**

COMMUNICATING THE RISKS OF OPIOID ANALGESICS: HOW CAN WE DO BETTER?

Chairs: Meredith Smith and Michael Wolf

Opioid analgesic risk communication to healthcare prescribers: Best practices

Gary Kreps, George Mason University, Fairfax, VA

Communicating the risks and benefits of opioid analgesics to pain patients

Lorraine Wallace, University of Tennessee Graduate School of Medicine-Knoxville,
Knoxville, TN

*The Internet as a communication tool for conveying risk information concerning opioid
analgesics: How best used, How best evaluated?*

Emil Chiauzzi, Inflexxion, Newton, MA

*Conveying information regarding the risks of opioid analgesics to the general public:
Challenges and opportunities*

Michael Wolf, Feinberg School of Medicine, Northwestern University, Chicago, IL

Workshop XII

**Bonanza
8:00 - 10:00 PM**

ADVANCES IN IMPLEMENTATION SCIENCE RELATED TO ADOLESCENT SUBSTANCE ABUSE TREATMENT

Chairs: Ashli J. Sheidow and Michael L. Dennis

Adolescent substance abuse treatment: Quality of implementation and outcome

Mark Lipsey, Vanderbilt Institute, Nashville, TN

*Therapist training and changes in knowledge for contingency management for adolescents and
their families*

Ashli J. Sheidow, MUSC, Charleston, SC

*A Phase 4 replication of MET/CBT5 in 36 sites to examine how findings vary by site, client
characteristics, and implementation fidelity*

Michael L. Dennis, Chestnut Health Systems, Normal, IL

*The relationship between exposure to A-CRA treatment procedures and adolescent substance
abuse treatment outcomes*

Susan H. Godley, Chestnut Health Systems, Normal, IL

Society for Adolescent Substance Abuse Treatment Effectiveness business meeting

Michael L. Dennis, Chestnut Health Systems, Normal, IL

BADGES MUST BE WORN IN ALL SCIENTIFIC SESSIONS

Public Policy Forum

Rose Ballroom A
8:30 - 9:55 AM

Chairs: Martin Iguchi and William Dewey

- 8:30 *Introduction*
Martin Iguchi
- 8:40 *Hope and change and biomedical research: The Obama Administration and the 111th Congress*
Ed Long
- 8:55 *Presentation of the Distinguished Service Award to William L. Dewey*
Introduction by Sharon L. Walsh
- 9:00 *The role of Friends of NIDA and CPDD in Public Policy*
William Dewey
- 9:15 *Reconsidering addiction treatment*
A. Thomas McLellan
- 9:45 *Discussion*

Symposium XII

Rose Ballroom A
10:00 AM - 12:00 PM

REGULATING NICOTINE IN TOBACCO PRODUCTS: STATE OF THE SCIENCE AND FUTURE POLICY

Chairs: Dorothy Hatsukami and Jack Henningfield

- 10:00 *Regulating the nicotine content of tobacco: Joining the science with policy*
Mitch Zeller, Pinney and Associates, Bethesda, MD
- 10:25 *Characterizing the effects of nicotine dose reduction on nicotine self-administration in animals*
Mark G. LeSage, Minneapolis Medical Research Foundation, Minneapolis, MN
- 10:50 *Reducing nicotine content in cigarettes: Effects on compensatory smoking*
Neal Benowitz, University of California, San Francisco, CA
- 11:15 *Denicotinized cigarettes as a cessation strategy*
Jed Rose, Center for Nicotine and Smoking Cessation Research, Duke University,
Durham, NC
- 11:40 *Discussant: Key issues and research recommendations*
Dorothy Hatsukami, Tobacco Use Research Center, Minneapolis, MN

Oral Communications 11

Ponderosa B
10:00 AM - 12:00 PM

UPPING THE ANTE: CRAVING STIMULANTS

Chairs: Yasmin Mashhoon and Anna Rose Childress

- 10:00 *Poor fronto-limbic connectivity: A brain endophenotype for rapid relapse to cocaine?*
J. J. Suh^{1,2}, R. N. Ehrman^{1,2}, Y. Li¹, Z. Wang¹, W. Jens¹, T. Franklin¹, A. Hole^{1,2}, M. Goldman¹,
C. P. O'Brien^{1,2}, A. R. Childress^{1,2}, ¹University of Pennsylvania, Philadelphia, PA, ²VA Medical
Center, Philadelphia, PA

- 10:15 *Circuits in methamphetamine cue craving and cue extinction*
R. Malcolm¹, X. Li¹, H. Myrick¹, S. Henderson¹, P. W. Kalivas², R. E. See², ¹Psychiatry, Medical University of South Carolina, Charleston, SC, ²Neurosciences, Medical University of South Carolina, Charleston, SC
- 10:30 *The rostral basolateral amygdala and prelimbic prefrontal cortex are serially connected to regulate reinstatement of cocaine-seeking behavior in rats*
Y. Mashhoon, A. M. Wells, K. M. Kantak, Psychology: Brain, Behavior, and Cognition, Boston University, Boston, MA
- 10:45 *Stimulation of medial prefrontal cortex 5-HT_{2C} receptors attenuates cocaine seeking, but not cocaine self-administration*
N. S. Pentkowski, F. Duke, S. Weber, E. C. Hamilton, L. A. Pockros, J. L. Neisewander, Psychology, Arizona State University, Tempe, AZ
- 11:00 *Enhanced brain metabolic effects of acute cocaine administration following an extended period of cocaine self-administration in nonhuman primates*
L. L. Howell^{1,2}, P. K. Henry¹, K. S. Murnane¹, J. R. Votaw^{1,3}, ¹Yerkes National Primate Research Center, Emory University, Atlanta, GA, ²Psychiatry and Behavioral Sciences, Emory University, Atlanta, GA, ³Radiology, Emory University, Atlanta, GA
- 11:15 *Dramatic elevations in extracellular glutamate within the medial prefrontal cortex of rats during extended access to cocaine self-administration*
J. DeMartini, G. A. Carosso, K. D. Lominac, A. W. Ary, K. K. Szumlinski, O. M. Ben-Shahar, Psychology, University California Santa Barbara, Santa Barbara, CA
- 11:30 *Cocaine-addicted individuals with prior trauma have a “cue-sensitive” brain*
A. Childress^{1,2}, C. A. Rudoy¹, J. J. Suh^{1,2}, Y. Li¹, Z. Wang¹, R. N. Ehrman^{1,2}, T. Franklin¹, M. Goldman¹, W. Jens¹, D. D. Langleben^{1,2}, C. P. O’Brien^{1,2}, ¹Psychiatry, University of Pennsylvania School of Medicine, Philadelphia, PA, ²VA VISN 4 MIRECC, Philadelphia VA Medical Center, Philadelphia, PA
- 11:45 *Role of dorsal hippocampus and rostral basolateral amygdala in cocaine cue extinction learning*
J. J. Szalay¹, N. P. Morin², K. M. Kantak^{1,2}, ¹Neuroscience, Boston University, Boston, MA, ²Psychology, Boston University, Boston, MA

Oral Communications 12

Rose Ballroom B

10:00 AM - 12:00 PM

SUBSTITUTION TREATMENT: A SAFE BET

Chairs: Kelly Dunn and Robert P. Schwartz

- 10:00 *Comparing jurisdictional policies to buprenorphine-naloxone in Australia*
K. Mammen^{1,2}, J. Bell^{1,2}, A. Quigley⁴, N. Lintzeris³, ¹Langton Centre, Sydney, NSW, Australia, ²National Drug and Alcohol Research Centre, Sydney, NSW, Australia, ³Drug Health Services RPAH, Sydney, NSW, Australia, ⁴Next Step Drug and Alcohol Services, Perth, WA, Australia
- 10:15 *Transdermal buprenorphine to switch patients from higher-dose methadone to buprenorphine without severe withdrawal symptoms*
M. Hess, R. Leisinger, L. Boesch, M. Schaub, R. Stohler, Research Group on Substance Use Disorders, Psychiatry, University Hospital, Zurich, Switzerland
- 10:30 *Predictors of outcome in buprenorphine treatment for opioid-dependent youth*
L. Marsch^{1,2}, S. K. Moore^{1,2}, R. Solhkhah², G. J. Badger³, ¹Center for Technology and Health, National Development and Research Institutes, New York, NY, ²St. Luke’s-Roosevelt Hospital Center, New York, NY, ³University of Vermont, Burlington, VT

- 10:45 *Randomized controlled trial using contingency management to promote smoking abstinence among opioid-maintained patients*
K. Dunn¹, S. Sigmon^{1,2}, E. Reimann², K. Saulsgiver², S. Higgins^{1,2}, ¹Psychology, University of Vermont, Burlington, NY, ²Psychiatry, University of Vermont, Burlington, VT
- 11:00 *Motivation for physical activity and leg disease in methadone maintenance patients*
T. N. Templin¹, B. Pieper¹, R. S. Kirsner², T. J. Birk¹, ¹Wayne State University, Detroit, MI, ²University of Miami, Miami, FL
- 11:15 *Interim vs. comprehensive vs. restored methadone treatment: Preliminary findings*
R. P. Schwartz^{1,2}, J. H. Jaffe^{1,3}, S. A. Kelly¹, D. Gandhi³, E. Weintraub³, J. Urbaitis⁴, S. Harrison⁴, K. E. O'Grady⁵, ¹Friends Research Institute, Baltimore, MD, ²Open Society Institute-Baltimore, Baltimore, MD, ³University of Maryland School of Medicine, Baltimore, MD, ⁴Sinai Hospital, Baltimore, MD, ⁵University of Maryland, College Park, MD
- 11:30 *Objective sleep (polysomnography) on entry to methadone maintenance treatment and following 6 months of treatment*
E. Peles, S. Schreiber, M. Adelson, Adelson Clinic for Drug Abuse Treatment and Research, Tel Aviv Medical Center and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
- 11:45 *Are methadone dose and "take home" status associated with hospital admission?*
J. H. Samet^{1,2,3}, D. M. Cheng², G. Johnson¹, T. Filippell¹, C. A. Chen², C. Pierce¹, D. P. Alford¹, A. Y. Walley^{1,3}, ¹Boston University School of Medicine, Boston, MA, ²Boston University School of Public Health, Boston, MA, ³Boston University Public Health Commission, Boston, MA

Oral Communications 13

Bonanza

10:00 AM - 12:00 PM

MDMA: NOT EXACTLY ECSTASY

Chairs: Elena Zakharova and Anthony Riley

- 10:00 *Mice lacking multidrug resistance protein 1a show altered dopaminergic responses to methylenedioxymethamphetamine in the striatum*
K. B. Scheidweiler¹, B. Ladenheim², J. L. Cadet², M. A. Huestis¹, ¹Chemistry and Drug Metabolism Section, NIDA-IRP, NIH, Baltimore, MD, ²Molecular Neuropsychiatry Branch, NIDA-IRP, NIH, Baltimore, MD
- 10:15 *Social and environmental factors alter the effects of MDMA on activity and cocaine conditioned place preference in adolescent rats*
E. Zakharova, J. Kelley, J. Ledon, I. Kichko, D. Wade, S. Izenwasser, University of Miami Miller School of Medicine, Miami, FL
- 10:30 *Antidepressant-like effects of MDMA in a animal model of depression*
I. Majumder, J. M. White, R. J. Irvine, Pharmacology, The University of Adelaide, Adelaide, SA, Australia
- 10:45 *The effects of MDMA preexposure on MDMA-induced taste aversions*
D. L. Albaugh, J. A. Rinker, A. L. Riley, Psychology, American University, Washington, DC
- 11:00 *Non-linear kinetics of (±)-3,4-methylenedioxymethamphetamine in rats*
M. H. Baumann¹, D. Zolkowska¹, I. Kim², K. B. Scheidweiler², R. B. Rothman¹, M. A. Huestis², ¹Clinical Psychopharmacology Section, NIDA/IRP, Baltimore, MD, ²Chemistry and Drug Metabolism Section, NIDA/IRP, Baltimore, MD

- 11:15 *Comparison of the pharmacology of methylenedioxyamphetamine and 3,4-methylenedioxymethamphetamine consumed in a recreational setting*
K. M. Morefield¹, R. J. Irvine¹, M. Keane¹, P. Felgate³, J. White¹, R. Roberts², ¹Pharmacology, University of Adelaide, Adelaide, SA, Australia, ²University of Otago, Christchurch, New Zealand, ³Forensic Sciences, Adelaide, SA, Australia
- 11:30 *Gender differences in ecstasy use, abuse and dependence*
V. Satyanarayana, A. B. Abdallah, L. B. Cottler, Washington University School of Medicine, St. Louis, MO
- 11:45 *3,4-Methylenedioxymethamphetamine decreases plasma asymmetric dimethylarginine: A placebo-controlled study in humans*
A. Kielstein¹, M. J. Baggott², J. C. Lopez², R. H. Boeger³, E. Schwedhelm³, J. T. Kielstein⁴, G. P. Galloway², J. Mendelson², ¹Psychotherapeutic Medicine and Psychotherapy, Universitätsklinik der Otto-von-Guericke Universität Magdeburg, Magdeburg, Germany, ²Addiction Pharmacology Research Laboratory, California Pacific Medical Center Research Institute, San Francisco, CA, ³Institut für Experimentelle und Klinische Pharmakologie, Universitätsklinikum Eppendorf, Hamburg, Germany, ⁴Nephrology, Medizinische Hochschule Hannover, Hannover, Germany

POSTER SESSION III (Lunch)

Pavilion
12:00 - 2:00 PM

Odd-numbered posters manned first hour;
Even-numbered, second hour

Set-up time begins Tuesday no earlier than 3:30 PM
Must be removed by Wednesday no later than 4:00 PM

COCAINE: ANIMALS I

- Qualitative differences in the self-administration of rats running an alley for intra-PFC and intra-NAcc cocaine*
J. M. Wenzel, A. Ettenberg, Psychology, University of California, Santa Barbara, CA
- Cocaine-seeking after cocaine self-administration is associated with plasticity of the serotonin 5-HT_{2C} receptor in the prefrontal cortex*
B. M. Witkin², B. A. Nic Dhonnchadha², S. J. Stutz¹, P. K. Seitz¹, R. G. Fox¹, K. A. Cunningham¹, ¹Pharmacology, University of Texas Medical Branch, Galveston, TX, ²Center for Addiction Research, University of Texas Medical Branch, Galveston, TX
- Involvement of basolateral amygdala dopamine D1 and D2 receptors on the expression of cocaine-induced conditioned place preference in rats*
M. Itasaka^{1,2}, N. Takahashi¹, N. Hironaka¹, K. Ikeda³, ¹SHIMOJO Implicit Brain Function Project, Japan Science and Technology Agency, Atsugi-shi, Japan, ²Psychology, Graduate School of the Humanities, Senshu University, Kawasaki-shi, Japan, ³Molecular Psychiatry Research, Tokyo Institute of Psychiatry, Setagaya-ku, Japan
- Behavioral sensitization to cocaine in rats: Evidence for temporal differences in dopamine D3 and D2 receptor sensitivity*
G. T. Collins¹, Y. N. Truong¹, B. Levant², J. H. Woods¹, ¹University of Michigan Medical School, Ann Arbor, MI, ²University of Kansas Medical Center, Kansas City, KS
- WITHDRAWN*
M. A. Balda¹, Y. Itzhak^{1,2}, ¹Neuroscience Program, University of Miami, Miami, FL, ²Psychiatry, University of Miami, Miami, FL

- 6 *Psychostimulant behavioral and neurochemical effects are more rapid in adolescent than adult rats*
Q. D. Walker, A. E. Arrant, C. M. Kuhn, Pharmacology, Duke Medical Center, Durham, NC
- 7 *Exposure to alcohol during adolescence or adulthood alters the aversive and locomotor-activating effects of cocaine in adult rats*
M. A. Hutchison, D. L. Albaugh, A. L. Riley, American University, Washington, DC
- 8 *Self-administered cocaine does not result in locomotor sensitization in monkeys*
N. M. Shinday^{1,2}, D. M. Platt¹, J. K. Rowlett^{1,2}, W. D. Yao^{1,2}, ¹New England Primate Research Center-Harvard Medical School, Southborough, MA, ²Neuroscience and Behavior, University of Massachusetts at Amherst, Amherst, MA
- 9 *Access to a nondrug alternative reinforcer produces a rightward shift in the cocaine discriminative stimulus*
S. Kohut, A. Riley, American University, Washington, DC
- 10 *Effects of cross-drug preexposure on cocaine- and desipramine-induced conditioned taste aversions*
K. M. Serafine, A. L. Riley, Psychology- Psychopharmacology Laboratory, American University, Washington, DC
- 11 *Effects of the tetrahydroprotoberberines l-tetrahydropalmatine and l-stepholidine on cocaine self-administration under fixed- and progressive-ratio schedules and cocaine discrimination in rats*
S. Wisniewski¹, Z. Yang², S. J. Li³, J. R. Mantsch¹, ¹Biomedical Sciences, Marquette University, Milwaukee, WI, ²Psychiatry, Beijing Institute of Basic Medical Science, Beijing, China, ³Biophysics, Medical College of Wisconsin, Milwaukee, WI
- 12 *Dose preference and dose escalation of cocaine in extended-access self-administration in Fischer and Lewis rats*
R. Picetti, M. J. Kreek, The Rockefeller University, New York, NY
- 13 *Effort to obtain cocaine modulates the effects of a differential-reinforcement-of-alternative-behavior schedule of alternative nondrug reinforcement on cocaine self-administration in rats*
M. G. LeSage, ¹Minneapolis Medical Research Foundation, Minneapolis, MN, ²University of Minnesota, Minneapolis, MN
- 14 *Effects of chronic modafinil on cocaine and food self-administration in rhesus monkeys*
J. Newman¹, S. S. Negus³, J. Bergman¹, T. Prisinzano², N. Mello¹, ¹Alcohol and Drug Abuse Research Center, McLean Hospital, Harvard Medical School, Belmont, MA, ²Medicinal Chemistry, University of Kansas, Lawrence, KS, ³Pharmacology and Toxicology, Virginia Commonwealth University, Richmond, VA
- 15 *Aerobic exercise attenuates the escalation of cocaine intake under extended-access conditions*
M. A. Smith, K. L. Walker, K. T. Cole, Davidson College, Davidson, NC

PEPTIDES/NEUROTRANSMITTERS

- 16 *Alterations in the density of group II mGluRs in the striatum of nonhuman primates following chronic cocaine self-administration*
T. J. Beveridge, H. R. Smith, M. A. Nader, L. J. Porrino, Physiology and Pharmacology, Wake Forest University School of Medicine, Winston Salem, NC
- 17 *Activation of mGluR2/3 selectively attenuates cocaine cue-mediated behavior in a novel nonhuman primate model of relapse*
D. Manvich, L. L. Howell, Division of Neuroscience, Yerkes National Primate Research Center, Emory University, Atlanta, GA

- 18 *Homer2 expression bidirectionally regulates PFC glutamate levels: Relation to cocaine reward*
A. W. Ary¹, K. D. Lominac¹, M. Klugmann², K. K. Szumlinski¹, ¹Psychology, University of California Santa Barbara, Santa Barbara, CA, ²Physiological Chemistry, University Mainz, Mainz, Germany
- 19 *Effects of the competitive NMDA receptor antagonist LY235959 on the antinociceptive response to acute and chronic morphine in WT and NR1 KD mice*
R. E. Balter¹, L. L. Miller², K. T. Schmidt², L. A. Dykstra^{1,2}, ¹Curriculum in Neurobiology, University of North Carolina- Chapel Hill, Chapel Hill, NC, ²Psychology, University of North Carolina- Chapel Hill, Chapel Hill, NC
- 20 *Morphine decreases innate immunity responses in an endotoxemia model in two strains of mice*
S. L. Cruz, I. K. Madera-Salcedo, C. Gonzalez-Espinosa, Pharmacobiology, Cinvestav, IPN, Mexico DF, Mexico
- 21 *The effect of gp120 on the antinociception induced by opioids in the cold water tail-flick test*
X. Chen, J. Palma, E. B. Geller, T. K. Eisenstein, M. W. Adler, Center for Substance Abuse Research, Temple University School of Medicine, Philadelphia, PA
- 22 *Intrahypothalamic administration of gp120 induces fever via CXCR4 receptors*
K. Benamar, M. Yondorf, S. Addou, J. Palma, E. Geller, T. Eisenstein, M. Adler, Center for Substance Abuse Research, Temple University School of Medicine, Philadelphia, PA
- 23 *Involvement of dopamine system on psychostimulant-like properties of p-fluoroamphetamine in mice*
M. Funada, N. Aoo, Y. Akitake, K. Wada, Drug Dependence Research, NIMH, NCNP, Kodaira, Japan
- 24 *Decreases in dopamine D2 receptor availability are associated with age in juvenile rhesus monkeys*
K. E. Gill, A. J. Bennett, P. J. Pierre, M. A. Nader, L. J. Porrino, Physiology and Pharmacology, Wake Forest University, Winston Salem, NC
- 25 *Generality of disruption of prepulse inhibition by the dopamine agonist apomorphine*
L. Moran, C. F. Mactutus, R. M. Booze, Psychology, Behavioral Neuroscience, University of South Carolina, Columbia, SC
- 26 *Effects of neuropeptide Y on the reinforcing efficacy of water and cocaine*
A. P. Caven¹, A. M. Gancarz¹, J. M. DiPirro², J. B. Richards³, A. C. Thompson³, ¹Psychology, University at Buffalo, Buffalo, NY, ²Psychology, Buffalo State College, Buffalo, NY, ³Research Institute on Addictions, University at Buffalo, Buffalo, NY
- 27 *Detection and quantification of endogenous arginine vasopressin in blood using mass spectrometry*
B. Reed^{1,2}, J. Varon¹, B. T. Chait², M. J. Kreek¹, ¹Laboratory of the Biology of Addictive Diseases, The Rockefeller University, New York, NY, ²Laboratory of Mass Spectrometry and Gaseous Ion Chemistry, The Rockefeller University, New York, NY
- 28 *Development of a plate assay to immuno-histochemically detect brain proteins in receptor and signaling pathways associated with addiction*
M. T. Reilly, R. A. Alyea, C. S. Watson, P. K. Seitz, K. Cunningham, Pharmacology, University of Texas Medical Branch, Galveston, TX

NICOTINE: HUMAN STUDIES

- 29 *Effect of nicotine on attentional networks in smokers and nonsmokers*
S. Heishman, C. S. Myers, R. C. Taylor, B. J. Salmeron, Nicotine Psychopharmacology, National Institute on Drug Abuse, Intramural Research Program, Baltimore, MD

- 30 *Initiating and maintaining smoking abstinence via the Internet*
P. A. Nuzzo^{1,4}, N. E. Schoenberg¹, C. A. Martin², J. Dallery³, C. J. Wong¹, W. W. Stoops^{1,4},
¹Behavioral Science, University of Kentucky, Lexington, KY, ²Psychiatry, University of
Kentucky, Lexington, KY, ³Psychology, University of Florida, Gainesville, FL, ⁴Center on Drug
and Alcohol Research, University of Kentucky, Lexington, KY
- 31 *The reinforcing efficacy of 3 vs. 6 puffs in smokers: Comparing traditional and demand analysis*
E. T. Mueller¹, W. Bickel¹, R. Yi¹, G. Badger², ¹Psychiatry, University of Arkansas for Medical
Sciences, Little Rock, AR, ²University of Vermont, Burlington, VT
- 32 *Craving and use of tobacco and cocaine: Findings from an ecological momentary assessment
study with polydrug users*
K. L. Preston, S. J. Heishman, R. Evans, G. F. Marrone, D. H. Epstein, NIDA Intramural
Research Program, Baltimore, MD
- 33 *Could low dependent smokers be more cue reactive than high dependent smokers?*
N. L. Watson¹, M. J. Carpenter¹, M. E. Saladin¹, K. M. Gray¹, S. A. McCullough¹,
E. M. Klintworth¹, C. E. Horne¹, H. P. Upadhyaya^{1,2}, ¹Medical University of South Carolina,
Charleston, SC, ²Eli Lilly and Company, Indianapolis, IN
- 34 *Menstrual phase differences in nicotine response after acute smoking abstinence*
A. M. Allen¹, S. S. Allen¹, M. al'Absi¹, D. K. Hatsukami², ¹Family Medicine and Community
Health, University of Minnesota, Minneapolis, MN, ²Psychiatry, University of Minnesota,
Minneapolis, MN
- 35 *Sex differences in brain responses to smoking cues vary as a function of smoking
satiety/abstinence*
B. Froeliger, R. V. Kozink, A. M. Lutz, F. J. McClernon, Psychiatry, Duke University Medical
Center, Durham, NC
- 36 *Acute negative affect relief from smoking may be related to the situation and unrelated to
nicotine intake*
K. Perkins, J. L. Karelitz, C. A. Conklin, M. A. Sayette, A. Grottenthaler, Psychiatry,
University of Pittsburgh, Pittsburgh, PA
- 37 *Influence of acute methylphenidate administration on cigarette smoking behavior in ADHD-
diagnosed adults*
A. R. Vansickel¹, M. Poole¹, W. W. Stoops¹, P. E. A. Glaser², C. R. Rush^{1,2}, ¹Psychology,
Behavioral Science, University of Kentucky, Lexington, KY, ²Psychiatry, University of
Kentucky, Lexington, KY
- 38 *Pre-quit brain fMRI responses to tobacco smoking-related cues predict slips during smoking
cessation treatment*
A. C. Janes¹, B. Frederick¹, S. Richardt¹, E. Merlo-Pich³, A. E. Evins², M. Fava²,
P. F. Renshaw¹, M. J. Kaufman¹, ¹Brain Imaging Center, McLean Hospital, Belmont, MA,
²Massachusetts General Hospital, Boston, MA, ³Psychiatry-CEDD, GlaxoSmithKline, Verona,
Italy
- 39 *The regulation of craving for cigarettes vs. food: An fMRI study of cigarette smokers*
H. Kober¹, E. Kross², P. Mende-Siedlecki¹, W. Mischel¹, C. Hart¹, K. Ochsner¹, ¹Psychology,
Columbia University, New York, NY, ²Psychology, University of Michigan, Ann Arbor, MI
- 40 *Smoking abstinence increases posterior insula–default network functional connectivity*
F. J. McClernon, B. E. Froeliger, R. V. Kozink, A. M. Lutz, Duke University Medical Center,
Durham, NC
- 41 *Ecological Momentary Assessment of smoking cessation in smokers with schizophrenia*
J. W. Tidey¹, C. J. Gwaltney², S. M. Colby¹, ¹Psychiatry and Human Behavior, Brown
University, Providence, RI, ²Community Health, Brown University, Providence, RI

- 42 *Nicotine occupancy of beta2*-nicotinic acetylcholine receptors after use of nicotine inhaler: Relationship to craving*
I. Esterlis¹, E. Mitsis⁴, J. Batis³, F. Bois¹, S. Stiklus¹, T. Kloczynski¹, E. Perry¹, G. Tamagnan^{3,1}, J. Seibyl^{3,1}, J. Staley^{1,2}, ¹Psychiatry, Yale University and VACHS, W Haven, CT, ²Diagnostic Radiology, Yale University and VACHS, West Haven, CT, ³Institute Neurodegen, New Haven, CT, ⁴Mount Sinai, New York, NY
- 43 *Reduced carbon monoxide in treatment-seeking cigarette smokers undergoing contingency management: Preliminary analysis*
D. M. Ledgerwood, C. L. Arfken, Psychiatry, Wayne State School of Medicine, Detroit, MI
- 44 *Do participants in randomized clinical trials for nicotine dependence reflect the general population of smokers?*
N. Dasgupta¹, A. C. Andorn², H. D. Chilcoat², ¹Epidemiology, University of North Carolina School of Public Health at Chapel Hill, Chapel Hill, NC, ²Worldwide Epidemiology, GlaxoSmithKline, Honolulu, HI
- 45 *A randomized, double-blind, placebo-controlled clinical trial of selegiline hydrochloride for smoking cessation: Preliminary results*
A. H. Weinberger¹, E. L. Reutenauer¹, M. N. Potenza¹, S. S. O'Malley¹, T. P. George^{2,3}, ¹Psychiatry, Yale University School of Medicine, New Haven, CT, ²Psychiatry, University of Toronto, Toronto, ON, Canada, ³Schizophrenia Program, Centre for Addiction and Mental Health, Toronto, ON, Canada

CANNABINOIDS/MARIJUANA

- 46 *Stopping marijuana increases alcohol use: An experimental verification of drug substitution*
E. N. Peters¹, J. R. Hughes², ¹Psychology, University of Vermont, Burlington, VT, ²Psychiatry, University of Vermont, Burlington, VT
- 47 *Life course trajectories of employment: Exploring the impacts of drug use*
Y. Hser¹, Y. C. Huang¹, M. Hara¹, R. Weiss², ¹Integrated Substance Abuse Programs, University of California, Los Angeles, CA, ²School of Public Health, Biostatistics, University of California, Los Angeles, CA
- 48 *Greater psychiatric symptoms in young marijuana users*
C. C. Cloak, I. Chin, D. Alicata, T. Ernst, L. Chang, University of Hawaii at Manoa, John A Burns School of Medicine, Honolulu, HI
- 49 *Male-female variations in cannabis smoking for U.S.-born vs. foreign-born Latinos and Asians in the United States, 2002-2003*
H. Cheng, J. C. Anthony, Michigan State University, East Lansing, MI
- 50 *The negative prognostic impact of cannabis dependence in a study of patients with bipolar disorder and substance use disorders*
W. B. Jaffee, M. Griffin, L. McDonald, S. Putnins, G. Fitzmaurice, R. Weiss, Alcohol and Drug Abuse Treatment Program, Harvard Medical School, McLean Hospital, Belmont, MA
- 51 *Beyond abstinence: Can Cognitive Behavioral Therapy reduce cannabis-related problems?*
K. Dittmer, E. Hoch, R. Noack, H. Rohrbacher, J. Henker, G. Bühringer, H. U. Wittchen, Institut für Klinische Psychologie und Psychotherapie, Technische Universität Dresden, Dresden, Germany
- 52 *Childhood predictors of first chance to use and use of cannabis by young adulthood*
C. L. Storr^{1,2}, F. A. Wagner³, C. Y. Chen⁴, J. C. Anthony⁵, ¹University of Maryland, Baltimore, MD, ²Johns Hopkins, Baltimore, MD, ³Morgan State University, Baltimore, MD, ⁴National Health Research Institute, Taipei, Taiwan, ⁵Michigan State University, East Lansing, MI

- 53 *Prediction of cannabis use disorder between childhood and young adulthood using cortisol reactivity, transmissible and non-transmissible liability indices*
L. Kirisci, R. Tarter, M. Vanyukov, M. Reynolds, A. Mezzich, T. Ridenour, Pharmaceutical Sciences, University of Pittsburgh, Pittsburgh, PA
- 54 *Smoked marijuana discrimination in humans*
L. H. Lundahl, C. L. Steinmiller, L. Sander, M. K. Greenwald, C. E. Johanson, Psychiatry and Behavioral Neuroscience, Wayne State University School of Medicine, Detroit, MI
- 55 *Gender differences in response to marijuana cues and stress in marijuana-dependent individuals*
K. Price, A. McRae-Clark, M. Saladin, R. Carter, K. Brady, Psychiatry, Medical University of South Carolina, Charleston, SC
- 56 *The substitution profile of the cannabinoid agonist nabilone in human subjects discriminating Δ^9 -THC*
J. A. Lile, L. R. Hays, T. H. Kelly, University of Kentucky College of Medicine, Lexington, KY
- 57 *Amygdala volumes in adolescent marijuana users*
T. McQueeny¹, C. B. Padula¹, J. S. Price¹, K. L. Medina¹, S. F. Tapert², ¹University of Cincinnati, Cincinnati, OH, ²University of California, San Diego, La Jolla, CA
- 58 *The effects of marijuana on creative problem solving*
S. K. Vosburg, R. W. Foltin, M. Haney, Substance Abuse, Columbia University/New York State Psychiatric Institute, New York, NY
- 59 *The effects of IV prenatal tetrahydrocannabinol exposure on passive avoidance performance in male and female juvenile rats*
L. C. Harte, A. Jackson, M. Iijima, N. Zhao, D. Dow-Edwards, Program on Neural and Behavioral Sciences, Physiology/Pharmacology, State University of New York Downstate, Brooklyn, NY

PREGNANCY AND DRUG ABUSE

- 60 *Neonatal abstinence syndrome and gender: Does sex matter?*
K. Kaltenbach, A. Holbrook, V. Nguyen, Pediatrics, Thomas Jefferson University, Philadelphia, PA
- 61 *Resilience to adolescent behavioral risk after intrauterine cocaine exposure*
J. Liebschutz, D. A. Frank, R. Rose-Jacobs, J. Gerteis, S. Soenksen, T. Heeren, B. Martin, H. Cabral, D. Appugliese, Boston University, Boston, MA
- 62 *Correlates of prenatal tobacco use in a treatment sample of pregnant drug-dependent women*
J. Gray¹, L. Phipps¹, N. Haug², M. Stitzer², D. Svikis¹, ¹Psychology, Virginia Commonwealth University, Richmond, VA, ²Psychiatry, Johns Hopkins, Baltimore, MD
- 63 *Social discounting among pregnant cigarette smokers*
M. Bradstreet¹, S. T. Higgins^{1,2}, ¹University of Vermont, Burlington, VT, ²Psychiatry, University of Vermont, Burlington, VT
- 64 *Smoking opinions and attitudes among pregnant smokers and spontaneous quitters*
E. Herrmann¹, S. Heil², S. Higgins^{1,2}, L. Solomon³, I. Bernstein⁴, ¹Psychology, University of Vermont, Burlington, VT, ²Psychiatry, University of Vermont, Burlington, VT, ³Family Medicine, University of Vermont, Burlington, VT, ⁴OB/Gyn, University of Vermont, Burlington, VT

- 65 *Legal issues among drug-using pregnant women*
T. Linares Scott¹, S. Heil¹, H. Jones², M. Wagner³, G. Fischer⁴, K. Kaltenbach⁵, S. Stine⁶, P. Martin⁷, M. Coyle⁸, P. Selby⁹, ¹U of Vermont, Burlington, VT, ²Johns Hopkins U, Baltimore, MD, ³U of Maryland, College Park, MD, ⁴Medical U of Vienna, Vienna, Austria, ⁵Thomas Jefferson U, Philadelphia, PA, ⁶Wayne State U, Detroit, MI, ⁷Vanderbilt U, Nashville, TN, ⁸Brown U, Providence, RI, ⁹U of Toronto, Toronto, ON, Canada
- 66 *Predictors of initial abstinence in newly pregnant women*
J. H. Yoon¹, S. T. Higgins^{2,3}, G. J. Badger⁴, M. P. Bradstreet³, ¹Psychiatry and Behavioral Research, Baylor College of Medicine, Houston, TX, ²Psychiatry, University of Vermont, Burlington, VT, ³Psychology, University of Vermont, Burlington, VT, ⁴Medical Biostatistics, University of Vermont, Burlington, VT
- 67 *Using a community coalition to develop a smoking cessation program to reduce infant mortality*
A. L. Sepulveda, M. G. Kennedy, J. B. Bradford, S. L. Garland, S. W. Masho, D. S. Svikis, W. R. Smith, Virginia Commonwealth University, Richmond, VA
- 68 *Characteristics associated with smoking severity during pregnancy*
S. H. Heil¹, S. Higgins¹, L. Solomon², I. Berstein³, ¹Psychiatry, University of Vermont, Burlington, VT, ²Family Practice, University of Vermont, Burlington, VT, ³OB/Gyn, University of Vermont, Burlington, VT
- 69 *Low educational attainment and cigarette smoking during pregnancy*
Y. Washio, S. T. Higgins, S. H. Heil, J. M. Skelly, G. J. Badger, L. J. Solomon, University of Vermont, Burlington, VT
- 70 *Women's perspectives on screening for alcohol and drug use in prenatal care*
S. Roberts, ¹School of Public Health, University of California, Berkeley, Berkeley, CA, ²Alcohol Research Group, Emeryville, CA
- 71 *Pregnant women in methadone maintenance: Barriers to treatment and treatment engagement*
L. Oberleitner, L. H. Lundahl, School of Medicine, Wayne State University, Detroit, MI
- 72 *Psychosocial functioning in methadone- and nonmethadone-maintained pregnant women: Relationships to treatment engagement and retention*
B. C. Jancaitis^{1,2}, J. May^{1,2}, S. Masho², D. Svikis², ¹Richmond Behavioral Health Authority, Richmond, VA, ²Virginia Commonwealth University, Richmond, VA
- 73 *There is no window of opportunity: Pregnancy and disparities in treatment need vs. receipt*
E. J. Smith, M. Terplan, Obstetrics and Gynecology, University of Chicago, Chicago, IL
- 74 *Preliminary findings on the efficacy of an HIV prevention intervention for pregnant African-American women in substance abuse treatment in the South*
F. Browne¹, R. Middlesteadt-Ellerson¹, A. Gentry¹, H. Jones², D. Haller³, W. Wechsberg¹, ¹RTI International, Research Triangle Park, NC, ²The Johns Hopkins University, Baltimore, MD, ³Columbia University, New York, NY
- 75 *Multidimensions of HIV risk for drug-dependent pregnant patients*
H. E. Jones¹, W. Wechsberg², K. O'Grady³, R. Chaudhury¹, M. Tuten¹, ¹Johns Hopkins University, Baltimore, MD, ²RTI International, Durham, NC, ³University of Maryland, College Park, MD
- 76 *Victimization, mental distress, crime, and substance use among pregnant adolescent girls*
V. H. Coleman, M. Dennis, Lighthouse Institute, Chestnut Health Systems, Normal, IL

IMPULSIVITY

- 77 *Effects of prenatal stress on lever-press acquisition, delay discounting, and ethanol self-administration in rats*
N. R. Bruner, K. G. Anderson, Psychology, West Virginia University, Morgantown, WV

- 78 *Impulsivity does not correlate with working memory or alcohol preference in rats bred for alcohol preference*
G. R. Wenger, Pharmacology and Toxicology, University of Arkansas for Medical Sciences, Little Rock, AR
- 79 *The effect of long and short access to d-amphetamine self-administration on a delay discounting task in rats*
C. Gipson, M. T. Bardo, Psychology, University of Kentucky, Lexington, KY
- 80 *Effects of signaled delays, delay order, and d-amphetamine on delay discounting*
J. M. Slezak, K. Anderson, Psychology, West Virginia University, Morgantown, WV
- 81 *Striatal dopamine D2/D3 receptors, impulsivity, and methamphetamine dependence*
B. Lee¹, R. A. Poldrack³, G. Tabibnia¹, M. A. Mandelkern^{4,5}, A. V. Bokarius¹, J. R. Monterosso⁶, A. Aron⁷, J. Farahi⁵, M. Dahlbom², R. M. Bilder¹, A. L. Brody^{1,5}, E. D. London^{1,2}, ¹Psychiatry and Biobehavioral Science, University of California, Los Angeles, CA, ²Molecular and Medical Pharmacology, University of California, Los Angeles, CA, ³Psychology, University of California, Los Angeles, CA, ⁴Physics, UCI, Los Angeles, CA, ⁵PET Center, VA, Los Angeles, CA, ⁶Psychology, USC, Los Angeles, CA, ⁷Psychology, UCSD, San Diego, CA
- 82 *The relationship between the responsivity to cocaine-related stimuli and other cognitive performance*
S. Liu¹, F. G. Moeller¹, S. D. Lane¹, K. A. Cunningham², ¹Psychiatry and Behavioral Sciences, University of Texas Houston, Houston, TX, ²Pharmacology and Toxicology, University of Texas Galveston, Galveston, TX
- 83 *Relationship of impulsivity and decision-making measures in cocaine dependence*
K. L. Kjome, S. D. Lane, J. M. Schmitz, C. Green, L. Ma, I. Prasla, A. C. Swann, F. G. Moeller, Psychiatry, University of Texas-Houston, Houston, TX
- 84 *Impulsivity, completion status, and ethnicity in a clinical trial for cocaine dependence*
W. V. Lechner¹, M. S. Schuler², S. D. Larowe¹, L. R. Rogers¹, R. J. Malcolm¹, ¹Psychiatry, Center for Drug and Alcohol Problems, Medical University of South Carolina, Charleston, SC, ²Biostatistics, Bioinformatics, and Epidemiology, Medical University of South Carolina, Charleston, SC
- 85 *Impact of adult ADHD and cocaine dependence on measures of attention and impulsivity*
D. J. Brooks¹, S. M. Evans^{2,1}, F. R. Levin^{2,1}, ¹Substance Abuse, New York State Psychiatric Institute, New York, NY, ²Psychiatry, Columbia University, New York, NY
- 86 *Characteristics of psychopathy in adolescent nonsmokers and smokers: Relations to delay discounting and self-reported impulsivity*
S. Melanko¹, B. Reynolds², ¹West Virginia University, Morgantown, WV, ²The Ohio State University, Columbus, OH
- 87 *Impulsive disinhibition in adolescent smokers and nonsmokers*
S. Fields, C. Collins, K. Leraas, S. Imhoff, B. Reynolds, Nationwide Childrens Hospital, Columbus, OH
- 88 *Depression and impulsivity in adolescent smokers and nonsmokers*
S. Imhoff, C. Collins, K. Leraas, S. Fields, B. Reynolds, Nationwide Childrens Hospital, Columbus, OH
- 89 *The effects of multimodal treatment on delay discounting in opioid-dependent individuals*
D. R. Christensen, R. D. Landes, W. K. Bickel, University of Arkansas for Medical Sciences, Little Rock, AR

- 90 *Delayed discounting and questionnaire measures of impulsive and inattentive behaviors are heterogeneous*
C. L. Steinmiller, M. K. Greenwald, Psychiatry and Behavioral Neurosciences, Wayne State University School of Medicine, Detroit, MI
- 91 *Impulsivity, risk-taking, and behavioral problems in treatment-seeking adolescents*
J. VanScoyoc, C. Stanger, A. J. Budney, University of Arkansas for Medical Sciences, Little Rock, AR
- 92 *Measuring impulsive behavior and cognition in inner-city substance abusers using translation procedures based on preclinical research*
M. E. Mattila-Evenden¹, J. Shack¹, C. Heeney-Buggey¹, J. Evenden², ¹Psychiatry and Behavioral Science, Temple University Hospital, Philadelphia, PA, ²WiltonLogic, Media, PA
- 93 *Head injury and intimate partner violence perpetration among alcohol-treatment-seeking men*
J. A. Schumacher¹, S. F. Coffey¹, K. E. Leonard², ¹Psychiatry and Human Behavior, University of Mississippi Medical Center, Jackson, MS, ²Research Institute on Addictions, University at Buffalo, Buffalo, NY

HIV/AIDS RISK

- 94 *Using latent class analysis to examine patterns of HIV risk behaviors among women with lifetime histories of illicit drug use*
C. E. Cavanaugh, C. Graham, S. Hedden, W. Latimer, Bloomberg School of Public Health, Mental Health, Johns Hopkins University, Baltimore, MD
- 95 *Chaos: The root of the problem for female crack users*
L. B. Cottler, C. C. O'Leary, S. E. Bradford, C. W. Striley, A. Ben Abdallah, Psychiatry, Washington University School of Medicine, St. Louis, MO
- 96 *Social network correlates of unprotected sex in Russian injection drug-using sexual partnerships*
V. Gyarmathy¹, N. Li², K. E. Tobin², I. F. Hoffman³, A. P. Kozlov⁴, A. B. Laudet⁵, C. A. Latkin², ¹European Centre for Drugs and Drug Addiction, Lisbon, Portugal, ²Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, ³University of North Carolina at Chapel Hill, Chapel Hill, NC, ⁴Biomedical Center, St. Petersburg State University, St. Petersburg, Russia, ⁵National Development and Research Institutes, Inc., New York, NY
- 97 *Double jeopardy for drug-using women in Russia: Injecting and sexual risks reported in a small trial*
W. M. Wechsberg¹, E. Krupitsky², T. Romanova², E. Zvartau², A. Gentry¹, F. Browne¹, R. Middlesteadt Ellerson¹, ¹RTI International, Durham, NC, ²St. Petersburg Pavlov State Medical University, St. Petersburg, Russia
- 98 *Risk behaviors of a sample of female injection drug users in Malaysia*
V. B. Kasinather¹, M. Mazlan², M. C. Chawarski³, R. S. Schottenfeld³, ¹Centre for Drug Research, University Sains Malaysia, Penang, Malaysia, ²Substance Abuse Research Centre, Muar, Malaysia, ³School of Medicine, Yale University, New Haven, CT
- 99 *Intervening to address drug use and sexual HIV risk among female sex workers in Durban, South Africa*
P. M. Petersen, T. Carney, A. Plüddemann, C. Parry, Alcohol and Drug Abuse Research Unit, Medical Research Council, Cape Town, South Africa
- 100 *The impact of social and emotional isolation on risky behaviors among women injection drug users in Portland, OR*
A. Hilde, J. Lapidus, Y. Michael, Public Health and Preventative Medicine, Oregon Health and Science University, Portland, OR

- 101 *Associations between sexual risk behavior patterns and HIV in female South African drug users*
S. L. Hedden, C. Cavanaugh, C. Graham, L. Floyd, W. W. Latimer, Mental Health, Johns Hopkins School of Public Health, Baltimore, MD
- 102 *HIV-positive drug users less likely to use condoms in South Africa*
C. Graham, S. L. Hedden, C. E. Cavanaugh, W. W. Latimer, Mental Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD
- 103 *The moderating effects of sex trade on the relationship between poly substance use and HIV among South Africans*
L. J. Floyd, C. Cavanaugh, A. Lawson, W. W. Latimer, Mental Health, Johns Hopkins University, Baltimore, MD
- 104 *HIV risk behaviors by sexual orientation after treatment for methamphetamine dependence*
C. Manneh, M. Hillhouse, S. Schroeder, R. Rawson, Integrated Substance Abuse Programs, University of California, Los Angeles, Los Angeles, CA
- 105 *Sexual orientation, drug use during sex, and HIV risk practices/preferences among men who use the Internet to find men for unprotected sex*
H. Klein, Center for the Study and Prevention of Drug Use, Morgan State University, Baltimore, MD
- 106 *HIV risk behaviors among substance-dependent non-gay-identifying men and women with same-gender sex experiences*
D. Allensworth-Davies¹, J. H. Samet², D. M. Cheng^{1,2}, A. Fitzgerald², T. W. Kim², J. Witas², R. Saitz², ¹Boston University School of Public Health, Boston, MA, ²Boston University School of Medicine/Boston Medical Center, Boston, MA
- 107 *The role of social context in the relationship between drug use and risky sexual behavior among individuals who use both heroin and crack/cocaine*
C. Kopetz¹, E. Reynolds¹, C. W. Lejuez¹, A. W. Kruglanski², ¹Center for Addiction, Personality and Emotion Research, University of Maryland, College Park, MD, ²Psychology, University of Maryland, College Park, MD
- 108 *Racial differences in HIV discordant sexual partnerships and sexual mixing between individuals with different social, drug use, and sexual risk*
M. Khan^{1,2}, M. Bolyard³, P. Mateu-Gelabert¹, S. R. Friedman¹, ¹National Development and Research Institutes, New York, NY, ²Public Health Solutions, New York, NY, ³Emory College of Arts and Sciences, Atlanta, GA
- 109 *Predicting recent event-level condom use using behavioral assessment among urban, minority substance users*
J. Magidson, E. Reynolds, C. Fuchs, S. Gorka, M. Bornovalova, S. Daughters, C. Lejuez, Psychology, University of Maryland, College Park, College Park, MD
- 110 *Factors associated with needle exchange program and pharmacy use among heroin and cocaine injectors in Baltimore, MD*
B. E. Mancha¹, D. Whitaker¹, S. G. Severtson¹, A. Nandi², S. Hedden¹, L. Floyd¹, W. W. Latimer¹, ¹Mental Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, ²Center for Population and Development Studies, Harvard School of Public Health, Boston, MA
- 111 *Buprenorphine detoxification: Effects on problem severity and AIDS risk behaviors*
S. J. Lookatch¹, E. M. Dunne¹, B. S. Brown^{2,3}, R. Schwartz³, S. D. King³, K. O'Grady⁴, D. Gandhi⁴, E. C. Katz^{1,3}, ¹Psychology, Towson University, Towson, MD, ²University of North Carolina, Wilmington, NC, ³Friends Research Institute, Baltimore, MD, ⁴University of Maryland, Baltimore, MD

- 112 *HIV sexual risk behaviors and physician screening in office-based buprenorphine treatment*
L. Sullivan, B. Moore, S. Cawley, R. Schottenfeld, D. Fiellin, Yale University, New Haven, CT

OPIATES: HUMAN STUDIES

- 113 *Behavioral naltrexone therapy plus depot naltrexone for heroin dependence: A randomized controlled trial*
M. A. Sullivan, K. M. Carpenter, J. M. Manubay, J. Kurtz, J. Lazar, E. V. Nunes, Columbia/New York State Psychiatric Institute, New York, NY
- 114 *Naltrexone-induced protracted opioid withdrawal*
J. J. Mariani, M. Sullivan, A. Bisaga, K. Carpenter, K. A. Murray, F. R. Levin, E. V. Nunes, Psychiatry/Division on Substance Abuse, Columbia University/New York State Psychiatric Institute, New York, NY
- 115 *Induction of opioid-dependent individuals onto buprenorphine and buprenorphine/naloxone film strips*
E. C. Strain, G. E. Bigelow, J. Harrison, Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD
- 116 *Risk-taking propensity as a predictor of induction onto naltrexone treatment for opioid dependence*
W. M. Aklin¹, G. Severtson², A. Umbricht³, M. Fingerhoo³, G. E. Bigelow³, K. Silverman³,
¹Behavioral and Integrative Treatment Branch, NIDA, Bethesda, MD, ²Public Health, Johns Hopkins University, Baltimore, MD, ³Psychiatry, Johns Hopkins University, Baltimore, MD
- 117 *Employment-based reinforcement of adherence to depot naltrexone pharmacotherapy*
J. Everly, A. Defulio, A. Umbricht, M. Fingerhoo, G. Bigelow, K. Silverman, Johns Hopkins University School of Medicine, Baltimore, MD
- 118 *One year of sustained-release naltrexone treatment for opioid dependence*
N. Kunø¹, P. P. Lobmaier¹, J. K. Vederhus², Ø. Kristensen², B. Hjerkin², S. Hegstad³, M. Gossop^{4,1}, H. Waal¹, ¹Norwegian Centre for Addiction Research, University of Oslo, Oslo, Norway, ²The Addiction Unit, Sørlandet Hospital, Kristiansand, Norway, ³Division of Forensic Toxicology and Drug Abuse, Norwegian Institute of Public Health, Oslo, Norway, ⁴National Addiction Centre, Institute of Psychiatry, King's College, London, United Kingdom
- 119 *Memory functioning of opiate-dependent individuals during Methadone Maintenance Treatment with Cognitive Behavioral Treatment*
M. C. Chawarski¹, B. Garnet², R. S. Schottenfeld¹, ¹Psychiatry, Yale University School of Medicine, New Haven, CT, ²APT Foundation, Inc., New Haven, CT
- 120 *Cognitive performance and methadone maintenance patients*
B. A. Kleykamp, R. Vandrey, G. Bigelow, M. Stitzer, E. Strain, M. Mintzer, School of Medicine, Johns Hopkins University, Baltimore, MD
- 121 *The provision of drug counseling services in office-based buprenorphine treatment*
J. E. Egan¹, J. Netherland¹, R. Finkelstein¹, D. Fiellin², T. Pugh¹, L. Weiss¹, ¹New York Academy of Medicine, New York, NY, ²Yale University School of Medicine, New Haven, CT
- 122 *Variation in retention by behavioral condition in buprenorphine treatment for opioid dependence*
M. P. Hillhouse, J. Fahey, J. Jenkins, W. Ling, R. Rawson, Integrated Substance Abuse Programs, University of California, Los Angeles, Los Angeles, CA
- 123 *Retention and transition to long-term treatment in opioid-dependent patients: Impact of Intensive Role Induction*
E. C. Katz^{1,3}, B. S. Brown^{2,3}, R. Schwartz³, S. D. King³, K. O'Grady⁴, D. Gandhi⁴, ¹Psychology, Towson University, Towson, MD, ²University of North Carolina, Wilmington, NC, ³Friends Research Institute, Baltimore, MD, ⁴University of Maryland, Baltimore, MD

- 124 *Treatment options for opiate dependence: Choices between buprenorphine and methadone*
M. R. Polen¹, D. McCarty², C. Green^{1,2}, ¹Center for Health Research, Kaiser Permanente, Portland, OR, ²Public Health and Preventive Medicine, Oregon Health & Science University, Portland, OR
- 125 *Treatment entry among individuals on a waiting list for methadone maintenance*
J. Gryczynski¹, R. P. Schwartz¹, K. E. O'Grady², J. H. Jaffe³, ¹Social Research Center, Friends Research Institute, Baltimore, MD, ²Psychology, University of Maryland, College Park, College Park, MD, ³School of Medicine, University of Maryland, Baltimore, MD
- 126 *Relationship between patient attitudes toward methadone and methadone treatment program retention*
S. Kelly¹, R. P. Schwartz¹, K. E. O'Grady², B. S. Brown³, ¹Friends Research Institute, Baltimore, MD, ²University of Maryland, College Park, MD, ³University of North Carolina, Wilmington, NC
- 127 *Satisfaction with methadone treatment centers of heroin-dependent patients who show poor response to this treatment*
J. Pérez de los Cobos, N. Siñol, J. Trujols, F. Batlle, M. Cardús, A. Rodríguez, Addictive Behaviors Unit (Psychiatry Department), Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
- 128 *The contribution of the quality of staff-patients' relationships to patients' satisfaction with methadone service*
S. Levit¹, M. Schiff², R. C. Moreno³, ¹Methadone Clinic in Jerusalem, Jerusalem, Israel, ²School of Social Work, Hebrew University, Jerusalem, Israel, ³Central Bureau of Statistics, Jerusalem, Israel
- 129 *The relation between illicit drug use in methadone maintenance treatment patients, psychopathic aspects and sense of coherence*
Y. Abramsohn, D. Potik, E. Peles, S. Schreiber, M. Adelson, Adelson Clinic, Tel-Aviv Sourasky Medical Center, Tel Aviv, Israel
- 130 *Use of complementary and alternative therapies among methadone maintenance patients*
C. L. Masson¹, L. Coffin², N. Pepper¹, C. McKnight², A. Morganstern¹, A. Jordan², D. C. Des Jarlais^{2,3}, D. C. Perlman^{2,3}, ¹Psychiatry, University of California, San Francisco, CA, ²Beth Israel Medical Center, New York, NY, ³NDRI, Inc., New York, NY
- 131 *Distribution of chronic venous disorders in a methadone-maintenance-treated sample*
B. Pieper¹, T. N. Templin¹, R. S. Kirsner², T. J. Birk¹, ¹College of Nursing, Wayne State University, Detroit, MI, ²School of Medicine, University of Miami, Miami, FL
- 132 *Medical care utilization and opiate dependence*
J. Fahey, M. Hillhouse, J. Jenkins, M. Torrington, C. Domier, W. Ling, Integrated Substance Abuse Programs, University of California, Los Angeles, Los Angeles, CA
- 133 *"For my daughter": Interpersonal motivators of heroin cessation in a community-based sample*
L. Weiss, J. Egan, J. Gass, C. Trezza, D. Vlahov, D. Ompad, Center for Urban Epidemiology Studies, The New York Academy of Medicine, New York, NY
- 134 *Quality of life in inpatients undergoing an opioid maintenance therapy after release from an addiction clinic*
B. Winklbaur, R. Loipl, S. Klug, V. Metz, D. Radler, G. Fischer, Psychiatry and Psychotherapy, Medical University Vienna, Vienna, Austria

Oral Communications 14

**Rose Ballroom A
2:00 - 4:00 PM**

BEFORE HITTING 21: DRUGS IN ADOLESCENCE

Chairs: Rajeev Ramchand and Yan Wang

- 2:00 *Developmental trajectories of HIV sexual risk behaviors from adolescence to young adulthood*
Y. D. Huang, D. Murphy, Y. Hser, Integrated Substance Abuse Programs, University of California, Los Angeles, CA
- 2:15 *Sustained abstinence in adolescence is associated with future economic well-being among high-risk adolescents*
B. Griffin, R. Ramchand, M. O. Edelen, D. McCaffrey, A. Morral, RAND Corporation, Arlington, VA
- 2:30 *Early childhood aggressive behavior, initial tobacco exposure opportunity and transition from opportunity to first tobacco use: A prospective study in urban African American youth*
Y. Wang¹, N. S. Ialongo², ¹School of Medicine, University of Maryland at Baltimore, Baltimore, MD, ²Mental Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD
- 2:45 *Dispelling the myth of smart drugs: Cannabis use problems and nonmedical use of prescription stimulants for studying*
A. Arria¹, H. Wilcox², K. Caldeira¹, K. Vincent¹, E. Wish¹, K. O'Grady³, ¹Center for Substance Abuse Research, University of Maryland, College Park, MD, ²Psychiatry, Johns Hopkins School of Medicine, Baltimore, MD, ³Psychology, University of Maryland, College Park, MD
- 3:00 *Anxious arousal and anhedonic depression symptoms and the frequency of current marijuana use: Testing the mediating role of marijuana use coping motives among active users*
K. Johnson¹, M. O. Bonn-Miller^{2,3}, T. M. Leyro¹, M. J. Zvolensky¹, ¹Psychology, University of Vermont, Burlington, VT, ²Center for Health Care Evaluation, VA Palo Alto Healthcare System, Palo Alto, CA, ³Psychiatry, Stanford University, Stanford, CA
- 3:15 *Conduct disorder predicts early but not late onset cocaine use and dependence: Evidence from the Family Study of Cocaine Dependence in St. Louis*
N. Presnall, J. Strickland, L. Cottler, L. Bierut, Psychiatry, Washington University in St. Louis, Saint Louis, MO
- 3:30 *Impact of adolescents' exposure to negative life events, poverty and war in Israel*
M. Schiff¹, R. Benbenishty², R. B. Hamburger³, ¹School of Social Work, Hebrew University and Columbia University, Jerusalem, Israel, ²School of Social Work, Hebrew University and Bar Ilan University, Jerusalem, Israel, ³The Israel Anti Drug and Alcohol Authority, Jerusalem, Israel
- 3:45 *Adolescent outpatient substance abuse treatment: Are manual-guided interventions superior to usual care?*
R. Ramchand¹, A. R. Morral¹, D. F. McCaffrey¹, M. Dennis², ¹RAND, Arlington, VA, ²Chestnut Health Systems, Bloomington, IL

BADGES MUST BE WORN IN ALL SCIENTIFIC SESSIONS

Oral Communications 15

**Ponderosa B
2:00 - 4:00 PM**

GABBING ABOUT GABA

Chairs: Donna Platt and Wouter Koek

- 2:00 *GABA-A receptor subtype mechanisms in the discriminative stimulus effects of ethanol in monkeys*
D. Platt¹, M. Van Linn², S. Rallapalli², T. Clayton², J. Cook², ¹Harvard Medical School/NE Primate Research Center, Southborough, MA, ²University of Wisconsin-Milwaukee, Milwaukee, WI
- 2:15 *A glutamatergic role in withdrawal from benzodiazepines as detected via drug discrimination analysis*
N. A. Ator¹, S. J. Kohut^{1,2}, ¹Psychiatry & Behavioral Sciences, Johns Hopkins School of Medicine, Baltimore, MD, ²Psychology, American University, Washington, DC
- 2:30 *The role of GABAA receptors in sex differences in cocaine-stimulated locomotion*
N. Siegal, D. Dow-Edwards, Physiology and Pharmacology, State University of New York Downstate College of Medicine, Brooklyn, NY
- 2:45 *Reversible inactivation of the basolateral amygdala, but not the dorsolateral caudate-putamen, attenuates the consolidation of cocaine-cue associative learning in an animal model of relapse*
A. Gabriele, A. M. Pacchioni, R. E. See, Neurosciences, Medical University of South Carolina, Charleston, SC
- 3:00 *Opiate history sensitizes dorsal raphe serotonin neurons to GABAergic synaptic inputs following stress-induced reinstatement*
J. W. Lunden, D. R. Staub, E. L. Freeman-Daniels, L. G. Kirby, Anatomy and Cell Biology and Center for Substance Abuse Research, Temple University School of Medicine, Philadelphia, PA
- 3:15 *GHB- and baclofen-induced hypothermia in mice: Interactions with the GABA-B receptor positive modulator CGP7930, the GABA-B receptor antagonist CGP35348, and the NOS inhibitor L-NAME*
W. Koek^{1,2}, P. S. Campos², C. P. France^{2,1}, K. Cheng³, K. C. Rice³, ¹Psychiatry, University of Texas Health Science Campsu, San Antonio, TX, ²Pharmacology, University of Texas Health Science Center, San Antonio, TX, ³Chemical Biology Research Branch, NIDA, Bethesda, MD
- 3:30 *The posterior cingulate: A functional and structural correlate of chronic administration of the GABA B agonist, baclofen in smokers*
T. Franklin¹, Z. Wang¹, D. Harper¹, K. Kampman¹, Y. Li¹, W. Jens¹, R. Viana¹, M. Goldman¹, J. Suh¹, J. Detre², C. O'Brien¹, A. Childress¹, ¹Psychiatry, University of Pennsylvania, Philadelphia, PA, ²Radiology, University of Pennsylvania, Philadelphia, PA
- 3:45 *Comparative neurochemical analysis of accumbens and ventral tegmentum during "speedball" cocaine and heroin self-administration*
S. E. Hemby¹, S. McIntosh¹, K. Egan¹, B. Horman¹, C. Co¹, L. Parsons², ¹Physiology and Pharmacology, Wake Forest University, Winston-Salem, NC, ²Committee on the Neurobiology of Addictive Disorders, The Scripps Research Institute, La Jolla, CA

BADGES MUST BE WORN IN ALL SCIENTIFIC SESSIONS

Symposium XIII

**Rose Ballroom B
2:00 - 3:00 PM**

RISK MANAGEMENT AND POST-MARKETING SURVEILLANCE OF CNS DRUGS

Chair: Robert L. Balster

- 2:00 *Introduction*
Robert L. Balster, Virginia Commonwealth University, Richmond, VA
- 2:05 *Monitoring risk: Post-marketing surveillance and signal detection*
Richard Dart, Denver Health, Rocky Mountain Poison and Drug Center, Denver, CO
- 2:25 *What constitutes a signal: Quantitative and qualitative aspects*
Sidney Schnoll, Pinney Associates, Bethesda, MD
- 2:45 *Recommendations and conclusions of the expert panel*
Charles Schuster, Chris-Ellyn Johanson, CRS Associates, LLC, Chicago, IL

Oral Communications 16

**Bonanza
2:00 - 3:00 PM**

GENES AND MOLECULES: THEY'RE IN OUR CARDS

Chairs: Nadezhda A. German and Ella M. Nikulina

- 2:00 *Mu-opioid receptor A118G polymorphism in healthy volunteers affects HPA-axis ACTH stress response to metyrapone*
E. A. Ducat, B. Ray, G. Bart, Y. Umemura, J. Varon, A. Ho, M. J. Kreek, Laboratory of the Biology of Addictive Disease, Rockefeller University, New York, NY
- 2:15 *Impact of CYP2D6 genotype on the pharmacodynamic effects of oxycodone in humans: A retrospective analysis*
J. D. Jones, W. J. Kowalczyk, M. A. Sullivan, S. K. Vosburg, S. D. Comer, Psychiatry, Columbia University and New York State Psychiatric Institute, New York, NY
- 2:30 *Des-formylflustrabromine and its analogs as positive allosteric modulators of $\alpha 4\beta 2$ neuronal nicotinic receptors*
N. A. German¹, J. S. Kim¹, A. Pandya², M. Weltzin², M. Schulte², R. A. Glennon¹, ¹Medicinal Chemistry, Virginia Commonwealth University, Richmond, VA, ²Chemistry and Biochemistry, University of Alaska Fairbanks, Fairbanks, AK
- 2:45 *Up-regulation of brain-derived neurotrophic factor in the ventral tegmental area induces FosB/ Δ FosB immunoreactivity in mesolimbic projections and facilitates sensitization after social stress*
E. M. Nikulina^{1,2}, S. Fanous², C. E. Bass³, X. Ren³, E. F. Terwilliger³, R. P. Hammer, Jr^{1,2}, ¹Basic Medical Sciences, University of Arizona, Phoenix, AZ, ²Tufts University, Boston, MA, ³Harvard Medical School, Boston, MA

BADGES MUST BE WORN IN ALL SCIENTIFIC SESSIONS

Symposium XIV

**Rose Ballroom B
3:15 - 4:15 PM**

DEVELOPMENT OF PROTEIN-BASED PHARMACOTHERAPIES FOR DRUG ADDICTION

Chairs: Thomas R. Kosten and C. Nora Chiang

- 3:15 *Cocaine and nicotine vaccines: Human studies and pre-clinical improvements*
Thomas R. Kosten, Baylor College of Medicine, Houston, TX
- 3:35 *Active and passive immunization for treating methamphetamine abuse*
W. B. Gentry, University of Arkansas for Medical Science, Little Rock, AR
- 3:55 *Bioengineered human butyrylcholinesterase as a protein therapeutic for cocaine addiction*
William S. Brimjoin, Mayo Foundation, Rochester, MN

Oral Communications 17

**Bonanza
3:15 - 4:15 PM**

DRUGS FOUND IN SPADES IN CLUBS

Chairs: Danielle C. Ompad and Rodney J. Irvine

- 3:15 *The effects of sublingual Salvinorin A, a naturally occurring kappa opioid receptor agonist, in humans*
J. Mendelson¹, J. C. Lopez¹, M. J. Baggott^{1,3}, K. Flower¹, E. Everhart², T. Munro⁴, B. Cohen⁴, G. Galloway¹, ¹Addiction Pharmacology, California Pacific Medical Center Research Institute, San Francisco, CA, ²Psychiatry, University of California, San Francisco, CA, ³Neuroscience, University of California Berkeley, Berkeley, CA, ⁴Psychiatry, Harvard Medical School, Belmont, MA
- 3:30 *Trends in ecstasy seizures and purity of seized ecstasy in Canada*
B. J. Sauv e, K. Richard, Office of Research and Surveillance, Health Canada, Ottawa, ON, Canada
- 3:45 *Availability and use of club drugs in New York City: A multi-level analysis*
D. C. Ompad¹, S. Galea², V. Nandi¹, D. Vlahov¹, ¹Center for Urban Epidemiologic Studies, New York Academy of Medicine, New York, NY, ²School of Public Health, University of Michigan, Ann Arbor, MI
- 4:00 *An objective quantitative method of monitoring illicit drug use*
R. J. Irvine¹, C. Kostakis², P. Felgate², J. M. White¹, ¹Pharmacology, University of Adelaide, Adelaide, SA, Australia, ²Forensic Sciences, Department of Justice, Adelaide, SA, Australia

CPDD BUSINESS MEETING (Members Only)

**Ponderosa B
4:30 - 5:30 PM**

DINNER AND DANCING

**Rose Ballroom
7:30 - 10:30 PM**

BADGES MUST BE WORN IN ALL SCIENTIFIC SESSIONS

POSTER SESSION IV (Breakfast)

**Pavilion
8:00 - 10:00 AM**

**Odd-numbered posters manned first hour;
Even-numbered, second hour**

**Set-up time begins Wednesday no earlier than 4:30 PM
Must be removed by Thursday no later than 1:30 PM**

BENZODIAZEPINES

- 1 *Changes in pregnanolone discriminative stimulus as a function of training dose in rats*
A. K. Eppolito, L. R. Gerak, Pharmacology, University of Texas Health Science Center San Antonio, San Antonio, TX
- 2 *Differential attenuation of the discriminative stimulus effects of benzodiazepines and neuroactive steroids by flumazenil or pentylentetrazole in diazepam-treated rhesus monkeys*
L. R. Gerak, C. P. France, Pharmacology, University of Texas Health Science Center, San Antonio, TX
- 3 *Role of GABA_A receptor subtypes in benzodiazepine self-administration by rhesus monkeys*
B. D. Fischer¹, D. M. Platt¹, M. L. Van Linn², S. Rallapalli², T. Clayton², J. M. Cook², J. K. Rowlett¹, ¹Harvard Medical School/New England Primate Research Center, Southborough, MA, ²Chemistry, University of Wisconsin, Milwaukee, Milwaukee, WI
- 4 *Abuse liability of chronic hypnotic use in insomniacs*
S. Randall, T. Roehrs, R. Maan, T. Roth, Sleep Disorders & Research Center, Henry Ford Health System, Detroit, MI
- 5 *Absence of rebound insomnia following chronic hypnotic use*
T. Roehrs, S. Randall, R. Maan, T. Roth, Sleep Disorders & Research Center, Henry Ford Health System, Detroit, MI
- 6 *Neuronal correlates of oral zolpidem administration: Magnetic resonance imaging studies in healthy volunteers*
S. C. Licata¹, S. B. Lowen¹, R. R. MacLean¹, D. M. Penetar¹, B. B. Frederick², S. E. Lukas^{1,2}, ¹Behavioral Psychopharmacology Research Laboratory, McLean Hospital/Harvard Medical School, Belmont, MA, ²Brain Imaging Center, McLean Hospital/Harvard Medical School, Belmont, MA
- 7 *Progesterone modulation of triazolam effects in healthy women*
S. Babalonis^{1,3}, J. A. Lile¹, C. A. Martin², T. H. Kelly^{1,2,3}, ¹Behavioral Science, University of Kentucky, Lexington, KY, ²Psychiatry, University of Kentucky, Lexington, KY, ³Psychology, University of Kentucky, Lexington, KY
- 8 *Is pregabalin (Lyrica®) a drug of abuse or protection against drug abuse? A comparison with gabapentin within the Norwegian prescription database*
J. G. Bramness^{1,3}, P. Sandvik², A. Engeland³, S. Skurtveit³, ¹Centre for Addiction Research, University of Oslo, Oslo, Norway, ²Norwegian University of Science and Technology, Trondheim, Norway, ³Pharmacoepidemiology, Norwegian Institute of Public Health, Oslo, Norway

HALLUCINOGENS

- 9 *Comparative pharmacology of dextromethorphan and triazolam*
C. J. Reissig¹, L. P. Carter², M. Z. Mintzer¹, M. W. Johnson¹, R. R. Griffiths¹, ¹Psychiatry and Behavioral Sciences, Johns Hopkins University, Baltimore, MD, ²Clinical Research and Development, Jazz Pharmaceuticals Inc., Palo Alto, CA

- 10 *Discriminative stimulus effects of the hallucinogen 5-methoxy-N-isopropyl-N-methyltryptamine*
M. B. Gatch, T. Carbonaro, M. Rutledge, C. Elskens, M. J. Forster, Pharmacology and Neuroscience, University of North Texas Health Science Center, Fort Worth, TX
- 11 *Tolerance development to hallucinogen-elicited head twitch behavior in mice*
W. E. Fantegrossi, Pharmacology and Toxicology, University of Arkansas for Medical Sciences, Little Rock, AR
- 12 *Behavioral and mechanistic studies of the hallucinogens DiPT and 4-OH-DiPT*
T. Carbonaro, T. Machu, M. B. Gatch, Pharmacology and Neuroscience, University of North Texas Health Science Center, Fort Worth, TX

COCAINE: ANIMALS II

- 13 *The effects of chronic cocaine on delay-discounting in rats*
K. L. Dandy¹, J. Miller¹, M. Gatch^{1,2}, ¹Psychology, Texas Christian University, Fort Worth, TX, ²Pharmacology and Neuroscience, University of North Texas Health Science Center, Fort Worth, TX
- 14 *Progesterone attenuates chronic cocaine-induced rearing responses but not dendritic spine increases in the nucleus accumbens core of female rats*
S. E. Diaz^{1,2}, S. Nygard^{1,2}, S. Jenab^{1,2}, V. Quinones-Jenab^{1,2}, ¹Psychology, Graduate Center of New York, City University of New York, New York, NY, ²Psychology, Hunter College, New York, NY
- 15 *Effect of sex and estrous on choice between food and cocaine in male and female rats*
K. A. Kerstetter, M. A. Wade, T. E. Kippin, Psychology and Neuroscience Research Institute, University of California, Santa Barbara, Santa Barbara, CA
- 16 *Progesterone metabolite allopregnanolone attenuates the escalation of cocaine-seeking behavior in female rats*
J. J. Anker, M. E. Carroll, University of Minnesota, St Paul, MN
- 17 *Effects of the combination of metyrapone and oxazepam on cue-induced reinstatement of cocaine seeking*
C. Keller¹, M. Vaswani^{2,1}, G. F. Guerin¹, N. E. Goeders¹, ¹Louisiana State University Health Sciences Center, Shreveport, LA, ²All India Institute of Medical Sciences, New Delhi, India
- 18 *Protective effects of environmental enrichment on cocaine-seeking behavior during abstinence*
K. J. Thiel, M. Painter, D. Hills, A. Crow, C. Cuhaciyani, F. Sanabria, N. S. Pentkowski, J. L. Neisewander, Psychology, Arizona State University, Tempe, AZ
- 19 *Effectiveness of cocaine esterases against cardiovascular toxicity and lethality produced by intravenous administration of cocaine in rats*
M. C. Ko^{1,2}, D. Narasimhan¹, R. K. Sunahara¹, J. H. Woods¹, ¹Pharmacology, University of Michigan, Ann Arbor, MI, ²Psychology and Institute of Neuroscience, National Cheng Chi University, Taipei City, Taiwan
- 20 *D-cycloserine delays reacquisition of cocaine self-administration by augmenting consolidation of extinction learning*
B. A. Nic Dhonnchadha¹, R. D. Spealman², K. M. Kantak¹, ¹Psychology, Boston University, Boston, MA, ²New England Primate Research Center, Harvard Medical School, Southborough, MA

- 21 *A new broad-spectrum anti-methamphetamine monoclonal antibody reverses acute METH effects in rats*

W. B. Gentry¹, S. M. Owens², J. C. Frank³, E. M. Laurenzana², ¹Anesthesiology, Pharmacology and Toxicology, University of Arkansas for Medical Sciences, Little Rock, AR, ²Pharmacology and Toxicology, University of Arkansas for Medical Sciences, Little Rock, AR, ³College of Medicine, University of Arkansas for Medical Sciences, Little Rock, AR

COCAINE: HUMAN

- 22 *Effects of modafinil on sleep architecture in chronic cocaine users*

P. Morgan¹, E. Pace-Schott², R. Stickgold², R. T. Malison¹, ¹Psychiatry, Yale University, New Haven, CT, ²Psychiatry, Harvard University, Boston, MA

- 23 *Valproate treatment enhances cue-induced cocaine craving*

M. S. Reid, E. Weinstein, V. Thakkar, Psychiatry, New York University, New York, NY

- 24 *Safety of oral aripiprazole alone and in combination with intravenous cocaine in humans*

L. Middleton¹, M. Lofwall^{1,2}, P. A. Nuzzo¹, S. L. Walsh^{1,2}, ¹Behavioral Science, Center on Drug and Alcohol Research, University of Kentucky, Lexington, KY, ²Psychiatry, University of Kentucky, Lexington, KY

- 25 *The acetylcholinesterase inhibitor donepezil modifies cocaine-induced cardiovascular and subjective effects*

K. Grasing^{1,2}, D. Mathur¹, T. F. Newton³, C. DeSouza¹, ¹Substance Abuse Research Laboratory, Kansas City VA Medical Center, Kansas City, MO, ²Clinical Pharmacology, University of Kansas School of Medicine, Kansas City, KS, ³Psychiatry and Behavioral Science, Baylor College of Medicine, Houston, TX

- 26 *Female vs. male prolactin response to dynorphin A1-13 in normal volunteer and cocaine-dependent subjects*

G. Bart^{1,2}, E. Ducat¹, B. Ray¹, J. Varon¹, J. Cassin¹, A. Ho¹, M. Kreek¹, ¹The Laboratory of the Biology of Addictive Diseases, The Rockefeller University, New York, NY, ²Medicine, Hennepin County Medical Center, Minneapolis, MN

- 27 *Employment-based abstinence reinforcement as a maintenance intervention for the treatment of persistent cocaine use in methadone patients with 24-month follow-up*

A. DeFulio, W. D. Donlin, C. J. Wong, K. Silverman, Johns Hopkins University School of Medicine, Baltimore, MD

- 28 *Consistency of self-reported drug use and urine drug screening for homeless men and women in a cocaine dependence treatment program*

M. Burns¹, J. B. Milby¹, D. Wallace², J. E. Schumacher¹, S. Mennemeyer¹, R. E. Vuchinich¹, ¹University of Alabama at Birmingham, Birmingham, AL, ²RTI International, Raleigh, NC

- 29 *Community reinforcement approach for cocaine dependence in a community setting: Individual- vs. group-based intervention*

R. Secades-Villa¹, E. Sánchez-Hervás², F. Zacarés Romaguera¹, O. García-Rodríguez³, F. J. Santonja Gómez⁴, G. García Fernandez¹, ¹Psychology, University of Oviedo, Oviedo, Spain, ²Dept 10, Valencia State Health Agency, Valencia, Spain, ³Clinical Psychology, University of Barcelona, Barcelona, Spain, ⁴Miguel Hernández University, Elche, Spain

ADOLESCENTS II

- 30 *Does crack cocaine increase sexual desires? Perceptions of HIV-positive crack cocaine users and gender differences*

L. Metsch¹, G. Cardenas¹, E. Valverde³, C. Bell², L. Gooden¹, E. Scharf², C. del Rio², A. Rodriguez¹, ¹University of Miami, Miami, FL, ²Emory University, Atlanta, GA, ³Centers for Disease Control and Prevention, Atlanta, GA

- 31 *Developing science-based treatment for opioid-dependent youth: Lessons learned*
S. K. Moore^{1,2}, L. A. Marsch^{1,2}, ¹Center for Technology and Health, National Development and Research Institutes, Inc., New York, NY, ²Behavioral Science Research, St. Luke's-Roosevelt Hospital, New York, NY
- 32 *Temporal and probabilistic discounting in adolescent substance users and controls*
S. K. Mikulich-Gilbertson^{1,2}, L. L. Thompson¹, T. J. Crowley¹, ¹Psychiatry, University of Colorado Denver, Aurora, CO, ²Biometrics/Informatics, University of Colorado Denver, Aurora, CO
- 33 *Moderators of the relationship between risk-taking propensity, substance use, and other risk behaviors in early adolescents*
F. L. Wang¹, L. MacPherson¹, E. K. Reynolds¹, N. Calvin¹, S. Daughters¹, J. Cassidy¹, L. Mayes², C. W. Lejuez¹, ¹Psychology, University of Maryland, College Park, College Park, MD, ²Child Study Center, Yale University School of Medicine, New Haven, CT
- 34 *Substance-dependent antisocial boys: Brain processing of reward/loss*
T. J. Crowley¹, M. Dalwani¹, S. K. Mikulich-Gilbertson¹, Y. Du¹, K. Raymond¹, M. T. Banich^{1,2}, ¹University of Colorado Denver, Denver, CO, ²University of Colorado Boulder, Boulder, CO
- 35 *Reward-seeking task performance: A validation study*
D. C. Lee, G. Robbins, T. H. Kelly, Behavioral Science, University of Kentucky, Lexington, KY
- 36 *Amygdala volumes and craving in adolescent marijuana users*
C. B. Padula¹, T. McQueeny¹, J. Price¹, K. L. Medina¹, S. F. Tapert², ¹University of Cincinnati, Cincinnati, OH, ²University of California, San Diego, La Jolla, CA
- 37 *Changes in HPA axis function and psychiatric symptoms in adolescent methamphetamine users*
G. R. King¹, D. Alicata², C. Cloak¹, I. Chin¹, J. Spiess², L. Chang¹, ¹Medicine, University of Hawaii, Honolulu, HI, ²Psychiatry, University of Hawaii, Honolulu, HI
- 38 *Attention-deficit/hyperactivity disorder and nicotine withdrawal symptoms among treatment-seeking adolescent smokers*
A. L. Lewis¹, K. M. Gray¹, M. J. Carpenter¹, N. L. Baker¹, E. M. Klintworth¹, A. S. Leinbach¹, H. P. Upadhyaya^{1,2}, ¹Medical University of South Carolina, Charleston, SC, ²Eli Lilly & Company, Indianapolis, IN

ALCOHOL

- 39 *Kudzu extract treatment does not increase the intoxicating effects of alcohol in human volunteers*
S. Lukas, R. R. MacLean, D. Lee, D. M. Penetar, Psychiatry, McLean Hospital/Harvard Medical School, Belmont, MA
- 40 *Zolmitriptan and its relationship to the aggression-heightening effects of alcohol*
J. Gowin, S. D. Lane, F. G. Moeller, J. Steinberg, A. Swann, University of Texas Health Science Center Houston, Houston, TX
- 41 *Dopamine and serotonin transporter availability during acute alcohol withdrawal: Effects of comorbid tobacco smoking*
K. Cosgrove^{1,2}, E. Frohlich^{1,2}, S. Stiklus^{1,2}, B. Pittman¹, G. Tamagnan³, R. Baldwin^{1,2}, F. Bois^{1,2}, J. Seibyl³, J. Krystal^{1,2}, S. O'Malley¹, J. Staley^{1,2}, ¹Psychiatry, Yale University School of Medicine, New Haven, CT, ²VA Connecticut Healthcare System, West Haven, CT, ³Institute for Neurodegenerative Disorders, New Haven, CT
- 42 *Patterns of alcohol consumption among college football tailgaters*
L. J. Merlo^{1,2}, A. M. Stone², A. Holtzman², C. Klingman², K. Alvarez², R. Gilbertson², R. Prather², A. Bibbey², F. Kobeissy², N. Graham², M. S. Gold², ¹Psychiatry, Washington University, St. Louis, MO, ²Psychiatry, University of Florida, Gainesville, FL

- 43 *Identifying poor prognosis patients in cocaine-alcohol dependence treatment trials*
L. C. Sacerio, K. M. Kampman, K. Lynch, H. M. Pettinati, Psychiatry, University of Pennsylvania, Philadelphia, PA
- 44 *Alcohol and substance use in traffic accident victims of Porto Alegre, Brazil*
R. De Boni¹, D. Benzano¹, G. Baldisserotto¹, B. Holmer¹, M. Soibelman¹, S. Porto Jr², T. Sousa², E. Correa², F. Santos³, J. Goldim³, F. Pechansky^{1,3}, ¹Psychiatry, CPAD- Federal University Rio Grande do Sul, Porto Alegre, Brazil, ²Economic Science, Federal University Rio Grande do Sul, Porto Alegre, Brazil, ³Clinicas Hospital, Porto Alegre, Brazil
- 45 *Pattern of alcohol use and associated factors: A cross-sectional study in a French emergency room*
R. Debrabant¹, F. Serre¹, M. Fatseas^{1,2}, C. Denis¹, P. Thoueilles², B. Fleury¹, M. Auriacombe^{1,2}, ¹Addiction Psychiatry EA4139/INSERM-IFR99, Universite Victor Segalen Bordeaux 2, Bordeaux, France, ²Addiction Medicine, CHU de Bordeaux, Bordeaux, France
- 46 *A study of substance abuse in the Asian Indian community in Ontario, Canada*
M. Hussain^{1,2}, A. Kaur², ¹Addiction Services, William Osler Health Centre, Brampton, ON, Canada, ²South Asian Addiction Program, Punjabi Community Health Services, Brampton, ON, Canada
- 47 *Alcohol abuse and dependence criteria among students at two schools in Puerto Rico: A latent class analysis*
A. Hulbert, B. E. Mancha, S. Hedden, S. G. Severtson, W. W. Latimer, Mental Health, John Hopkins Bloomberg School of Public Health, Baltimore, MD
- 48 *Validation of triage criteria for deciding which apparently inebriated persons require emergency department care*
K. Flower¹, J. Mendelson¹, J. Sussman², N. Tangherlini³, M. Pletcher², ¹Addiction Pharmacology Research Lab, California Pacific Medical Center Research Institute, San Francisco, CA, ²Epidemiology and Biostatistics, University of California, San Francisco, CA, ³San Francisco Fire Department/EMS, City and County of San Francisco, San Francisco, CA
- 49
- 50 *Reduction of addiction severity in alcohol and drugs: A bivariate multilevel modeling approach*
M. Hara^{1,2}, Y. Huang¹, Y. Hser¹, ¹Integrated Substance Abuse Programs, University of California, Los Angeles, Los Angeles, CA, ²Graduate School of Education and Information Studies, University of California, Los Angeles, Los Angeles, CA

EPIDEMIOLOGY II

- 51 *The Mexican migration to the U.S. and substance use in Northern Mexico*
G. Borges¹, M. Medina-Mora¹, R. Orozco¹, C. Fleis¹, C. Cherpitel², J. Breslau³, ¹Epidemiology, Instituto Nacional de Psiquiatria, Mexico, Mexico, ²Alcohol Research Group, Emeryville, CA, ³Center for Reducing Health Disparities, University of California, Davis, School of Medicine, Sacramento, CA
- 52 *Substance use of French university students at exam periods: A cross-sectional survey in Bordeaux*
J. Alexandre¹, M. Fatseas¹, C. Denis¹, E. Lavie¹, B. Merle², F. Touchard³, S. Maurice-Tison², M. Auriacombe¹, ¹Addiction Psychiatry EA4139/INSERM-IFR99, Universite Victor Segalen Bordeaux 2, Bordeaux, France, ²INSERM U330, Universite Victor Segalen Bordeaux 2, Bordeaux, France, ³Student Health Care Service, Universite Bordeaux 4, Bordeaux, France
- 53 *Factors of drug abuse for Black and Caribbean emerging adults*
B. Longmire-Avital, ¹Public Health Solutions, New York, NY, ²National Development and Research Institutes, Inc., New York, NY

- 54 *Irish travellers and drug use*
M. A. Van Hout, Health, Waterford, Waterford, Ireland
- 55 *South Asian women and domestic violence: Isolation, social support, help-seeking, and addressing risks of co-occurrence of substance abuse among intimate partners*
N. Mahapatra, School of Social Work, The University of Texas at Austin, Austin, TX
- 56 *Back out there: Subject retrieval among recovering populations*
N. J. Tiburcio, B. D. Johnson, National Development and Research Institutes, Inc., New York, NY
- 57 *Conditional odds of recent drug use disorders in relation to PTSD history: USA, 2004-5*
K. M. Bohnert, N. Breslau, J. C. Anthony, Epidemiology, Michigan State University, East Lansing, MI
- 58 *Stigma feelings attached to drug dependence and depression vary as a function of medical students' own depression history*
V. Cruz^{1,2}, G. F. Alvarado^{1,3}, D. Barondess¹, M. Radovanovic^{1,4}, J. C. Anthony¹, ¹Epidemiology, Michigan State University, East Lansing, MI, ²Office of Epidemiology, Peruvian National Institute of Mental Health, Lima, Peru, ³Cayetano Heredia Peruvian University, Lima, Peru, ⁴Psychiatric Clinic Rudnik, Ljubljana, Slovenia
- 59 *Stigma attached to drug dependence and depression: Perceptions of future health professionals*
B. K. Ahmedani^{1,4}, S. P. Kubiak¹, C. F. Rios-Bedoya², M. A. Mickus³, J. C. Anthony⁴, ¹School of Social Work, Michigan State University, East Lansing, MI, ²Family Medicine, Michigan State University, East Lansing, MI, ³Psychiatry, Michigan State University, East Lansing, MI, ⁴Epidemiology, Michigan State University, East Lansing, MI
- 60 *Ethnicity and recent-onset tobacco smoking: Epidemiological evidence, 2004-06*
D. A. Barondess, M. Radovanovic, J. C. Anthony, Epidemiology, Michigan State University, College of Human Medicine, East Lansing, MI
- 61 *Race and gender trends of CPDD members and meeting attendees*
G. Widner, R. K. Price, Psychiatry, Washington University School of Medicine, St. Louis, MO

CRIMINAL JUSTICE

- 62 *The impact of the Inmate Pre-Release Assessment on rural inmate's 12-step attendance and treatment entry*
C. B. Oser, J. Havens, K. Harp, M. Staton-Tindall, H. Knudsen, J. Mooney, J. Duvall, C. Leukefeld, University of Kentucky, Lexington, KY
- 63 *Examining the relationship between risk of criminal recidivism and substance use and treatment history in a sample of probationers*
A. J. Trotman¹, M. E. Wilson², F. S. Taxman¹, ¹Administration of Justice, George Mason University, Manassas, VA, ²Friends Research Institute, Baltimore, MD
- 64 *Gender differences in criminal rationalization among prison-based substance abuse treatment participants nearing community re-entry*
J. Mooney, C. Oser, C. Leukefeld, Center on Drug and Alcohol Research, University of Kentucky, Lexington, KY
- 65 *Strengths-based case management for drug-abusing parolees: Outcomes at three and nine months using two causal models*
M. Prendergast¹, J. Sacks², L. Frisman³, M. Staton-Tindall⁴, L. Greenwell¹, H. Lin³, ¹University of California Los Angeles Integrated Substance Abuse Programs, Los Angeles, CA, ²National Development and Research Institutes, New York, NY, ³Connecticut Department of Mental Health and Addiction Services, Hartford, CT, ⁴University of Kentucky, Lexington, KY

- 66 *Predictors of risky sexual behavior in incarcerated drug users in Sri Lanka*
A. Stadlin¹, L. O. Dissabandara¹, S. Dias², H. Gamini³, N. J. Loxton⁴, ¹School of Medical Science, Griffith University, Southport, QLD, Australia, ²Psychiatry, University of Peradeniya, Kandy, Sri Lanka, ³Faculty of Medicine, University of Peradeniya, Kandy, Sri Lanka, ⁴Psychology, University of Queensland, Brisbane, QLD, Australia
- 67 *Deconstructing HIV interventions among female offenders*
C. O'Leary, L. B. Cottler, Psychiatry, Washington University School of Medicine, St. Louis, MO
- 68 *HIV risk behaviors: Results from a randomized study of methadone maintenance for prisoners*
M. E. Wilson¹, T. W. Kinlock¹, R. P. Schwartz¹, M. S. Gordon¹, K. E. O'Grady², ¹Friends Research Institute, Baltimore, MD, ²University of Maryland College Park, College Park, MD
- 69 *Cost offset analysis of an enhanced HIV intervention for rural probationers*
J. L. Duvall, C. Oser, C. Leukefeld, University of Kentucky, Lexington, KY

DIAGNOSIS AND ASSESSMENT

- 70 *The Addiction Potential Scale: A validation study*
E. R. Grekin¹, S. J. Ondersma², D. S. Svikis³, P. K. Lam², V. M. Connors², ¹Psychology, Wayne State University, Detroit, MI, ²Psychiatry and Behavioral Neuroscience, Wayne State University, Detroit, MI, ³Psychology, Virginia Commonwealth University, Richmond, VA
- 71 *Development of an indirect screener for perinatal drug use (Wayne Indirect Drug Use Screener)*
S. J. Ondersma¹, D. S. Svikis², P. K. Lam¹, V. M. Connors¹, E. R. Grekin³, ¹Psychiatry and Behavioral Neuroscience, Wayne State University, Detroit, MI, ²Psychology, Virginia Commonwealth University, Richmond, VA, ³Psychology, Wayne State University, Detroit, MI
- 72 *Reliability and validity of the Short Inventory of Problems modified for drug use*
R. Saitz¹, D. Allensworth-Davies², D. M. Cheng^{2,1}, P. C. Smith¹, J. H. Samet¹, ¹Boston University School of Medicine/Boston Medical Center, Boston, MA, ²Boston University School of Public Health, Boston, MA
- 73 *Effect size, time and dose-response profiles of drugs of abuse in human abuse potential studies*
D. Milovan¹, K. A. Schoedel¹, M. K. Romach¹, E. M. Sellers^{1,2}, ¹Kendle Early Stage, Toronto, ON, Canada, ²Pharmacology, Psychiatry, and Medicine, University of Toronto, Toronto, ON, Canada
- 74 *Identifying prescription drug disorder in primary care chronic pain patients prescribed opioids: Diagnostic characteristics of the Current Opioid Misuse Measure*
E. C. Meltzer, D. Rybin, R. Saitz, J. H. Samet, S. Schwartz, S. Butler, J. Liebschutz, Section of General Internal Medicine, Boston University Medical Center, Boston, MA
- 75 *Validation of the clinical opiate withdrawal scale*
D. A. Tompkins¹, J. A. Harrison¹, G. E. Bigelow¹, R. E. Johnson², P. J. Fudala², L. J. Felch¹, E. C. Strain¹, ¹Psychiatry, The Johns Hopkins University School of Medicine, Baltimore, MD, ²Reckitt Benckiser Pharmaceuticals Inc., Richmond, VA
- 76 *Inter-rater reliability and validity of DSM-IV opioid dependence in a Hmong isolate using the Semi-Structured Assessment for Drug Dependence and Alcoholism Thai version*
R. T. Malison¹, R. Kalayasiri⁴, K. Sanichwankul⁶, A. Sughondhabirom⁴, A. Mutirangura⁵, B. Pittman¹, R. Gueorguieva^{1,3}, H. Kranzler⁷, J. Gelernter^{1,2}, ¹Psychiatry, Yale School of Medicine, New Haven, CT, ²Genetics, and Neurobiology, Yale School of Medicine, New Haven, CT, ³Yale School of Public Health, New Haven, CT, ⁴Psychiatry, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand, ⁵Anatomy, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand, ⁶Suan Prung Psychiatric Hospital, Chiang Mai, Thailand, ⁷Psychiatry, University of Connecticut School of Medicine, Farmington, CT

- 77 *Substance dependence criteria (DSM-IV) in daily cannabis users*
L. A. Maciel, A. R. Noto, Psicobiologia, UNIFESP-EPM, São Paulo, Brazil
- 78 *Assessment of nicotine dependence among adolescent smokers: A comparison of measures*
M. J. Carpenter¹, N. L. Baker¹, K. M. Gray¹, A. L. Lewis¹, E. Klintworth¹, A. Leinbach¹,
H. P. Upadhyaya^{1,2}, ¹Medical University of South Carolina, Charleston, SC, ²Eli Lilly &
Company, Indianapolis, IN
- 79 *Validation of Comprehensive Health Assessment Tool: An interactive, multimedia scale to assess alcohol and substance addiction severity among adolescents*
K. J. Trudeau¹, S. Lord^{1,2}, R. A. Black¹, L. Lorin¹, B. Cooney¹, A. Villapiano¹, S. F. Butler¹,
¹Inflexxion, Inc., Newton, MA, ²National Development and Research Institutes, New York, NY
- 80 *Utility of various screening instruments for attention-deficit hyperactivity disorder in research participants seeking treatment for cocaine dependence*
A. L. Mahony^{1,2}, S. S. Berhane^{1,2}, D. J. Brooks^{1,2}, J. J. Mariani^{1,2}, F. R. Levin^{1,2}, ¹New York State Psychiatric Institute, New York, NY, ²Columbia University, New York, NY
- 81 *Crossvalidation and integration of four mental health screeners using item response theory*
B. Riley¹, B. R. Rush^{2,4}, S. Castel^{3,4}, B. Brands^{5,4}, S. Veldhuizen², M. Dennis¹, ¹Chestnut Health Systems, Normal, IL, ²Centre for Addiction and Mental Health, Toronto, ON, Canada, ³Sunnybrook Health Sciences Centre, Toronto, ON, Canada, ⁴University of Toronto, Toronto, ON, Canada, ⁵Health Canada, Ottawa, ON, Canada
- 82 *Impact of recent drug use on the validation of screening tools for mental disorders*
B. R. Rush^{1,4}, S. Castel^{2,4}, B. Brands³, S. Veldhuizen¹, ¹Centre for Addiction and Mental Health, Toronto, ON, Canada, ²Sunnybrook Health Sciences, Toronto, ON, Canada, ³Health Canada, Toronto, ON, Canada, ⁴Psychiatry, University of Toronto, Toronto, ON, Canada

THEORETICAL

- 83 *Mathematical model of effects of first-order schedules on drug self-administration*
V. L. Tsibulsky, A. B. Norman, Psychiatry, University of Cincinnati, Cincinnati, OH
- 84 *Assessment of effort on neuropsychological testing in drug abuse research*
A. M. Horton, Neuropsychology Section, Psych Associates, Bethesda, MD
- 85 *A potential method for examining the stimulus properties of drugs under conditions comparable to those used with exteroceptive stimuli*
G. M. Sizemore, D. Morgan, Psychiatry, University of Florida, Gainesville, FL
- 86 *An in vitro pharmacological model of maintained agonist self-administration*
A. B. Norman, M. K. Norman, V. L. Tsibulsky, Psychiatry, University of Cincinnati, Cincinnati, OH
- 87 *Development of cognitive behavioral therapy platform targeting both cocaine dependence and ADHD*
D. V. Herin¹, N. J. Moukaddam², J. M. Schmitz², P. M. McCleary², D. V. Rinker², C. Malcolm²,
F. R. Levin³, J. Grabowski¹, ¹Psychiatry, University of Minnesota, Minneapolis, MN,
²Psychiatry, University of Texas Health Science Center Houston, Houston, TX, ³Psychiatry,
Columbia University, New York, NY
- 88 *Cocaine and well-being: Entries, exits*
P. Pharo¹, B. Badin de Montjoye², P. Podevin³, ¹CNRS - Université Paris Descartes, Paris,
France, ²Hôpital Cochin, Paris, France, ³Centre Hospitalier Léon Binet, Provins, France
- 89 *Methamphetamine use: Does it increase violent sexual activity in women?*
N. E. Goeders¹, A. B. Hamilton², ¹Pharmacology, Toxicology and Neuroscience, Louisiana
State University Health Sciences Center, Shreveport, LA, ²Psychiatry, University of California
Los Angeles, Los Angeles, CA

- 90 *Use of an adaptive treatment research design in a CTN study of prescription opioid dependence treatment*
R. D. Weiss¹, J. Potter¹, M. Byrne², C. Sullivan², W. Ling³, ¹McLean Hospital, Belmont, MA, ²West Virginia University School of Medicine, Morgantown, WV, ³University of California Los Angeles School of Medicine, Los Angeles, CA
- 91 *Participation in substance abuse clinical trials: Comparing gender and racial/ethnic groups*
C. L. Rosa, P. G. Wakim, CCTN, NIDA, Bethesda, MD
- 92 *Cross-country variations in illegal drug involvement and DSM-IV clinical features of drug abuse in the Americas*
F. A. Fiestas¹, M. Radovanovic¹, M. E. Medina-Mora², J. Posada-Villa^{3,4}, J. C. Anthony¹, ¹Epidemiology, Michigan State University, East Lansing, MI, ²Institute of Psychiatry, Mexico DF, Mexico, ³Colegio Mayor de Cundinamarca University, Bogota, Colombia, ⁴The Social Protection Ministry, Bogota, Colombia
- 93 *Assessment of addictive behavior among the elderly: What about “geriatric addiction”?*
M. Fatseas, R. Icick, M. Auriacombe, Addiction Psychiatry EA4139/INSERM-IFR99, Universite Victor Segalen Bordeaux 2, Bordeaux, France
- 94 *Drug court and treatment: An ethnographic exploration*
K. Kaye, ¹Social and Cultural Analysis, New York University, New York, NY, ²Behavioral Sciences Training in Drug Abuse Research, Public Health Solutions, New York City, NY
- 95 *Legalization of marijuana use in México*
A. Gutierrez-Padilla^{2,1}, O. Campollo^{1,3}, ¹Center of Studies on Alcohol and Addictions, University of Guadalajara, Guadalajara, Mexico, ²Unidad de Cuidados Intensivos Neonatales, Antiguo Hospital Civil de Guadalajara, Guadalajara, Mexico, ³Clínica para Dejar de Fumar, Antiguo Hospital Civil de Guadalajara, Guadalajara, Mexico
- 96 *Re-entry strategies for California ex-offenders*
W. Tsai¹, D. Watson¹, E. Williams², ¹University of California Los Angeles/Friends Research Institute, Torrance, CA, ²Regional Congregations Neighborhood Organizations, Los Angeles, CA
- 97 *Methods for assessing the cumulative treatment effect on subsequent drug use abstinence*
L. Li, E. Evans, Y. Hser, University of California Los Angeles Integrated Substance Abuse Programs, Los Angeles, CA
- 98 *Measuring the impact of change: Developing statewide Process Improvement Performance Measurement systems*
J. H. Ford¹, A. Quanbeck¹, C. Kraeff², M. Stathum³, T. Molfenter¹, ¹University of Wisconsin - Madison, Madison, WI, ²South Carolina Department of Alcohol and Other Drug Abuse Services, Columbia, SC, ³Oklahoma Department of Mental Health and Substance Abuse Services, Oklahoma City, OK
- 99 *The power of eliciting consumer input to design effective treatment systems*
L. Madden¹, A. Quanbeck², S. O. Farnum², J. H. Ford², S. Ball¹, ¹APT Foundation and Yale University, New Haven, CT, ²University of Wisconsin, Madison, WI
- 100 *Times, Organizations, Offices, Lives and Systems Evolution Project*
M. Neely², C. Branch², D. Watson¹, W. Tsai¹, D. Osborne², ¹University of California Los Angeles/Friends Research Institute, Torrance, CA, ²Los Angeles Metropolitan Churches, Los Angeles, CA

PROGRAM DESCRIPTION

- 101 *WITHDRAWN*
- 102 *Los Angeles Youth Collaborative for substance use and violence prevention among gang-exposed youth*
C. Branch², D. Osborne², C. Jones², T. Mcfollins², D. W. Watson¹, M. Mouttapa³, W. Tsai¹, A. Asghar³, ¹University of California Los Angeles/Friends Research Institute, Torrance, CA, ²Los Angeles Metropolitan Churches, Los Angeles, CA, ³California State University at Fullerton, Fullerton, CA
- 103 *Supporting Opportunities for Adolescent Recovery*
H. Hatanaka¹, H. Levy¹, C. Wright¹, J. Schott¹, D. Malak-Lopez¹, F. McKinney¹, L. Cosio¹, D. Montenegro¹, E. Vasquez¹, D. Watson², M. Mouttapa³, W. Tsai², ¹Special Service for Groups/Homeless Outreach Program Family Center, Los Angeles, CA, ²University of California Los Angeles Integrated Substance Abuse Programs/Friends Research Institute, Torrance, CA, ³California State University at Fullerton, Fullerton, CA
- 104 *Group Reality Therapy: Is it an effective tool in working with opioid-dependent young adults in methadone maintenance treatment?*
M. Lawental Schori¹, E. Lawental^{2,3}, L. Altus², M. Gur², ¹School of Social Policy and Practice, University of Pennsylvania, Philadelphia, PA, ²Haifa Drug Abuse Treatment Center, Haifa, Israel, ³School of Social Work, Tel Hai Academic College, Upper Galilee, Israel
- 105 *Patterns of buprenorphine dose reduction in opioid-dependent patients*
J. Manubay^{1,2}, S. K. Vosburg^{1,2}, E. Yango¹, H. D. Kleber^{1,2}, ¹Psychiatry, Columbia University, New York, NY, ²Substance Abuse, New York State Psychiatric Institute, New York, NY
- 106 *NIDA's Clinical Trials Network delivers evidence-based treatments through comparative effectiveness research*
S. Sparenborg, U. Ghitza, B. Tai, Center for the Clinical Trials Network, National Institute on Drug Abuse, Rockville, MD
- 107 *A clinical trial comparison of two formulations of depot buprenorphine for pain*
W. Ling, M. Hillhouse, J. Jenkins, K. Miotto, L. Mooney, M. Torrington, S. Reed, L. McGraw, D. Chim, Integrated Substance Abuse Programs, University of California, Los Angeles, CA
- 108 *Clinical guidelines for the management of cannabis use disorder*
A. Frewen, J. Copeland, National Cannabis Prevention and Information Centre, University of NSW, Sydney, NSW, Australia
- 109 *Assessment of a process improvement initiative in substance abuse treatment settings*
A. M. Williams, R. Springer, T. G. Durham, The Danya Institute, Inc., Silver Spring, MD
- 110 *Building momentum for improving client engagement and retention in treatment: The California experience*
B. A. Rutkowski¹, S. Gallon², R. A. Rawson¹, T. E. Freese¹, A. Bruehl³, D. Crevecoeur-MacPhail¹, W. Sugita³, K. Johnson⁴, T. Molfenter⁴, F. Cotter⁵, ¹Integrated Substance Abuse Programs, University of California, Los Angeles, Los Angeles, CA, ²Oregon Health and Science University, Portland, OR, ³Alcohol and Drug Program Administration, County of Los Angeles Department of Public Health, Alhambra, CA, ⁴University of Wisconsin-Madison, Madison, WI, ⁵SAMHSA/CSAT, Rockville, MD
- 111 *Assessing addiction treatment information systems in Maryland: Gaps and redundancies*
P. Sheikhattari, T. Rice, F. A. Wagner, Center for Health Disparity Solutions, Morgan State University, Baltimore, MD

- 112 *Implementation of an electronic information system to enhance practice at an opioid treatment program*
M. Chu, S. A. Kritz, C. John-Hull, B. Louie, C. Madray, L. S. Brown, Medical Services, Research and Information Technology, Addiction Research and Treatment Corporation, Brooklyn, NY
- 113 *Can opiate pharmacotherapy improve virological response to anti-hepatitis C treatment in former drug abusers (Injecting Drug Users)? Case report about 3 ex-IDU*
L. Gourarier¹, J. Jungman¹, A. Gervais², J. L. Boujenah³, S. Pol⁴, ¹CASAT, La Terrasse / Maison Blanche, Paris, France, ²Maladies Infectieuses & Tropicales, Bichat/APHP, Paris, France, ³Hépatologie, Pitié-Salpêtrière/APHP, Paris, France, ⁴Hépatologie, Cochin/APHP, Paris, France
- 114 *A brief culturally sensitive HIV and hepatitis prevention intervention for urban American Indians: Development and preliminary evaluation*
D. Caldwell¹, J. Johnson¹, J. Gryczynski¹, K. Lessard², S. Wiechelt³, S. Roth⁴, ¹Social Research Center, Friends Research Institute, Baltimore, MD, ²Chase Brexton Health Services, Baltimore, MD, ³Social Work, University of Maryland, Baltimore County, Baltimore, MD, ⁴LifeLines Foundation, Baltimore, MD
- 115 *Using respondent-driven sampling to enhance recruitment of dually diagnosed adolescent clinical trial participants*
B. W. Holmes¹, K. Pressley¹, L. Haynes², C. Tyson², P. Riggs, MD³, ¹NIDA Clinical Trials Network, Lexington Richland Alcohol and Drug Abuse Council, Columbia, SC, ²Psychiatry and Behavioral Sciences, Medical University of South Carolina, Columbia, SC, ³Health Sciences Center, University of Colorado, Denver, CO
- 116 *Disseminating evidence-based practices for treating co-occurring disorders in children and their caregivers*
T. E. Freese, S. Larkins, R. Rawson, J. Peck, Integrated Substance Abuse Programs, University of California, Los Angeles, Los Angeles, CA
- 117 *Using Web-based technology to enhance practical applications: Increasing access to problem gambling resources*
J. W. Hays, J. E. Norland, S. J. Asteriadis, J. A. Hartje, N. A. Roget, Center for the Application of Substance Abuse Technologies, University of Nevada, Reno, Reno, NV
- 118 *WITHDRAWN*
- 119 *Gender and the global drug trade: The case of incarcerated women in Lima, Peru*
S. Campos, NDRI/Public Health Solutions, New York City, NY
- 120 *Gender differences in employment and employment barriers among drug abusers*
M. Webster^{1,2}, M. Staton-Tindall^{3,2}, M. Dickson^{1,2}, C. Leukefeld^{1,2}, J. Wilson¹, ¹Behavioral Science, University of Kentucky, Lexington, KY, ²Center on Drug and Alcohol Research, University of Kentucky, Lexington, KY, ³Social Work, University of Kentucky, Lexington, KY
- 121 *Workforce development for faith-based substance abuse treatment providers*
D. W. Watson¹, B. Finnerty¹, C. Branch², T. Freese¹, R. Rawson¹, W. Tsai¹, ¹University of California Los Angeles Integrated Substance Abuse Programs, Torrance, CA, ²Los Angeles Metropolitan Churches, Los Angeles, CA
- 122 *Research opportunities in NIDA's Division of Epidemiology, Services and Prevention Research*
W. Compton, K. P. Conway, Division of Epidemiology, Services and Prevention Research, National Institute on Drug Abuse, Bethesda, MD

- 123 *How useful is what we have? Limitations of Cochrane reviews, the case of substance treatment in pregnancy*
M. Terplan¹, E. J. Smith¹, S. Lui², ¹Obstetrics and Gynecology, University of Chicago, Chicago, IL, ²Human and Health Sciences, University of Huddersfield, Queensgate, United Kingdom
- 124 *Systematic review of computer-based treatments for drug abuse and dependence*
B. A. Moore¹, B. Garnet², C. Cutter¹, D. Barry¹, ¹Psychiatry, Yale University, New Haven, CT, ²APT Foundation, New Haven, CT
- 125 *The interaction between opioids and alcohol: Results from a global literature review*
B. Setnik¹, R. Colucci², C. Mannino¹, S. Siegel¹, L. Wase¹, ¹King Pharmaceuticals®, Inc., Bridgewater, NJ, ²Colucci & Associates, LLC, Newtown, CT
- 126 *HIV prevention in problem-solving courts: A review*
J. L. Sorensen, M. Chartier, S. E. Larios, J. Dilley, D. McNeil, C. Masson, J. Guydish, S. Fordwood, Psychiatry, University of California, San Francisco, CA
- 127 *A systematic review of gender differences in HIV sexual risk behaviors among stimulant and opioid abusers*
J. S. Potter^{1,2,3}, C. S. Meade^{2,3}, A. T. Peterson², ¹University of Texas Health Science Center, San Antonio, TX, ²McLean Hospital, Belmont, MA, ³Harvard Medical School, Boston, MA
- 128 *Methamphetamine use and sexual HIV risk behavior in Cape Town, South Africa: A review of data from 8 studies (2004-2007)*
C. D. Parry¹, A. Pluddemann¹, B. J. Myers-Franchi¹, W. M. Wechsberg², A. J. Flisher³, ¹Alcohol and Drug Abuse Research Unit, Medical Research Council, Cape Town, South Africa, ²Substance Abuse Treatment Evaluations and Interventions Research, RTI International, Research Triangle Park, NC, ³Psychiatry and Mental Health, University of Cape Town, Cape Town, South Africa
- 129 *What is best practice in the treatment of co-occurring substance use and post traumatic stress disorder?*
K. L. Mills, National Drug and Alcohol Research Centre, University of New South Wales, Sydney, NSW, Australia

Symposium XV

Rose Ballroom A
10:00 AM - 12:00 PM

FROM TRIALS TO PRACTICE: THE IMPLICATIONS OF INCLUSION AND EXCLUSION CRITERIA IN CLINICAL TRIALS OF PHARMACOTHERAPIES TO TREAT DRUG DEPENDENCE

Chairs: Howard Chilcoat and Anne Andorn

- 10:00 *Generalizability of clinical trials for alcohol dependence to community samples*
Carlos Blanco, New York State Psychiatric Institute/College of Physicians and Surgeons of Columbia University, New York, NY
- 10:25 *Generalizing from laboratory and clinical studies of nicotine dependence pharmacotherapies*
Caryn Lerman, Transdisciplinary Tobacco Use Research Center, University of Pennsylvania, Philadelphia, PA
- 10:50 *Using epidemiologic data on natural history of drug dependence to evaluate necessity of clinical trial exclusion/inclusion criteria*
Howard Chilcoat, Worldwide Epidemiology, GlaxoSmithKline, Research Triangle Park, NC

- 11:15 *Impact of inclusion and exclusion criteria on clinical trials of drug abuse pharmacotherapies*
Ivan Montoya, National Institute on Drug Abuse/National Institutes of Health, Bethesda, MD
- 11:40 *Discussant*
Frank Vocci, Friends Research Institute, Baltimore, MD

Oral Communications 18

Ponderosa B
10:00 AM - 12:00 PM

PULLING THE LEVER FOR STIMULANTS: BEHAVIORAL STUDIES

Chairs: Deanne Buffalari and Francesco Leri

- 10:00 *Effect of modafinil on stress-induced cocaine seeking and cocaine cross-sensitization in laboratory rats*
F. Leri¹, Y. Zhou², M. J. Kreek², D. Jacklin¹, ¹Psychology, University of Guelph, Guelph, ON, Canada, ²Rockefeller University, New York, NY
- 10:15 *Methylphenidate as an intravenous reinforcer in rats: Individual differences in impulsivity predict self-administration*
J. A. Marusich, M. T. Bardo, University of Kentucky, Lexington, KY
- 10:30 *Reinstatement of nicotine-seeking behavior in rats: Effects of nicotine cues, priming, stress, and their combination*
X. Liu, Psychiatry and Human Behavior, University of Mississippi Medical Center, Jackson, MS
- 10:45 *Role of inhibitory neurosteroids in reducing cocaine self-administration and cue-induced reinstatement*
C. D. Schmoutz¹, S. P. Runyon², N. E. Goeders¹, ¹Pharmacology, Toxicology, and Neuroscience, Louisiana State University Health Sciences Center, Shreveport, LA, ²Organic and Medicinal Chemistry, Research Triangle Institute, Research Triangle Park, NC
- 11:00 *A novel cue reinstates extinguished cocaine-seeking behavior*
P. R. Kufahl, K. Heintzelman, C. Vargas, M. Painter, V. Routt, K. J. Thiel, J. L. Neisewander, Psychology, Arizona State University, Tempe, AZ
- 11:15 *Stress and cue interaction in the reinstatement of cocaine-seeking in female rats*
D. Buffalari, M. W. Feltenstein, R. E. See, Neuroscience, Medical University of South Carolina, Charleston, SC
- 11:30 *Effects of extended access and withdrawal on the reinforcing strength of cocaine using a cocaine vs. food concurrent-choice procedure in rhesus monkeys*
M. Banks¹, S. Negus^{1,2}, ¹Pharmacology and Toxicology, Virginia Commonwealth University, Richmond, VA, ²Alcohol and Drug Abuse Research Center, McLean Hospital/Harvard Medical School, Belmont, MA
- 11:45 *D-Cycloserine attenuates reactivity to smoking cues in nicotine-dependent smokers*
E. Santa Ana, B. Rounsaville, T. Frankforter, C. Nich, T. Babuscio, J. Poling, K. Gonsai, K. Hill, K. Carroll, Psychiatry, Yale University School of Medicine and VA CT Healthcare System, New Haven, CT

Oral Communications 19

Bonanza

10:00 AM - 12:00 PM

IMPULSIVITY AND AGGRESSION

Chairs: Joseph T. Sakai and Staci Gruber

- 10:00 *Structural brain differences between male adolescent patients with serious substance and conduct problems and controls: Comparing two automated analytic methods and examining cortical thickness*
J. T. Sakai¹, M. Dalwani¹, S. K. Mikulich-Gilbertson¹, J. Tanabe¹, K. Raymond¹, S. McWilliams¹, L. Thompson¹, M. Banich², T. J. Crowley¹, ¹University of Colorado Denver School of Medicine, Aurora, CO, ²Institute of Cognitive Science, University of Colorado Boulder, Boulder, CO
- 10:15 *fMRI brain activation during a delay discounting task in HIV-positive adults with cocaine dependence*
C. S. Meade^{1,2}, S. B. Lowen², R. R. MacLean², S. E. Lukas², ¹Psychiatry and Behavioral Sciences, Duke University, Durham, NC, ²Psychiatry, Harvard Medical School, Belmont, MA
- 10:30 *Neural correlates of aggressive responding in alcohol-dependent and control subjects*
S. D. Lane¹, J. L. Steinberg¹, N. Rathnayaka¹, D. R. Cherek¹, L. A. Kramer², P. A. Narayana², F. G. Moeller¹, ¹Psychiatry and Behavioral Sciences, University of Texas Health Science Center, Houston, Houston, TX, ²Diagnostic and Interventional Imaging, University of Texas Health Science Center, Houston, Houston, TX
- 10:45 *Impulsivity is correlated with white matter alterations in chronic marijuana smokers*
S. Gruber¹, M. Silveri¹, M. Dahlgren¹, D. Yurgelun-Todd², ¹Neuroimaging Center/Psychiatry, McLean Hospital/Harvard Medical School, Belmont, MA, ²Brain Institute, University of Utah, Salt Lake City, UT
- 11:00 *Temporal discounting and procrastination as predictors in a laboratory model of smoking abstinence*
R. Yi, A. E. Carter, Center for Addiction Research, University of Arkansas for Medical Sciences, Little Rock, AR
- 11:15 *Negative affect interacts with impulsivity to predict distress tolerance in a sample of inner-city substance users*
J. M. Richards, C. W. Lejuez, S. B. Daughters, E. Reynolds, M. Bornovalova, Clinical Psychology, University of Maryland, College Park, College Park, MD
- 11:30 *Substance use and aggression in the adolescent offspring of teenage mothers*
N. M. De Genna, M. Cornelius, Psychiatry, University of Pittsburgh, Pittsburgh, PA
- 11:45 *Differences in D2 receptor availability in high and low impulsive monkeys*
S. Groman¹, B. Lee², R. Rivera¹, E. London², D. Jentsch^{1,2}, ¹Psychology, University of California, Los Angeles, Los Angeles, CA, ²Psychiatry and Biobehavioral Sciences, University of California, Los Angeles, CA

Symposium XVI

**Rose Ballroom B
10:00 - 11:00 AM**

PRECLINICAL RESEARCH ON STRESS AND ADDICTION

Chairs: John R. Mantsch and Klaus A. Miczek

- 10:00 *The vicious cycle of stress and drug use: Glucocorticoid-dependent plasticity and CRF systems in cocaine addiction*
John R. Mantsch, Marquette University, Milwaukee, WI
- 10:20 *Episodic and continuous social stress: Divergent changes in cocaine reward and tegmental BDNF*
Klaus A. Miczek, Tufts University, Medford, MA
- 10:40 *Pro-addictive actions of dynorphin opioids*
Charles Chavkin, University of Washington, Seattle, WA

Symposium XVII

**Rose Ballroom B
11:15 AM - 12:15 PM**

COCAINE COCKTAILS: THE IMPACT OF CONCURRENT DRUG USE ON TREATMENT OF COCAINE

Chairs: Joy Schmitz and Alison Oliveto

- 11:15 *Comorbid opioid dependence status and treatment response to medications for cocaine dependence: The example of disulfiram*
Alison Oliveto, UAMS, Little Rock, AR
- 11:35 *Challenges in evaluating novel treatments for combined cocaine and alcohol*
Kyle M. Kampman, University of Pennsylvania, Philadelphia, PA
- 11:55 *The influence of concurrent marijuana use on treatment of cocaine dependence*
Joy Schmitz, University of Texas Medical School-Houston, Houston, TX

BRUNCH WITH CHAMPIONS (Pre-Registrants Only)

**Poolside Terrace
12:00 - 1:30 PM**

Symposium XVIII

**Rose Ballroom A
1:30 - 3:30 PM**

NICOTINIC CHOLINERGIC MECHANISMS IN DRUG DEPENDENCE: RECEPTOR SUBTYPES AND LIGANDS

Chairs: William A. Corrigall and David Shurtleff

- 1:30 *Presynaptic nAChR subtypes that modulate dopamine release; possibilities for selective activation of $\alpha 6\beta 2$ nAChRs*
Sharon Grady, University of Colorado, Boulder, CO
- 1:55 *The role of accessory subunits in modifying the function of alpha4beta2 receptors*
Jon Lindstrom, University of Pennsylvania, Philadelphia, PA
- 2:20 *Modulation of nicotine receptor functional tone by therapeutic agents and endogenous factors*
Roger Papke, University of Florida, Gainesville, FL
- 2:45 *The alpha5 nAChR subunit in nicotine dependence and cancer risk*
Thorgerir Thorgeirsson, deCode, Reykjavik, Iceland

3:10 *Drug discovery efforts in the nicotine receptor field*
Murali Gopalakrishnan, Abbott Laboratories, Abbott Park, IL

Oral Communications 20

Rose Ballroom B
1:30 - 3:30 PM

KEEPING THE FOCUS ON ADHD

Chairs: Scott Kollins and Lisa J. Merlo

- 1:30 *A double-blind, placebo-controlled trial of osmotic-release methylphenidate in initiating and maintaining abstinence in smokers with attention deficit hyperactivity disorder*
T. Winhusen¹, E. Somoza¹, G. Brigham¹, D. Liu², C. Green³, L. Covey⁴, I. Croghan⁵, L. Adler⁶, R. Weiss⁷, J. Leimberger⁸, D. Lewis¹, E. Dorer¹, ¹Psychiatry, University of Cincinnati, Cincinnati, OH, ²National Institute on Drug Abuse, Bethesda, MD, ³Kaiser Permanente Northwest, Portland, OR, ⁴New York State Psychiatric Institute, New York, NY, ⁵Mayo Clinic, Rochester, MN, ⁶New York University, New York, NY, ⁷Harvard University, Belmont, MA, ⁸Cancer Research Institute, Duke University, Durham, NC
- 1:45 *Prospective study of ADHD and risk for drug abuse*
K. Winters^{1,2}, G. August¹, G. Realmuto¹, ¹Psychiatry, University of Minnesota, Minneapolis, MN, ²Treatment Research Institute, Philadelphia, PA
- 2:00 *Prospective examination of the association of stimulant medication history and drug use outcomes in ADHD youth*
G. August, K. Winters, C. Realmuto, Psychiatry, University of Minnesota, Minneapolis, MN
- 2:15 *Adolescent methylphenidate treatment augments later vulnerability to cocaine addiction in rats with an ADHD phenotype*
R. C. Harvey, K. M. Kantak, Psychology, Boston University, Boston, MA
- 2:30 *Contingency management for smoking cessation in adults with and without Attention Deficit Hyperactivity Disorder*
S. Kollins, F. J. McClernon, E. VanVoorhees, J. S. English, M. Hallyburton, A. Holdaway, Duke University Medical Center, Durham, NC
- 2:45 *Sex effects on nicotine withdrawal in smokers with and without ADHD*
E. E. Van Voorhees, S. Kollins, F. J. McClernon, J. E. Rose, Duke University Medical Center, Durham, NC
- 3:00 *Attitudes of college students toward use and misuse of psychiatric medications*
A. M. Stone¹, L. J. Merlo^{2,1}, ¹Psychiatry, University of Florida, Gainesville, FL, ²Psychiatry, Washington University, St. Louis, MO

Oral Communications 21

Ponderosa B
1:30 - 3:30 PM

DOUBLE DOWN WITH MOM AND BABY: DRUGS OF ABUSE IN PREGNANCY

Chairs: Loretta Finnegan and Susan Stine

- 1:30 *Using community-based participatory research techniques to screen for substance abuse in low-income pregnant women receiving WIC services*
L. Keyser-Marcus, M. Welch, R. Singleton, D. Svikis, Psychology, Virginia Commonwealth University, Richmond, VA

- 1:45 *Characteristics associated with cocaine use in pregnant opioid-dependent women: Preliminary results from the Maternal Opioid Treatment, Human Experimental Research study*
S. Stine¹, A. Arria², K. O'Grady², K. Kaltenbach³, G. Fischer⁴, P. Martin⁵, S. Heil⁶, M. Coyle⁷, P. Selby⁸, H. Jones², ¹Psychiatry and Behavioral Neurosciences, Wayne State University School of Medicine, Detroit, MI, ²Johns Hopkins U, Baltimore, MD, ³Thomas Jefferson U, Philadelphia, PA, ⁴Medical U Vienna, Vienna, Austria, ⁵Vanderbilt U, Nashville, TN, ⁶U of Vermont, Burlington, VT, ⁷Brown U, Providence, RI, ⁸U of Toronto, Toronto, ON, Canada
- 2:00 *Telling the whole truth and nothing but the truth: Relationship between self-report measures of drug use and urine/hair assay results in post-partum women*
C. Smith¹, S. Ondersma², P. Lam², V. Conners², D. Svikis¹, ¹Psychology, VCU, Richmond, VA, ²Psychiatry, Wayne State, Detroit, MI
- 2:15 *Cigarette smoking and its treatment in pregnant, polysubstance-dependent women: Knowledge, attitudes and practice of patients and staff*
M. Chisolm, E. C. Pfeil, M. Tuten, E. C. Strain, H. E. Jones, Johns Hopkins University School of Medicine, Baltimore, MD
- 2:30 *Delivery and neonatal outcomes of methadone-maintained pregnant patients with and without a current mood disorder*
M. Tuten¹, H. Jones¹, K. O'Grady², H. Fitzsimons¹, S. Heil³, M. Chisolm¹, ¹Johns Hopkins University, Baltimore, MD, ²University of Maryland, College Park, College Park, MD, ³University of Vermont, Burlington, VT
- 2:45 *Neonatal isolation alters mother-pup interactions*
T. A. Kosten¹, P. Kehoe², ¹Psychiatry, Baylor College of Medicine, Houston, TX, ²University of California School of Nursing, Los Angeles, CA
- 3:00 *Smoking cessation and breastfeeding*
T. M. Higgins¹, S. T. Higgins², S. H. Heil², G. J. Badger², ¹Bates College, Lewiston, ME, ²University of Vermont, Burlington, VT
- 3:15 *Abnormal brain metabolite levels in children with prenatal nicotine exposure*
L. Chang, C. Cloak, L. Anderson, R. Kitamura, C. Jiang, S. Buchthal, A. Hoo, T. Ernst, Medicine, Division of Neurology, John A. Burns School of Medicine, University of Hawaii at Manoa, Honolulu, HI

Oral Communications 22

Bonanza
1:30 - 3:30 PM

METHAMPHETAMINE

Chairs: Leonard L. Howell and Sunmee Wee

- 1:30 *A receptor mechanism for methamphetamine action in dopamine transporter regulation*
Z. Xie, G. M. Miller, Neuroscience, New England Primate Research Center of Harvard Medical School, Southborough, MA
- 1:45 *Increased reward thresholds ("dysphoric"-like state) in rats with extended access to methamphetamine self-administration*
S. Wee¹, G. Schulteis², G. F. Koob¹, ¹Committee on the Neurobiology of Addictive Disorders, The Scripps Research Institute, La Jolla, CA, ²Anesthesiology, University of California San Diego, La Jolla, CA

- 2:00 *Behavioral inhibition is predicted by self-report measures of drug intoxication and withdrawal in methamphetamine-dependent people*
J. R. Coyle, M. J. Baggott, J. Mendelson, G. P. Galloway, Addiction Pharmacology, California Pacific Medical Center Research Institute, San Francisco, CA
- 2:15 *Effects of amphetamine derivatives on memory performance and tissue content of monoamine and amino acid neurotransmitters in mice*
K. S. Murnane¹, S. A. Perrine², W. E. Fantegrossi^{1,3}, M. P. Galloway², L. L. Howell^{1,4}, ¹Yerkes National Primate Research Center, Atlanta, GA, ²Wayne State University School of Medicine, Detroit, MI, ³University of Arkansas for Medical Sciences, Little Rock, AR, ⁴Emory University School of Medicine, Atlanta, GA
- 2:30 *Effects of catecholamine reuptake inhibitors and modafinil on methamphetamine self-administration in rats*
J. Jentsch, A. S. James, Psychology, University of California, Los Angeles, CA
- 2:45 *Modafinil improves cognitive performance in methamphetamine abusers: Evidence from human behavioral and fMRI studies*
D. G. Ghahremani¹, G. Tabibnia¹, J. Monterosso¹, R. A. Poldrack^{1,2}, E. D. London^{1,3}, ¹Psychiatry and Biobehavioral Science, University of California, Los Angeles, CA, ²Psychology, University of California, Los Angeles, CA, ³Molecular and Medical Pharmacology, University of California, Los Angeles, CA
- 3:00 *Functional MRI of methamphetamine users using a Go No-Go Task*
A. Stenger¹, W. Deng¹, H. Nakama², C. Gonzalez³, W. Haning², G. Fein¹, L. Chang¹, ¹Medicine, University of Hawaii John A. Burns School of Medicine, Honolulu, HI, ²Psychiatry, University of Hawaii John A. Burns School of Medicine, Honolulu, HI, ³Psychology, University of Hawaii, Honolulu, HI
- 3:15 *Neuropsychological test performance in current and abstinent methamphetamine users*
H. Nakama¹, C. Gonzales³, V. A. Stenger², L. Chang², ¹Psychiatry, University of Hawaii, Honolulu, HI, ²Medicine, University of Hawaii, Honolulu, HI, ³Psychology, University of Hawaii, Honolulu, HI

SWEEPSTAKES DRAWING

**Rose Ballroom A
3:35 - 4:05 PM**

***YOU MUST BE SEATED IN ONE OF THE SESSIONS AT
3:15 PM IN ORDER TO HAVE YOUR BADGE COLLECTED***

HAVE A SAFE TRIP HOME

SEE YOU IN SCOTTSDALE, ARIZONA, JUNE, 12-17, 2010

BADGES MUST BE WORN IN ALL SCIENTIFIC SESSIONS

AUTHOR INDEX

- Abdallah, A.B. 52
 Ablondi, K. 18
 Abood, M. 8, 9
 Abraham, A. 8
 Abrams, L.C. 21
 Abramssohn, Y. 36, 63
 Accornero, V.H. 31
 Aceto, M.D. 21
 Achat-Mendes, C. 17
 Acosta, M.C. 18
 Acri, J.B. 28
 Addou, S. 54
 Addy, C. 44
 Adelaja, O.A. 11
 Adelson, M. 36, 51, 63
 Adinoff, B. 31, 43
 Adler, L. 83
 Adler, M.W. 54
 Agar, M.H. 23
 Ahmedani, B.K. 73
 Akgun, E. 21
 Akins, C.K. 16
 Akitake, Y. 54
 Aklin, W.M. 62
 al'Absi, M. 55
 Albaugh, D.L. 51, 53
 Alexandre, J. 72
 Alford, D.P. 33, 51
 Ali, R. 25
 Alicata, D. 56, 71
 Allen, A.M. 55
 Allen, S.S. 55
 Allensworth-Davies, D. 61, 74
 Altus, L. 77
 Alvanzo, A. 19
 Alvarado, G.F. 73
 Alvarez, K. 71
 Alvarez-González, C. 12
 Alyea, R.A. 54
 Amador, N.J. 21
 Amano, T. 17
 Amass, L. 10
 Amen, S.L. 43
 Ananthan, S. 16
 Anderson, K. 59
 Anderson, K.G. 58
 Anderson, L. 84
 Andorn, A.C. 56, 79
 Andrews, G. 12
 Ang, A. 24
 Angiolieri, T. 36
 Anglin, M.D. 10
 Anker, J.J. 20, 69
 Annaheim, B. 41
 Anselmo, E. 13
 Anstice, S. 13
 Anthony, J.C. 4, 11, 20, 44, 56, 73, 76
 Aoo, N. 54
 Appugliese, D. 57
 Archibald, L. 18
 Arfken, C.L. 56
 Arnsten, J. 39
 Aron, A. 59
 Arrant, A.E. 53
 Arria, A. 64, 84
 Ary, A.W. 50, 54
 Asato, M. 14
 Asghar, A. 77
 Ashrafioun, L. 16
 Asteriadis, S.J. 78
 Aston-Jones, G. 27
 Ator, N.A. 65
 Auclair, C. 22
 August, G. 83
 Auriacombe, M. 34, 36, 39, 72, 76
 Authier, N.A. 22
 Avison, M.J. 31
 Babalonis, S. 68
 Babor, T. 25
 Babuscio, T. 80
 Back, S.E. 11, 19, 34, 35, 38
 Badger, G.J. 50, 55, 58, 84
 Badin de Montjoye, B. 75
 Baella, S.A. 14
 Baggott, M.J. 3, 15, 34, 52, 67, 85
 Bailey, J.E. 11, 37, 38
 Baker, A. 35
 Baker, N.L. 3, 71, 75
 Bakken, N.W. 11
 Baladi, M. 14
 Balasingam Kasinather, V. 41
 Balda, M.A. 52
 Baldisserotto, G. 72
 Baldwin, R. 71
 Ball, S. 76
 Balster, R. 1, 66
 Balter, R.E. 54
 Bandstra, E.S. 31
 Banich, M. 81
 Banich, M.T. 71
 Banks, M. 80
 Bantchevska, D. 13
 Bardo, M. 45
 Bardo, M.T. 14, 16, 59, 80
 Bar-Hamburger, R. 12
 Baron, D.A. 36
 Barondess, D.A. 73
 Barr, G. 21
 Barr, J. 30
 Barrett, E.L. 10, 35
 Barrick, C. 40
 Barry, D. 38, 79
 Bart, G. 66, 70
 Bartle-Haring, S. 13
 Basak, A. 26
 Bass, C.E. 66
 Batis, J. 56
 Batki, S.L. 39
 Batlle, F. 63
 Battisti, M.C. 41
 Bauernfeind, A. 13
 Baumann, M.H. 51
 Beach, M.C. 38
 Beardsley, P. M. 45
 Beardsley, P. 28
 Beatty, L.A. 44
 Becker, J. 24, 25
 Beckmann, J. 45
 Bedi, G. 45
 Beesdo, K. 44
 Behonick, G. 4
 Behrendt, S. 44
 Bell, C. 70
 Bell, J. 50
 Bellows, A. 24
 Ben Abdallah, A. 3, 10, 60
 Benamar, K. 54

AUTHOR INDEX

- Benbenishty, R. 64
 Bennett, A.J. 54
 Benowitz, N. 49
 Ben-Shahar, O.M. 50
 Benson, P. 22
 Benzano, D.B. 41, 42, 72
 Bergman, J. 53
 Bergthold, T.L. 34, 35
 Berhane, S.S. 75
 Bernstein, I. 57
 Berry, M.S. 40
 Berstein, I. 58
 Berthel, T. 40
 Best, A. 37
 Best, S.E. 31
 Beveridge, T.J. 53
 Bevins, R. 30
 Bibbey, A. 71
 Bickel, W.K. 13, 46, 55, 59
 Bidlack, J.M. 26
 Bierut, L. 64
 Bigelow, G.E. 35, 62, 74
 Bilder, R.M. 59
 Birk, T.J. 51, 63
 Bisaga, A. 17, 62
 Black, A.C. 18
 Black, R.A. 7, 75
 Blackford, J.U. 26
 Blanchard, J. 36
 Blanco, C. 79
 Blendy, J. 1
 Bliss, C. 39
 Bloom, A.S. 43
 Blough, B.E. 16
 Bluthenthal, R. 4, 41
 Bobashev, G. 47
 Bockman, C.S. 30
 Boeger, R.H. 52
 Boesch, L. 50
 Bogenschutz, M.P. 19
 Bohnert, K.M. 73
 Boileau, I. 45
 Bois, F. 56, 71
 Bokarius, A.V. 59
 Bolin, B.L. 16
 Bolyard, M. 61
 Bonn-Miller, M.O. 64
 Boos, T.L. 23
 Booth, C. 30
 Booth, R.E. 9
 Booth, R.G. 15
 Booze, R.M. 54
 Borah, E. 23
 Borges, G. 28, 72
 Bornovalova, M.A. 20, 24, 61, 81
 Bösch, L. 23
 Bosch, P. 15
 Boschen, K. 45
 Botsko, M. 9
 Boujenah, J.L. 78
 Bouju, G. 34
 Bourgois, P. 4, 41
 Bowen, B.C. 31
 Bowen, S.E. 26
 Bradford, J.B. 58
 Bradford, S.E. 60
 Bradstreet, M.P. 57, 58
 Brady, K.T. 2, 3, 11, 32, 34, 35, 38, 57
 Bramness, J.G. 68
 Branch, C. 76, 77, 78
 Brands, B. 11, 19, 36, 75
 Brecht, M.L. 10, 24
 Breland, A. 8
 Breslau, J. 72
 Breslau, N. 73
 Brigham, G. 22, 83
 Brimijoin, W.S. 67
 Broadus, A.D. 34, 40
 Brody, A.L. 59
 Bronnec, M. 34
 Brooks, A. 9
 Brooks, D.J. 17, 35, 59, 75
 Brooner, R.K. 35
 Brown, B.S. 9, 23, 61, 62, 63
 Brown, L.L. 16
 Brown, L.S. 78
 Browne, F. 58, 60
 Brownstein, J.S. 7, 11
 Brucker, D. 8
 Bruehl, A. 77
 Bruner, N.R. 58
 Brunzell, D. H. 45
 Bryan, B.R. 18
 Buadze, A. 35
 Buchthal, S. 84
 Buckwalter, M. 32
 Budde, H. 13
 Budman, S.H. 7
 Budney, A.J. 28, 46, 60
 Buffalari, D. 80
 Bühringer, G. 24, 56
 Burakov, A. 3
 Burden, M.J. 31
 Burns, M. 70
 Buscemi, R. 3
 Bushara, N. 3
 Busto, B. 45
 Butler, S.F. 7, 11, 74, 75
 Byrne, M. 76
 Cabral, H. 57
 Cacciola, J. 29
 Cacoub, P. 38
 Cadet, J.L. 51
 Caldeira, K. 64
 Calderon, J.M. 12
 Caldwell, D. 78
 Callaghan, R. 36
 Calsyn, D.A. 9, 45
 Calvin, N. 71
 Campbell, R.H. 14
 Campollo, O. 12, 76
 Campos, M. 10
 Campos, P.S. 65
 Campos, S. 78
 Canfield, K.M. 39
 Cao, A. 32
 Carbonaro, T. 69
 Cardenas, G. 70
 Cardús, M. 63
 Caretta, H. 33
 Cargile, C.S. 3, 18
 Carise, D. 29
 Carlini, C. 12
 Carlson, R. 42
 Carney, T. 60
 Carosso, G.A. 50
 Carpenter, K.M. 40, 62
 Carpenter, L. 4

AUTHOR INDEX

- Carpenter, M.J. 3, 55, 71, 75
 Carr, G.V. 27
 Carr, S.M. 23
 Carroll, F. 2
 Carroll, K. 80
 Carroll, M.E. 20, 25, 69
 Carter, A.E. 81
 Carter, L.P. 68
 Carter, R.E. 3, 19, 57
 Cassidy, J. 71
 Cassidy, T.A. 7
 Cassin, J. 70
 Castel, S. 75
 Castellanos, E. 13
 Catacora, M.M. 20
 Cavanaugh, C.E. 60, 61
 Caven, A.P. 54
 Cawley, S. 62
 Chait, B.T. 54
 Chakraborty, B. 14, 44
 Chandler, S. 23, 38
 Chang, L. 43, 56, 71, 84, 85
 Chaplin, T. 2
 Chapman, C.D. 14
 Chapman, E. 32
 Charboneau, E.J. 13, 26
 Chartier, M. 79
 Chaudhry, A.A. 9
 Chaudhury, R. 58
 Chaves, T. 13
 Chavkin, C. 82
 Chawarski, M.C. 39, 41, 60, 62
 Chen, C.A. 51
 Chen, C.Y. 56
 Chen, N. 44, 46
 Chen, S. 47
 Chen, S.A. 30
 Chen, X. 54
 Cheng, D.M. 51, 61, 74
 Cheng, H. 56
 Cheng, K. 65
 Cherek, D.R. 81
 Cherpitel, C. 72
 Chiang, C. 67
 Chiauzzi, E. 48
 Chilcoat, H.D. 3, 4, 19, 20, 56, 79
 Childress, A.R. 31, 49, 50, 65
 Chim, D. 77
 Chin, I. 56, 71
 Chisolm, M. 84
 Chiuccariello, L. 45
 Choi, J. 25
 Chopra, M. 3
 Choustermann, M. 38
 Christensen, D.R. 59
 Chu, M. 78
 Chu, P. 33
 Cicero, T. 7
 Ciller Valverde, L. 20
 Cios, H. 43
 Clark, L. 42
 Clark, N. 25
 Clarke, J. 9, 10
 Clatts, M. 37
 Clausen, T. 4, 40
 Clayton, T. 65, 68
 Cleland, C. 4
 Cleveland, J. 37
 Clinkinbeard, S.S. 40
 Cloak, C.C. 56, 71, 84
 Co, C. 65
 Coffey, S.F. 35, 60
 Coffin, L. 22, 63
 Cohen, B. 67
 Cohn, J. 38
 Coker, A.R. 17
 Colby, S.M. 55
 Cole, K.T. 53
 Coleman, V.H. 58
 Colescott, P. 24
 Colfax, G. 33
 Collier, W. 43
 Collins, C. 11, 12, 22, 59
 Collins, G.T. 52
 Colucci, R. 21, 37, 79
 Comer, S.D. 37, 66
 Comerford, M. 19
 Compton, P.A. 46
 Compton, W. 78
 Conklin, C.A. 55
 Conn, N. 46
 Conner, B. 10
 Connor, J.P. 36
 Connors, V.M. 74, 84
 Conway, K.P. 78
 Cook, J.M. 65, 68
 Cooney, B. 75
 Coop, A. 16
 Cooper, D.C. 31
 Cooper, Z.D. 37
 Copeland, J. 77
 Cornelius, J.R. 37
 Cornelius, M. 36, 81
 Correa, E. 72
 Corrigan, W.A. 30, 82
 Corsi, K.F. 9
 Cosgrove, K. 71
 Cosio, L. 77
 Cotlar, R. 36
 Cotter, F. 77
 Cottler, L.B. 3, 7, 10, 46, 52, 60, 64, 74
 Cotton, D. 39
 Courty, P.Y. 22
 Cousins, S.J. 8, 24
 Covey, L. 83
 Coviello, D.M. 23
 Cowan, R.L. 13, 26, 31, 32
 Coyle, J.R. 34, 85
 Coyle, M. 58, 84
 Craft, R.M. 20
 Cravatt, B. 9
 Crawford, C.A. 14
 Crecelius, R. 10
 Creemers, H.E. 44
 Crevecoeur-MacPhail, D.A. 33, 77
 Crits-Christoph, P. 40
 Croghan, I. 83
 Crooks, P. 45
 Crow, A. 69
 Crowley, T.J. 9, 28, 71, 81
 Cruz, M.A. 12
 Cruz, S.L. 54
 Cruz, V. 73
 Cuhaciyan, C. 69
 Culmer, T. 43
 Cummings, A.M. 19
 Cunningham, J.K. 33
 Cunningham, K.A. 52, 54, 59
 Curley, L.E. 15

AUTHOR INDEX

- Cutter, C. 79
 Czerczyk, C. 12
 Czoty, P.W. 31
- Daamen, M. 15
 Dahlbom, M. 59
 Dahlgren, M. 81
 Dallery, J. 55
 Dalwani, M. 71, 81
 Dandy, K.L. 69
 Daniels, S. 21
 Dart, R.C. 11, 37, 38, 66
 Das-Douglas, M. 33
 Dasgupta, N. 4, 56
 Daugherty, D.E. 27
 Daughters, S.B. 20, 24, 34, 61, 71, 81
 Daulouede, J. 36
 Davis, C.M. 27
 Day, D. 15
 De Boni, R. 72
 De Genna, N.M. 36, 81
 De La Garza, II, R. 43
 de la Paz, D. 13
 de Toni, E.C. 14
 de Wit, H. 45
 Deadwyler, S. 31
 Dean, A.C. 33
 DeBoni, R. 41
 Debrabant, R. 72
 DeFulio, A. 62, 70
 Degenhardt, L. 25
 del Rio, C. 70
 DeMartini, J. 50
 Denehy, E. 45
 Deng, W. 85
 Denis, C. 34, 36, 72
 Dennis, K. 32
 Dennis, M.J. 18
 Dennis, M.L. 18, 48, 58, 64, 75
 Dersch, C.M. 16
 Des Jarlais, D.C. 22, 63
 DeSantis, S.M. 34
 Desmond, R.C. 19
 DeSouza, C. 70
 Dess, N.K. 14
 Detre, J. 31, 65
- Devous, M.D. 31
 Dewey, W. 49
 Dias, S. 74
 Diaz, S.E. 69
 Dickerson, D.L. 24, 40
 Dickson, M. 78
 Diederichs, C. 21
 Diehl, B. 32
 Diemen, L.V. 42
 Dierst-Davies, R. 10
 Dietrich, M.S. 13, 26, 32
 Dilley, J. 79
 DiPirro, J.M. 54
 DiRocco, D. 3
 Dissabandara, L.O. 74
 Dittmer, K. 56
 Dobscha, S.K. 22
 Dodge, N.C. 31
 Dogra, M. 22
 Doll, W. 32
 Domier, C. 24, 33, 63
 Donlin, W.D. 70
 Dorer, E. 83
 Doty, P. 5
 Douville, K. 43
 Dow-Edwards, D. 57, 65
 Driscoll, J.R. 17
 Du, Y. 71
 Duan, Y. 46
 Dubray, C. 22
 Ducat, E.A. 66, 70
 Duff, H. 12
 Duke, F. 50
 Dumchev, K. 23, 38
 Duncan, A. 40
 Dunlap, E. 23, 42
 Dunn, K. 11, 28, 50, 51
 Dunne, E.M. 61
 DuPree, J.P. 15
 Durgerian, S. 43
 Durham, T.G. 77
 Duvall, J.L. 10, 73, 74
 Dwoskin, L. 45
 Dwoskin, L.P. 16
 Dykstra, L.A. 1, 21, 27, 43, 54
- Earleywine, M. 37
 Edelen, M.O. 64
 Edmundson, E. 6, 8
 Egan, J.E. 9, 22, 62, 63
 Egan, K. 65
 Egorova, V. 3
 Ehrman, R.N. 31, 49, 50
 Eisenstein, T.K. 54
 El-guebay, N. 7
 Elkader, A.K. 36
 Elliott, M. 17
 Elman, I. 34
 Elsken, C. 69
 Engeland, A. 68
 English, J.S. 83
 Enman, N. 16
 Eppolito, A.K. 68
 Epstein, D.H. 19, 45, 55
 Ermer, J. 32
 Ernst, T. 56, 84
 Eschalier, A. 22
 Espinoza, M.T. 13
 Esterlis, I. 56
 Estrada, B. 9
 Ettenberg, A. 20, 52
 Evans, C. 1
 Evans, E. 10, 33, 76
 Evans, R.J. 12, 55
 Evans, S.M. 32, 59
 Evenden, J. 60
 Everhart, E. 32, 67
 Everly, J. 62
 Evins, A.E. 55
- Fahey, J. 62, 63
 Falck, R. 42
 Faller, S. 42
 Fan, J. 10
 Fang, W. 32
 Fanous, S. 66
 Fantegrossi, W.E. 69, 85
 Farabee, D.J. 24
 Farahi, J. 59
 Fariás, P.P. 13
 Farley, C.M. 14
 Farnum, S.O. 76
 Farrell-Moore, D. 8

AUTHOR INDEX

- Fatseas, M. 34, 36, 72, 76
 Fava, M. 55
 Feeney, G. 36
 Fein, G. 85
 Felch, L.J. 74
 Feldman, D. 17
 Feldman, Z. 3
 Felgate, P. 52, 67
 Feltenstein, M.W. 30, 34, 80
 Feltner, D. 5
 Feltz, D.L. 20
 Ferguson, D.M. 2
 Fernandez, E. 32
 Ferreira, E.F. 13
 Feske, U. 36
 Festinger, D. 29
 Fields, H.L. 17
 Fields, S. 11, 59
 Fiellin, D. 9, 22, 38, 62
 Fiestas, F.A. 20, 76
 Filippell, T. 51
 Fingerhood, M. 62
 Finkelstein, R. 62
 Finnegan, L. 83
 Finnerty, B. 78
 Fischer, B.D. 68
 Fischer, G. 58, 63, 84
 Fishback, J.A. 32
 Fiske, L. 3
 Fitzgerald, A. 61
 Fitzmaurice, G. 56
 Fitzsimons, H. 84
 Flanigan, T. 9
 Fleis, C. 72
 Fleury, B. 72
 Flisher, A.J. 79
 Florence, T.J. 42
 Flower, K. 3, 67, 72
 Floyd, L.J. 12, 39, 61
 Foley, K. 19
 Folk, J.E. 21
 Follent, A. 12
 Foltin, R.W. 57
 Fong, C. 4
 Fontanges, T. 38
 Forcehimes, A.A. 19
 Ford, J.H. 8, 23, 76
 Fordwood, S. 79
 Foresti, K. 14
 Forman, R. 40
 Forster, M.J. 69
 Fosdick, J. 30
 Fox, H. 34
 Fox, R.G. 52
 France, C.P. 14, 27, 65, 68
 Frank, D.A. 57
 Frank, J.C. 70
 Frankforter, T. 80
 Franklin, T. 31, 49, 50, 65
 Frazier, L. 8
 Frederick, B.B. 55, 68
 Freeland, D. 21
 Freeman-Daniels, E.L. 65
 Freese, T.E. 8, 77, 78
 Frewen, A. 77
 Friedman, S.R. 61
 Friedmann, P.D. 10
 Frisman, L. 9, 10, 73
 Froeliger, B.E. 55
 Frohlich, E. 71
 Frost, J. 18
 Fry, J. 41
 Fuchs, C. 61
 Fudala, P.J. 74
 Fukuda, K. 14
 Fuller, C. 38
 Funada, M. 54
 Funk, R. 13
 Furr-Holden, C. 41
 Fussell, H.E. 22
 Gabriele, A. 65
 Gage, H.D. 31
 Galea, S. 67
 Gallon, S. 77
 Gallop, R. 19, 40
 Galloway, G.P. 3, 15, 34, 52, 67, 85
 Galloway, M.P. 26, 85
 Gamini, H. 74
 Gancarz, A.M. 16, 54
 Gandhi, D. 51, 61, 62
 García Fernandez, G. 70
 Garcia, E.E. 31
 Garcia, F. 46
 García-Rodríguez, O. 20, 70
 Garcia-Villarreal, M.D. 33
 Garland, S.L. 58
 Garner, B. 13
 Garnet, B. 62, 79
 Garren, R. 13
 Garrison, K.J. 15, 34
 Gass, J. 42, 63
 Gatch, M.B. 69
 Geiger, T. 20
 Gelernter, J. 74
 Gelhorn, H. 9
 Geller, E.B. 54
 Gentry, A. 58, 60
 Gentry, W.B. 18, 67, 70
 George, T.P. 45, 56
 Gerak, L.R. 68
 German, N.A. 66
 Gerteis, J. 57
 Gervais, A. 78
 Ghahremani, D.G. 85
 Ghitza, U. 77
 Gholson, M. 22
 Ghozland, S. 23
 Gilbert, D. 7
 Gilbertson, R. 71
 Gill, K.E. 54
 Gilmour, B.P. 32
 Gilpin, M. 22
 Gipson, C. 59
 Glaser, P.E.A. 55
 Glasmacher, C. 15
 Glasner-Edwards, S. 24
 Glennon, R.A. 66
 Glick, S. 14
 Gmel, G. 41
 Godley, M. 13
 Godley, S.H. 13, 48
 Goeders, N.E. 33, 69, 75, 80
 Gold, M. 36
 Gold, M.S. 7, 71
 Goldberger, B.A. 7
 Goldim, J. 72
 Goldman, M. 31, 49, 50, 65
 Goldsamt, L. 37
 Gomes, C.M. 13

AUTHOR INDEX

- Gonsai, K. 80
 Gonzales, C. 85
 Gonzales, R. 10, 24, 33
 Gonzalez, C. 19, 85
 Gonzalez, G. 46
 González, P. 13
 Gonzalez-Espinosa, C. 54
 Gooden, L. 70
 Gopalakrishnan, M. 83
 Gordon, M.S. 74
 Gorelick, D. 12, 18
 Gorka, S.M. 24, 34, 61
 Gossop, M. 4, 10, 62
 Gould, T.J. 30
 Goulet, J. 38
 Gourarier, L. 78
 Gourevitch, M. 3
 Govan, S. 14
 Govindaraju, V. 31
 Gowin, J. 71
 Grabowski, J. 75
 Grady, S. 82
 Graham, C. 60, 61
 Graham, N.A. 7, 71
 Grasing, K. 43, 70
 Graves, S.M. 15
 Gray, J. 57
 Gray, K.M. 3, 55, 71, 75
 Green, C. 18, 59, 63, 83
 Green, T.C. 7
 Greenfield, S.F. 9, 19
 Greenwald, M.K. 21, 22, 33, 57, 60
 Greenwell, L. 24, 73
 Gregorio, L. 19
 Grekin, E.R. 74
 Griffin, B. 64
 Griffin, M. 56
 Griffiths, R.R. 18, 68
 Groman, S. 81
 Grossman, E. 3
 Grottenthaler, A. 55
 Gruber, S.A. 31, 81
 Gruber, V. 38
 Gryczynski, J. 63, 78
 Gueorguieva, R. 74
 Guerin, G.F. 33, 69
 Guillou, M. 34
 Gunderson, E.W. 18
 Gur, M. 77
 Gust, S.W. 29
 Gustafson, D.H. 8, 23
 Gutierrez-Padilla, A. 76
 Gutkin, B. 47
 Guydish, J. 22, 79
 Guzman, D. 20
 Gwaltney, C.J. 55
 Gyarmathy, V. 60
 Haffey, M. 32
 Hakun, J. 31
 Hall, E. 19
 Haller, D.L. 18, 58
 Hallyburton, M. 83
 Halpern, J.H. 44
 Hamburger, R.B. 64
 Hamilton, A.B. 33, 75
 Hamilton, E.C. 50
 Hammer, Jr, R.P. 66
 Hamon, S. 17
 Hampson, R. 31
 Haney, M. 7, 57
 Haning, W. 24, 44, 85
 Hanlon, C.A. 26, 47
 Hannigan, J.H. 26
 Hansen, S. 34
 Hao, X. 46
 Hara, M. 56, 72
 Harbonnier, J. 39
 Harocopos, A. 37
 Harp, K. 73
 Harper, D. 65
 Harris, G.C. 27
 Harris, L.S. 1, 8, 9, 21
 Harris, T.S. 31
 Harrison, J.A. 62, 74
 Harrison, S. 51
 Harrod, S.B. 30
 Hart, C.L. 15, 55
 Hart, N. 45
 Harte, L.C. 57
 Hartje, J.A. 34, 40, 46, 78
 Hartwell, K. 34
 Harvey, R.C. 83
 Hasan, K.M. 26
 Hatanaka, H. 77
 Hatsukami, D.K. 11, 49, 55
 Hatton, K.W. 8
 Haug, N. 57
 Havens, J.R. 9, 10, 73
 Hawken, A. 10
 Hayden, V. 13
 Haynes, L. 19, 78
 Hays, J.W. 78
 Hays, L.R. 32, 57
 Heapy, A. 38
 Hedden, S.L. 39, 60, 61, 72
 Heeney-Buggey, C. 60
 Heeren, T. 39, 57
 Hegstad, S. 62
 Heil, S.H. 11, 57, 58, 84
 Heilig, M.A. 30
 Heinisch, S. 26
 Heintzelman, K. 80
 Heinzerling, K.G. 33, 42
 Heishman, S.J. 45, 54, 55
 Hemberg, J. 24
 Hemby, S.E. 43, 65
 Henderson, S. 50
 Hendrick, E. S. 45
 Henker, J. 24, 56
 Henningfield, J. 5, 22, 49, 66
 Henry, P.K. 50
 Henslee, A.M. 35
 Herbert, M.S. 14
 Herin, D.V. 18, 75
 Herrmann, E. 57
 Herrold, A.A. 27
 Hersh, D. 22
 Hess, M. 50
 Hewitt, J. 9
 Hidalgo, C.G. 13
 Higgins, S.T. 1, 11, 51, 57, 58, 84
 Higgins, T.M. 84
 Hilde, A. 60
 Hile, M. 8
 Hill, E. 12
 Hill, K. 80
 Hillard, C.J. 43

AUTHOR INDEX

- Hillhouse, M.P. 19, 24, 33, 61,
62, 63, 77
- Hills, D. 69
- Hironaka, N. 52
- Hjerkinn, B. 62
- Ho, A. 16, 17, 25, 39, 66, 70
- Hoch, E. 24, 56
- Hoffman, I.F. 60
- Hoffman, K. 23
- Höfler, M. 24, 44
- Holbrook, A. 57
- Holdaway, A. 83
- Hole, A.V. 31, 49
- Holmer, B. 72
- Holmes, B.W. 78
- Holtz, N. 20
- Holtzman, A. 71
- Homish, G.G. 37, 40
- Hoo, A. 84
- Hopfer, C. 9
- Hopwood, S. 35
- Horman, B. 65
- Horn, L.R. 14
- Horne, C.E. 55
- Horton, A.M. 75
- Horton, D. 45
- Horvatich, P. 6
- Hosmane, B. 37
- Houck, J.M. 19
- Houle, S. 45
- Howell, L.L. 16, 50, 53, 84, 85
- Hser, Y. 24, 33, 40, 56, 64, 72,
76
- Huang, W. 46
- Huang, Y.C. 56, 72
- Huang, Y.D. 64
- Huestis, M.A. 51
- Hughes, J.R. 56
- Huizink, A. 2, 44
- Hulbert, A. 72
- Hunter, B. 13
- Hunter, D. 21
- Hunter, J. 10, 24
- Hussain, M. 72
- Hutchison, M.A. 30, 53
- Huynh, J. 25
- Hwang, J. 31
- Hyde, M. 21
- Hyman, S.M. 34
- Ialongo, N.S. 18, 64
- Icick, R. 76
- Iguchi, M. 4, 41, 49
- Iijima, M. 57
- Ikeda, K. 41, 52
- Ikegami, D. 14
- Imhoff, S. 11, 59
- Inciardi, J.A. 10, 11
- Indlekofer, F. 15
- Irvine, R.J. 15, 51, 52, 67
- Islam, L. 19
- Itasaka, M. 52
- Itzhak, Y. 52
- Izenwasser, S. 25, 30, 45, 51
- Jacklin, D. 80
- Jackson Bloom, J. 37
- Jackson, A. 57
- Jackson, C. 17, 39
- Jacob III, P. 32
- Jacobson, J.L. 31
- Jacobson, S.W. 31
- Jaehne, E.J. 15
- Jaffe, J.H. 51, 63
- Jaffee, W.B. 56
- Jain, R. 37
- Jairl, C.A. 17
- James, A.S. 17, 85
- Jancaitis, B.C. 58
- Janes, A.C. 55
- Janisse, J. 36
- Jaramillo, A. 13
- Jenab, S. 20, 21, 69
- Jenkins, J. 62, 63, 77
- Jenkins, L.M. 34
- Jens, W. 31, 49, 50, 65
- Jentsch, J.D. 17, 81, 85
- Jia, Z. 2
- Jiang, C. 84
- Johanson, C.E. 57, 66
- John-Hull, C. 78
- Johnson, B.D. 42, 73
- Johnson, E. 41
- Johnson, F. 21
- Johnson, G. 51
- Johnson, J. 78
- Johnson, K. 64, 77
- Johnson, M.W. 18, 68
- Johnson, R.E. 74
- Johnston, A. 41
- Jones, B. 3, 35
- Jones, B.A. 13
- Jones, C. 77
- Jones, H.E. 58, 84
- Jones, J.D. 66
- Jones, K. 38
- Jones, R.T. 32
- Jordan, A. 22, 63
- Jungman, J. 78
- Justice, A. 38
- Jutkiewicz, E.M. 30
- Kadunc, J. 23
- Kakibuchi, Y. 41
- Kalayasiri, R. 74
- Kalechstein, A.D. 33
- Kalivas, P.W. 50
- Kaltenbach, K. 5, 57, 58, 84
- Kamien, J.B. 10
- Kampman, K.M. 31, 65, 72, 82
- Kangarlu, A. 46
- Kantak, K.M. 50, 69, 83
- Kaplan, J.R. 31
- Kaprio, J. 44
- Karageorgiou, J. 26
- Karelitz, J.L. 55
- Kasinather, V.B. 60
- Katz, E.C. 9, 61, 62
- Kaufman, M.J. 1, 55
- Kaur, A. 72
- Kaushal, N. 16
- Kaye, K. 76
- Keane, M. 52
- Kehoe, P. 46, 84
- Kellam, S. 18
- Keller, C. 69
- Kelley, J. 51
- Kelley, M. 5
- Kelly, S.M. 23, 51, 63
- Kelly, T.H. 57, 68, 71
- Kennedy, M.G. 58
- Kerns, R. 38

AUTHOR INDEX

- Kerstetter, K.A. 20, 69
 Kertesz, S. 3, 35
 Kerwin, M. 5
 Kessler, F.H. 13, 42
 Keyser-Marcus, L. 19, 83
 Khan, M. 61
 Khodneva, Y. 3, 35
 Kichko, I. 51
 Kielstein, A. 52
 Kielstein, J.T. 52
 Killeen, T.K. 3
 Kim, H.J. 31
 Kim, I. 51
 Kim, J.S. 66
 Kim, K. 14
 Kim, N. 31
 Kim, T.W. 61
 Kimmel, H.L. 16
 King, A.C. 45
 King, G.R. 71
 King, S.D. 9, 61, 62
 King, V.L. 35
 Kinlock, T.W. 74
 Kippin, T.E. 20, 69
 Kirby, K.C. 29
 Kirby, L.G. 26, 65
 Kirisci, L. 57
 Kirk, I.J. 15
 Kirsner, R.S. 51, 63
 Kirtland, M. 37
 Kitamura, R. 84
 Kitchen, C.M. 33
 Kivell, B.M. 15
 Kjome, K.L. 59
 Kleber, H.D. 77
 Klein, C. 13
 Klein, H. 61
 Kleykamp, B.A. 62
 Kline, R. 2
 Klingman, C. 71
 Klintworth, E.M. 3, 55, 71, 75
 Kloczynski, T. 56
 Klorman, R. 31
 Klug, S. 63
 Klugmann, M. 54
 Knowlton, A.R. 39
 Knudsen, H.K. 10, 22, 73
 Ko, J. 19, 20
 Ko, M.C. 69
 Koak, W. 14
 Kobeissy, F. 71
 Kober, H. 55
 Koch, J.R. 8
 Kochanska, K. 24
 Koek, W. 27, 65
 Kohon, J. 22
 Kohut, S.J. 53, 65
 Kollins, S. 83
 Koob, G.F. 84
 Kopetz, C.E. 20, 61
 Korhonen, T. 44
 Korthuis, P.T. 38
 Kostakis, C. 67
 Kosten, T.A. 84
 Kosten, T.R. 46, 67
 Kotz, C.M. 30
 Kowalczyk, W.J. 37, 66
 Kowalewski, R.R. 23
 Kozink, R.V. 55
 Kozlov, A.P. 60
 Kraeff, C. 76
 Kral, A. 4, 41
 Kramer, L.A. 26, 81
 Kranzler, H. 74
 Krauss, R.M. 15
 Kreek, M.J. 1, 16, 17, 25, 34, 39, 53, 54, 66, 70, 80
 Kreps, G. 48
 Kristensen, Ø. 40, 62
 Kritz, S.A. 78
 Kross, E. 55
 Kruglanski, A.W. 61
 Krupitsky, E. 3, 60
 Krystal, J. 71
 Kubiak, S.P. 73
 Kufahl, P.R. 80
 Kuhar, M. 47
 Kuhn, C.M. 25, 53
 Kulaga, A. 40
 Kunøe, N. 10, 62
 Kuper, L.E. 19
 Kuramoto, S.J. 19, 20, 38
 Kurtz, J. 62
 Kurtz, S.P. 11
 Kuzumaki, N. 14, 17
 Kydd, R.R. 14, 15
 Lacy, R.T. 30
 Ladenheim, B. 51
 Lake, B. 15
 Lam, P.K. 74, 84
 Landes, R.D. 13, 59
 Lane, S.D. 26, 59, 71, 81
 Lang, J. 38
 Lange, K.W. 15
 Langleben, D.D. 50
 Lankenau, S. 37
 Lapidus, J. 60
 Larios, S.E. 38, 79
 Larkins, S. 8, 78
 Larowe, S.D. 59
 Lasagna, A. 13
 Latimer, W.W. 12, 39, 60, 61, 72
 Latkin, C.A. 38, 60
 Laudet, A.B. 18, 40, 60
 Laurenzana, E.M. 70
 Lavie, E. 36, 39, 72
 Lawental Schori, M. 77
 Lawental, E. 77
 Lawhorn, C. 16
 Lawson, A. 61
 Lazar, J. 62
 Lazar-Wesley, E. 47
 Le Foll, B. 45
 Lechner, W.V. 59
 Ledgerwood, D.M. 56
 Ledon, J. 30, 51
 Lee, B. 59, 81
 Lee, D.C. 71
 Lee, G.P. 37
 Lee, H. 14, 35
 Lee, J.D. 3
 Lehman, W.K. 9
 Leiderman, D. 5
 Leimberger, J. 83
 Leinbach, A.S. 3, 71, 75
 Leisinger, R. 50
 Lejuez, C.W. 20, 61, 71, 81
 Lenoir, M. 30
 Leonard, K.E. 37, 60

AUTHOR INDEX

- Leone, M.C. 34
 Leraas, K. 11, 59
 Leri, F. 80
 Lerman, C. 79
 LeSage, M.G. 30, 49, 53
 Lessard, K. 78
 Lester, B. 13
 Letcher, A. 13
 Leukefeld, C.G. 9, 10, 41, 73, 74, 78
 Leung, K.S. 3
 Levant, B. 52
 Levin, F. 46
 Levin, F.R. 17, 18, 32, 35, 40, 59, 62, 75
 Levit, S. 63
 Levran, O. 16, 17
 Levy, H. 77
 Lewis, A.L. 71, 75
 Lewis, D. 83
 Leyro, T.M. 64
 Li, J. 27
 Li, L. 32, 33, 76
 Li, N. 60
 Li, S.J. 43, 53
 Li, X. 50
 Li, Y. 31, 49, 50, 65
 Licata, S.C. 68
 Lieb, R. 15, 44
 Liebreuz, M. 35
 Liebschutz, J. 57, 74
 Liguori, A. 26
 Lile, J.A. 57, 68
 Lin, H. 9, 73
 Linares Scott, T. 58
 Lindsay, J.A. 18
 Lindsey, K. 34
 Lindsey, K.P. 46
 Lindstrom, J. 82
 Ling, W. 46
 Ling, W. 24, 33, 62, 63, 76, 77
 Lintzeris, N. 50
 Lipsey, M. 48
 Little, S. 22
 Liu, D. 83
 Liu, P. 39
 Liu, S. 59
 Liu, X. 80
 Lo, S.J. 22
 Lobmaier, P.P. 10, 62
 Lodge, P. 12
 Lofwall, M.R. 8, 32, 46, 70
 Loipl, R. 63
 Lokhnygina, Y. 9
 Lominac, K.D. 15, 50, 54
 London, E.D. 33, 59, 81, 85
 Long, E. 49
 Longmire-Avital, B. 72
 Looby, A. 37
 Lookatch, S.J. 61
 Lopez, J.C. 52, 67
 Lopez-Quintero, C. 12
 Lord, S. 75
 Lorin, L. 75
 Lotfi, S. 23
 Louie, B. 78
 Lowen, S.B. 46, 68, 81
 Loxton, N.J. 74
 Lucas, G. 9
 Luce, J. 13
 Lui, S. 79
 Lukas, S.E. 31, 46, 68, 71, 81
 Lum, P. 22
 Lundahl, L.H. 33, 57, 58
 Lunden, J.W. 65
 Luo, L. 39
 Lutz, A.M. 55
 Lynch, K. 72
 Lynch, W. 24
 Lyoo, I. 31
 Lyvers, M. 12, 36
 Ma, L. 26, 59
 Maan, R. 68
 Machu, T. 69
 Maciel, L.A. 75
 MacLean, R. 46
 MacLean, R.R. 68, 71, 81
 MacPherson, L. 71
 Mactutus, C.F. 30, 54
 Madden, L. 8, 76
 Madeja, C. 36
 Madera-Salcedo, I.K. 54
 Madray, C. 78
 Maes, A. 44
 Magidson, J. 61
 Magura, S. 4, 36, 41
 Mahapatra, N. 73
 Mahony, A.L. 75
 Mainampally, P.N. 43, 44
 Maisonneuve, I. 14
 Majumder, I. 15, 51
 Makriyannis, A. 9
 Malak-Lopez, D. 77
 Malcolm, C. 75
 Malcolm, R.J. 50, 59
 Maldonado, R. 1
 Malison, R.T. 70, 74
 Mallya, G. 46
 Mammen, K. 50
 Mancha, B.E. 39, 61, 72
 Mancino, M.J. 3, 18
 Mandelkern, M.A. 59
 Mandler, R. 45
 Mangrum, L. 19
 Mann, R.E. 11
 Manneh, C. 24, 61
 Manniche, P. 14
 Manning, D. 21
 Mannino, C. 79
 Mantsch, J.R. 33, 53, 82
 Manubay, J.M. 37, 62, 77
 Manvich, D.F. 16, 53
 Marcellin, P. 38
 Margolis, E.B. 17
 Mariani, J.J. 17, 35, 62, 75
 Marinelli-Casey, P. 24, 33, 40
 Marrone, G. 45
 Marrone, G.F. 15, 55
 Marsch, L.A. 50, 71
 Marsh, R. 46
 Martin, B. 57
 Martin, C.A. 55, 68
 Martin, D.M. 7
 Martin, P. 32, 58, 84
 Martin, P.R. 13
 Martinez, D. 46
 Martins, S.S. 4, 19, 20, 37
 Marusich, J.A. 80
 Masalov, D. 3
 Mashhoon, Y. 49, 50

AUTHOR INDEX

- Masho, S.W. 58
 Masson, C.L. 22, 63, 79
 Mastroianni, F.C. 22
 Mateu-Gelabert, P. 61
 Mathew, T. 21
 Mathur, D. 70
 Matos, T.D. 12
 Matsumoto, R.R. 16, 17, 32
 Matsushima, Y. 17
 Matthews, P. 18
 Mattila-Evenden, M.E. 60
 Maudsley, A. 31
 Maurice-Tison, S. 72
 Maxwell, J.C. 22, 33
 May, J. 8, 58
 Mayes, L. 2, 71
 Mazlan, M. 41, 60
 McCaffrey, D.F. 64
 McCance-Katz, E.F. 32
 McCann, U. 46
 McCarty, D. 6, 8, 22, 23, 38, 63
 McCleary, P.M. 75
 McClernon, F.J. 55, 83
 McClung, J.C. 16
 McClure, B. 40
 McConnell, J. 23
 McCoy, C.B. 19
 McCullough, S.A. 55
 McCurdy, C.R. 2, 16, 17, 32
 McDonald, L. 56
 Mcfollins, T. 77
 McGraw, L. 77
 McIntosh, J. M. 45
 McIntosh, S. 65
 McKendrick, K. 10, 38
 McKinney, F. 77
 McKnight, C. 22, 63
 McLaughlin, G. 6, 47
 McLaughlin, J.P. 26
 McLellan, A. 29, 49
 McMahan, L. 7
 McMahan, T. 5
 McNair, N. 15
 McNiel, D. 79
 McQueeney, T. 57, 71
 McRae-Clark, A.L. 3, 32, 34, 57
 McWilliams, S. 81
 Meade, C.S. 9, 79, 81
 Medina, K.L. 57, 71
 Medina, M. 16
 Medina-Mora, M.E. 72, 76
 Meier, D. 14
 Melanko, S. 59
 Melin, P. 38
 Mello, N. 53
 Melnick, G. 40
 Meltzer, E.C. 74
 Mendelson, J. 3, 15, 32, 34, 52, 67, 72, 85
 Mende-Siedlecki, P. 55
 Mendez, I.A. 45
 Mennemeyer, S. 70
 Mennis, J. 36
 Merle, B. 72
 Merlo, L.J. 71, 83
 Merlo-Pich, E. 55
 Merz, S. 35
 Meshberg-Cohen, S. 35
 Messina, N. 19
 Metsch, L. 45, 70
 Metz, V. 63
 Meyer, E. 4
 Mezzich, A. 57
 Michael, Y. 60
 Mickiewicz, A.L. 27
 Mickus, M.A. 73
 Miczek, K.A. 82
 Middlesteadt-Ellerson, R. 58, 60
 Middleton, L. 70
 Mikulich-Gilbertson, S.K. 12, 13, 71, 81
 Milam, A. 41
 Milby, J.B. 70
 Miller, G.M. 84
 Miller, J. 69
 Miller, J.H. 15
 Miller, J.S. 16
 Miller, L.L. 21, 27, 43, 54
 Miller, N.S. 11
 Mills, K.L. 10, 35, 41, 79
 Millson, M. 13
 Milovan, D. 74
 Mintzer, M.Z. 35, 62, 68
 Miotto, K. 24, 77
 Mischel, W. 55
 Mitchell, J.M. 17
 Mitchell, M.R. 45
 Mitchell, S.G. 23
 Mitola, A. 19
 Mitsis, E. 56
 Mittelstet, B. 30
 Mitty, J. 9, 22
 Miyatake, M. 14
 Moeller, F.G. 26, 59, 71, 81
 Molfenter, T. 8, 76, 77
 Montenegro, D. 77
 Monterosso, J.R. 59, 85
 Montoya, A. 11
 Montoya, I. 80
 Moody, D.E. 32
 Moolchan, E. 12, 22
 Mooney, J. 10, 73
 Mooney, L. 24, 77
 Mooney, M.E. 11, 20
 Moore, B.A. 62, 79
 Moore, R.D. 38
 Moore, S.K. 50, 71
 Moran, L. 54
 Moran-Santa Maria, M. 34
 Morasco, B.J. 22
 Morefield, K.M. 52
 Moreno, R.C. 63
 Morgan, D. 15, 75
 Morgan, P. 70
 Morganstern, A. 22, 63
 Mori, T. 14
 Morin, N.P. 50
 Morisano, D. 45
 Moroz, L. 23, 38
 Morral, A.R. 64
 Morris, T. 8
 Morrow, C.E. 31
 Moukaddam, N.J. 75
 Moura, H. 42
 Moura, Y.G. 12, 13
 Mouttapa, M. 77
 Mueller, E.T. 55
 Mueller, M. 41
 Munro, T. 67

AUTHOR INDEX

- Murnane, K.S. 50, 85
 Murphy, D. 64
 Murray, J. 30
 Murray, K.A. 62
 Murthy, P. 34
 Mutirangura, A. 74
 Myers, C.S. 54
 Myers-Franchi, B.J. 79
 Myrick, H. 50
- Nader, M.A. 28, 31, 53, 54
 Nagarajaiah, A. 34
 Nakama, H. 85
 Nandi, A. 61
 Nandi, V. 42, 67
 Napier, T.C. 15, 27
 Nappo, S. 13
 Narasimhan, D. 69
 Narayana, P.A. 26, 81
 Narayanan, G. 46
 Narita, M. 14, 17
 Nash, W. 22
 Nation, J.R. 45
 Nattala, P. 34
 Navarro, H.A. 32
 Nazarian, A. 20
 Neely, M. 76
 Negron-Ayala, J.L. 12
 Negus, S.S. 7, 21, 53, 80
 Neisewander, J.L. 50, 69, 80
 Nelson, E. 19
 Netherland, J. 62
 Neugebauer, N.M. 16
 Neumark, Y. 12
 Newlin, D. 47
 Newman, J. 53
 Newton, N.C. 12
 Newton, T.F. 70
 Newville, H. 18
 Nguyen, V. 57
 Nic Dhonnchadha, B.A. 52, 69
 Nich, C. 80
 Nielsen, D.A. 17, 46
 Nikulina, E.M. 66
 Nilson, D. 35
 Noack, R. 24, 56
 Norland, J.E. 78
- Norman, A.B. 75
 Norman, M.K. 75
 Noto, A.R. 12, 13, 22, 41, 75
 Novak, S. 41
 Nunes, D. 39
 Nunes, E.V. 26, 35, 40, 62
 Nuño, M. 10
 Nuzzo, P.A. 4, 8, 32, 55, 70
 Nygard, S. 69
- O'Brien, C.P. 9, 28, 31, 49, 50, 65
 O'Connell, D.J. 11
 O'Grady, K.E. 9, 23, 51, 58, 61, 62, 63, 64, 74, 84
 O'Leary, C.C. 10, 60, 74
 O'Leary-Moore, S.K. 26
 O'Malley, S.S. 56, 71
 Oberleitner, L. 58
 Ochsner, K. 55
 Ogai, Y. 41
 Oliver, A.J. 11
 Oliveto, A. 3, 18, 82
 Oltmanns, T. 46
 Ompad, D.C. 42, 63, 67
 Ondersma, S.J. 74, 84
 Opaleye, E.S. 12, 13
 Opris, I. 31
 Ormel, J. 44
 Orozco, R. 72
 Osborne, D. 76, 77
 Oser, C.B. 9, 10, 73, 74
 Ott, J. 17
 Ouzan, D. 38
 Owens, S.M. 70
- Pacchioni, A.M. 65
 Pace-Schott, E. 70
 Packard, M. 46
 Padula, C.B. 57, 71
 Page, R. 32
 Painter, M. 69, 80
 Palatkin, V. 3
 Palma, J. 26, 54
 Palmer, C. 46
 Palmer, H. 10
 Pandya, A. 66
- Papke, R. 82
 Paquette, C. 12
 Pardo, J.S. 15
 Park, S. 13
 Parrino, M. 4
 Parry, C.D. 60, 79
 Parsons, L. 65
 Partilla, J.S. 16
 Passetti, L. 13
 Patterson, A. 22
 Payne, R. 38
 Pearce, V.J. 24
 Pearson, F.S. 24
 Pechansky, F. 13, 41, 42, 72
 Peck, J.A. 10, 78
 Peirce, J.M. 35
 Peles, E. 36, 51, 63
 Penetar, D. 46
 Penetar, D.M. 68, 71
 Pennick, M. 32
 Pentkowski, N.S. 50, 69
 Pepper, N. 22, 63
 Pereira, R. 14
 Pérez de los Cobos, J. 63
 Perez, G. 18
 Perkins, K. 55
 Perlman, D.C. 22, 63
 Perrine, S.A. 25, 26, 85
 Perry, E. 56
 Perry, J.L. 30
 Persch, K.N. 14
 Peters, E.N. 56
 Petersen, P.M. 60
 Peterson, A.T. 79
 Peterson, B. 46
 Peterson, J.A. 23
 Petit, G. 12
 Pettinati, H.M. 72
 Pfeil, E.C. 84
 Pfister, H. 15
 Pharo, P. 75
 Phipps, L. 57
 Picetti, R. 53
 Picker, M.J. 21, 27
 Piechatzek, M. 15
 Pieper, B. 51, 63
 Pierce, C. 51

AUTHOR INDEX

- Pierre, P.J. 54
 Pittman, B. 71, 74
 Pixa, A. 24
 Platt, D.M. 17, 53, 65, 68
 Plemmons, G. 13
 Pletcher, M. 3, 35, 72
 Ploutz-Snyder, R.J. 39
 Plüddemann, A. 60, 79
 Pockros, L.A. 50
 Podevin, P. 75
 Podus, D. 22, 24
 Pol, S. 78
 Polcin, D. 3
 Poldrack, R.A. 59, 85
 Polen, M.R. 63
 Poling, J. 46, 80
 Pontell, M.E. 16
 Poole, M.M. 32, 55
 Porrino, L.J. 26, 53, 54
 Portenoy, R. 22
 Porto Jr, S. 72
 Portoghese, P.S. 21
 Posada-Villa, J. 76
 Potenza, M.N. 42, 56
 Potik, D. 36, 63
 Potter, J.S. 3, 9, 76, 79
 Powelson, E. 38
 Poznyak (WHO), V. 25
 Prasla, I. 59
 Prather, R. 71
 Prendergast, M. 9, 19, 24, 73
 Presnall, N. 64
 Pressley, K. 78
 Preston, K.L. 18, 19, 45, 55
 Price, J.S. 57, 71
 Price, K.L. 32, 34, 57
 Price, R.K. 44, 73
 Pricolo, A. 47
 Prioleau, C. 23
 Priszano, T. 53
 Pryweller, J. 31
 Pugh, T. 62
 Pulvermacher, A. 8, 23
 Purcell, D. 39
 Putnins, S. 56
 Quanbeck, A. 23, 76
 Quick, D.F. 34
 Quigley, A. 50
 Quiñones-Jenab, V. 20, 21, 69
 Quiroga, C. 13
 Raby, W.N. 26, 35
 Radler, D. 63
 Radovanovic, M. 20, 73, 76
 Rainey, P.M. 32
 Rallapalli, S. 65, 68
 Ramchand, R. 64
 Randall, S. 68
 Rataemane, L. 40
 Rataemane, S. 40
 Rathnayaka, N. 81
 Rawson, R.A. 8, 10, 24, 33, 40, 61, 62, 77, 78
 Ray, B. 66, 70
 Raymond, K. 71, 81
 Realmuto, G. 83
 Reback, C.J. 10
 Rebok, G. 18
 Reddy, K. 26
 Reed, B. 54
 Reed, S. 77
 Reed, S.C. 32
 Reichel, C. 30
 Reid, M.S. 70
 Reilly, M.T. 54
 Reimann, E. 51
 Reisinger, H.S. 23
 Reissig, C.J. 68
 Ren, X. 66
 Renshaw, P.F. 31, 55
 Resnick, M.P. 22
 Reutenauer, E.L. 56
 Reyes-Pulliza, J.C. 12
 Reynolds, A.R. 32
 Reynolds, B. 11, 59
 Reynolds, E.K. 20, 61, 71, 81
 Reynolds, M. 57
 Rhodes, A.G. 10, 30
 Rice, K.C. 21, 27, 65
 Rice, T. 77
 Richard, K. 67
 Richards, J.B. 16, 54
 Richards, J.M. 34, 81
 Richardt, S. 55
 Riddick, N.V. 31
 Ridenour, T. 57
 Rieckmann, T. 19, 22
 Riggs, P.D. 12, 13, 40, 78
 Riley, A.L. 27, 30, 51, 53
 Riley, B. 75
 Ring-Kurtz, S. 40
 Rinker, D.V. 75
 Rinker, J.A. 30, 51
 Rios-Bedoya, C.F. 20, 73
 Rivera, R. 81
 Roache, J.D. 28
 Robbins, G. 71
 Roberts, R. 52
 Roberts, S. 58
 Robinson, J. 23
 Robles, R.R. 12
 Rocha, N.S. 42
 Roddy, J.K. 22
 Rodolico, J. 46
 Rodríguez, A. 63, 70
 Rodriguez, T. 13
 Roehrs, T. 21, 68
 Rogers, L.R. 59
 Rogers, R. 42
 Roget, N.A. 6, 34, 40, 46, 78
 Rogowska, J. 31
 Rohrbacher, H. 24, 56
 Roland, C. 37
 Romach, M.K. 74
 Roman, P. 8
 Romano, E. 31
 Romanova, T. 3, 60
 Rosa, C.L. 76
 Rosa, M.C. 13
 Rose, J.E. 49, 83
 Rose-Jacobs, R. 57
 Rosen, M.I. 18
 Rosenblum, A. 4, 36
 Rosenfeld, J. 35
 Rosenheck, R.A. 18
 Rosenthal, R.N. 3
 Rosko, K. 44
 Roth, S. 78
 Roth, T. 21, 68

AUTHOR INDEX

- Rothenberg, L.R. 17
 Rothman, R.B. 16, 51
 Rotily, M. 38
 Rotrosen, J. 3, 40
 Rounsaville, B.J. 18, 80
 Routt, V. 80
 Rowlett, J.K. 17, 53, 68
 Roy, É. 12
 Rubio, N. 46
 Rudolph, A.E. 38
 Rudoy, C.A. 31, 50
 Ruehlmann, A. 24
 Ruiz, J. 47
 Runyon, S.P. 32, 80
 Rush, B. 19
 Rush, B.R. 75
 Rush, C.R. 32, 41, 55
 Rusjan, P. 45
 Russell, B.R. 14, 15
 Rutkowski, B.A. 10, 77
 Rutledge, M. 69
 Rybin, D. 74
- Sacco, K.A. 45
 Saccone, P.A. 37
 Sacerio, L.C. 72
 Sacks, J. 38, 73
 Sacks, S. 10
 Saeki, M. 14
 Saha, S. 38
 Saitz, R. 61, 74
 Sakai, J.T. 81
 Saladin, M.E. 32, 55, 57
 Salas, J. 13
 Salem, A. 15
 Salmeron, B.J. 54
 Salomon, R.M. 26
 Salomonsen-Sautel, S. 12, 13
 Samet, J.H. 51, 61, 74
 San George, M.A. 16
 Sanabria, F. 69
 Sánchez, H. 12
 Sanchez, Z.V. 12, 13
 Sánchez-Hervás, E. 70
 Sancho, A. 23
 Sandefer, E. 32
 Sander, L. 57
- Sanderson, S. 30
 Sandvik, P. 68
 Sanfilippo, L.C. 26, 35
 Sanichwankul, K. 74
 Sannerud, C.A. 23
 Sannibale, C. 35
 Santa Ana, E. 80
 Santiago, O.J. 20
 Santis, R. 13
 Santonja Gómez, F.J. 70
 Santos, D. 33
 Santos, F. 72
 Santos, G. 33
 Santos, M.P. 42
 Sargeant, M.N. 36
 Sarnocinska Hart, A. 13
 Satyanarayana, V. 3, 52
 Saulsgiver, K.A. 11, 51
 Sauv e, B.J. 67
 Sayette, M.A. 55
 Scharf, E. 70
 Schaub, M.P. 23, 40, 41, 50
 Scheidweiler, K.B. 51
 Schenk, S. 15
 Schiff, M. 63, 64
 Schlussman, S.D. 16
 Schmidt, K.T. 21, 54
 Schmidt, L. 8
 Schmitz, J.M. 18, 59, 75, 82
 Schmoutz, C.D. 80
 Schnoll, S. 66
 Schoedel, K. 46
 Schoedel, K.A. 5, 14, 44, 74
 Schoenberg, N.E. 55
 Schoener, E. 36
 Schott, J. 77
 Schottenfeld, R.S. 39, 41, 60, 62
 Schreiber, S. 36, 51, 63
 Schroeder, J. 12
 Schroeder, S. 24, 61
 Schuler, M.S. 59
 Schulte, M. 66
 Schulteis, G. 84
 Schumacher, J.A. 35, 60
 Schumacher, J.E. 23, 38, 70
 Schuster, C. 66
- Sch utz, C.G. 15
 Schwappach, D. 41
 Schwartz, R.P. 9, 23, 50, 51, 61, 62, 63, 74
 Schwartz, S. 74
 Schwarzkopf, L. 30
 Schwedhelm, E. 52
 Scrivo, N. 13
 Secades-Villa, R. 70
 Secker, R. 32
 See, R.E. 30, 50, 65, 80
 Seewald, R. 22
 Seibyl, J. 56, 71
 Seitz, P.K. 52, 54
 Selby, P. 36, 58, 84
 Sellers, E.M. 5, 14, 44, 46, 74
 Selley, D.E. 43
 Seminerio, M.J. 16
 Senoo, E. 41
 Sepulveda, A.L. 19, 58
 Serafine, K.M. 53
 Serre, F. 72
 Setlow, B. 45
 Setnik, B. 37, 79
 Seu, E. 17
 Sevak, R.J. 32
 Severtson, S.G. 37, 39, 61, 62, 72
 Shack, J. 60
 Shade, S. 39
 Shadley, M.L. 34
 Shaikh, J. 16, 17
 Sharp, V. 38
 Sheer, A. 12
 Sheidow, A.J. 48
 Sheikhattari, P. 12, 77
 Shin, C. 37
 Shinday, N.M. 53
 Shiokawa, M. 17
 Shivers, K.Y. 21
 Shoptaw, S. 9, 33, 42
 Shurtleff, D. 82
 Siegal, N. 65
 Siegel, S. 37, 79
 Siegrist, J.D. 3, 34
 Sigmon, S.C. 11, 28, 51
 Silveira, J.D. 22

AUTHOR INDEX

- Silveri, M. 81
 Silverman, K. 62, 70
 Simon, N.W. 45
 Simoni-Wastila, L. 41
 Simpson, G.R. 31
 Sim-Selley, L.J. 43
 Singleton, R. 83
 Singley, E.D. 30
 Sinha, R. 2, 34
 Siñol, N. 63
 Sircar, R. 25, 26
 Siripurapu, K. 45
 Sizemore, G.M. 75
 Skelly, J.M. 58
 Skinstad, A.H. 6, 34, 35, 46
 Skolnik, P.R. 39
 Skurtveit, S. 68
 Slade, T. 41
 Slavina, T. 3
 Slavutzky, S.B. 13
 Slesnick, N. 13
 Slezak, J.M. 59
 Slobodyanyuk, P. 23, 38
 Slock, J. 18
 Smart, M. 41
 Smith, C. 84
 Smith, D.M. 16
 Smith, E.J. 58, 79
 Smith, H.R. 53
 Smith, M. 37, 46, 48
 Smith, M.A. 53
 Smith, P.C. 74
 Smith, W.R. 58
 Smyth, E. 39
 Sneider, J.T. 31
 Sodano, R. 40
 Soenksen, S. 57
 Sofuoglu, M. 20
 Soibelman, M. 72
 Solhkhah, R. 50
 Solomon, L.J. 57, 58
 Somoza, E. 83
 Sonne, S.C. 3
 Sorensen, J.L. 38, 79
 Sousa, T. 72
 Sparatore, F. 30
 Sparenborg, S. 77
 Spealman, R.D. 17, 69
 Spear, MS, S.E. 24
 Spence, R. 23
 Spiess, J. 71
 Spiller, H.A. 37, 38
 Spiller, S.S. 37, 38
 Spivey, R. 21, 37
 Springer, R. 77
 Sproule, B.A. 36
 Stabile, P. 41
 Stadlin, A. 74
 Stahler, G. 36
 Staios, G. 36
 Stairs, D.J. 30
 Staley, J. 56, 71
 Stallings, M. 9
 Stanger, C. 60
 Stasiewicz, P.R. 35
 Stathum, M. 76
 Staton-Tindall, M. 9, 73, 78
 Staub, D.R. 65
 Stauffer, J. 21
 Steinberg, J.
 Steinberg, J.L. 26, 71, 81
 Steinmiller, C.L. 22, 33, 57, 60
 Stenger, A. 85
 Stenger, V.A. 85
 Stevens Manser, S. 23
 Stevens, C.W. 17
 Stevens, D. 3
 Stickgold, R. 70
 Stiklus, S. 56, 71
 Stine, S. 58, 83, 84
 Stitzer, M. 19, 41, 57, 62
 Stoduto, G. 11
 Stohler, R. 23, 35, 40, 50
 Stoller, K.B. 35
 Stone, A.M. 71, 83
 Stoops, W.W. 7, 8, 32, 41, 55
 Storr, C.L. 37, 56
 Stotts, A.L. 18
 Strain, E.C. 18, 35, 62, 74, 84
 Strickland, J. 64
 Strike, C. 13
 Striley, C.W. 3, 10, 60
 Stroud, Z.B. 11
 Studts, J.L. 22
 Stutz, S.J. 52
 Stuver, S. 39
 Su, Z. 20
 Suárez Vázquez, R. 20
 Suchman, N. 5
 Sugar, C.A. 33
 Sughondhabirom, A. 74
 Sugita, W. 77
 Suh, J.J. 31, 49, 50, 65
 Sullivan, C. 76
 Sullivan, K.A. 36
 Sullivan, L. 62
 Sullivan, M.A. 37, 62, 66
 Summers, K.M. 34, 35
 Sun, W. 20
 Sun, Z. 15
 Sunahara, R.K. 69
 Sung, Y. 31
 Surratt, C.K. 2
 Surratt, H.L. 9, 10, 11
 Sussman, J. 72
 Suwal, K. 35
 Suzuki, T. 14, 17
 Svikis, D.S. 8, 19, 35, 57, 58,
 83, 74, 84
 Sviridova, V. 23
 Swann, A.C. 59, 71
 Swanson, A.N. 33, 42
 Szalay, J.J. 50
 Szobot, C. 42
 Szumlinski, K.K. 15, 50, 54
 Tabibnia, G. 59, 85
 Tahsili-Fahadan, P. 26, 27
 Tai, B. 77
 Tajima, B. 22
 Takagi, S. 17
 Takahashi, N. 52
 Takei, D. 17
 Talal, A. 39
 Tamagnan, G. 56, 71
 Tanabe, J. 42, 81
 Tangherlini, N. 72
 Tapert, S.F. 57, 71
 Taraschenko, O. 14
 Tartarini, W. 46
 Tarter, R. 57

AUTHOR INDEX

- Tasso, B. 30
 Tau, G. 46
 Taxman, F. 8
 Taxman, F.S. 10, 73
 Taylor, P. 45
 Taylor, R.C. 54
 Teesson, M. 10, 12, 35, 41
 Tella, S.R. 23, 28
 Temes, C. 40
 Templin, T.N. 51, 63
 Terplan, M. 58, 79
 Teruya, C. 10, 40
 Terwilliger, E.F. 66
 Teske, J.A. 30
 Thakkar, V. 70
 Thawley, R. 22
 Thiel, K.J. 69, 80
 Thomas, B.F. 32
 Thomas, R.K. 11
 Thompson, A.C. 16, 54
 Thompson, L.L. 71, 81
 Thorberg, F.A. 36
 Thorgeirsson, T. 82
 Thouelies, P. 72
 Thurstone, C. 12, 13
 Tiburcio, N.J. 42, 73
 Tidey, J.W. 55
 Tindall, M. 10
 Tobin, K.E. 38, 60
 Tolliver, B. 32
 Tompkins, D.A. 35, 74
 Torigoe, K. 17
 Toro, J. 12
 Torrence, M.C. 26
 Torrington, M. 63, 77
 Touchard, F. 72
 Tracy, M. 30
 Travis, D. 23
 Treese, M. 37
 Tres, I. 14
 Trezza, C. 63
 Tross, S. 45
 Trotman, A.J. 73
 Trudeau, K.J. 75
 Trujols, J. 63
 Truong, Y.N. 52
 Tsai, W. 76, 77, 78
 Tsamis, V.J. 18
 Tschibelu, E. 34
 Tsibulsky, V. 47
 Tsibulsky, V.L. 75
 Tsoi, M. 3
 Tucha, O. 15
 Tucker, J. 3, 35
 Tuten, M. 58, 84
 Twiggs, R. 42
 Tyson, C. 3, 78
 Tyurina, A. 3
 Tzall, D. 9
 Umbricht, A. 35, 62
 Umemura, Y. 66
 Unterwald, E.M. 16
 Upadhyaya, H.P. 3, 55, 71, 75
 Urada, D. 10
 Urbaitis, J. 51
 Valdez, G.R. 17
 Valverde, E. 70
 van den Brink, W. 42
 Van Hout, M.A. 73
 Van Linn, M.L. 65, 68
 Van Voorhees, E.E. 83
 Van Zastrow, M. 1
 Vandrey, R. 41, 46, 62
 VanScoyoc, J. 60
 Vansickel, A.R. 32, 55
 Vanyukov, M. 57
 Varastet, M. 38
 Vargas, C. 80
 Varon, J. 39, 54, 66, 70
 Vasquez, E. 77
 Vaswani, M. 69
 Vederhus, J.K. 40, 62
 Velduizen, S. 75
 Venisse, J. 34
 Verbitskaya, E. 3
 Verendeev, A. 27
 Verhulst, F. 44
 Viana, R. 65
 Villapiano, A. 75
 Vincent, K. 64
 Vittinghoff, E. 33
 Vlahov, D. 42, 63, 67
 Vocci, F. 80
 Voci, S. 36
 Vogl, L.E. 12
 Volkow, N. 1
 Vollebergh, W. 44
 Vosburg, S.K. 18, 37, 57, 66, 77
 Votaw, J.R. 50
 Vuchinich, R.E. 70
 Waal, H. 4, 10, 62
 Wada, K. 54
 Wade, D. 51
 Wade, M.A. 69
 Wagner, F.A. 12, 41, 56, 77
 Wagner, M. 58
 Wakim, P.G. 76
 Wakley, A.A. 20
 Waldrop, A.E. 38
 Walker, K.L. 53
 Walker, Q.D. 53
 Wallace, D. 70
 Wallace, L. 48
 Walley, A.Y. 39, 51
 Walquist, A. 19
 Walsh, S.L. 1, 4, 8, 25, 32, 46, 49, 70
 Walton, M. 14
 Wan, R. 14
 Wang, C. 21
 Wang, F.L. 71
 Wang, J. 42
 Wang, M. 23
 Wang, Y. 64
 Wang, Z. 31, 46, 49, 50, 65
 Warda, U. 19
 Wase, L. 37, 79
 Washio, Y. 58
 Waters, P. 6
 Watson, C.S. 54
 Watson, D.W. 40, 76, 77, 78
 Watson, N.L. 55
 Weaver, J.C. 11
 Weber, S. 50
 Webster, M. 78
 Wechsberg, W.M. 58, 60, 79
 Wee, S. 84

AUTHOR INDEX

- Weinberger, A.H. 56
 Weinstein, E. 70
 Weintraub, E. 51
 Weiss, L. 9, 62, 63
 Weiss, R.D. 56, 76, 83
 Welch, M. 83
 Welch, S.P. 43
 Wellman, P.J. 45
 Wells, A.M. 50
 Weltzin, M. 66
 Wender, C. 13
 Wendt, W. 46
 Wenger, G.R. 59
 Wenger, L. 4, 41
 Wenzel, J.M. 52
 Wesley, M.J. 26
 Wesnoski, S.A. 23
 West, D. 13
 Wetherington, C. 24
 Weyer, A. 33
 Wheelock, A. 23
 Whitaker, D. 39, 41, 61
 White, J.M. 51, 52, 67
 Widner, G. 73
 Wiechelt, S. 78
 Wilcox, H. 64
 Wiley, J. 8
 Wilkinson, J. 39
 Williams, A.M. 77
 Williams, E. 76
 Williams, K.L. 40
 Williams, M.J. 31
 Willner-Reid, J. 19
 Wilson, A. 45
 Wilson, J. 78
 Wilson, M.E. 73, 74
 Windsor, L.C. 23
 Winhusen, T. 83
 Winklbaaur, B. 63
- Winstanley, E.L. 35
 Winters, K. 7, 83
 Wish, E. 64
 Wisniewski, S. 53
 Witas, J. 61
 Witkin, B.M. 52
 Wittchen, H.U. 15, 24, 44, 56
 Wolf, M. 48
 Wong, C.J. 55, 70
 Wong, L.L. 23
 Wood, R. 37
 Woods, J.H. 30, 52, 69
 Woods, W.L. 40
 Woodson, T. 9
 Woodward, N.D. 26
 Woody, G.E. 3, 25
 Wooters, T.E. 14
 Wright, C. 77
 Wu, F. 40
 Wu, G. 46
 Wu, H. 2
 Wu, L. 26
 Wunsch, M.J. 4, 46
 Wyman, B.J. 35
- Xie, Z. 84
 Xu, D. 46
 Xu, Y. 17
 Xue, L. 31
- Yakovenko, V. 14
 Yang, J. 10
 Yang, Z. 53
 Yango, E. 77
 Yao, W.D. 53
 Yi, R. 13, 46, 55, 81
 Yondorf, M. 54
 Yoon, J.H. 58
 Yoon, S.J. 31
- Yoshizawa, K. 14
 Young, R.M. 36
 Young, S. 9
 Yu, S. 46
 Yuferov, V. 17
 Yurgelun-Todd, D. 31, 81
- Zacarés Romaguera, F. 70
 Zack, M. 36
 Zagidullin, M. 46
 Zakharova, E. 30, 51
 Zalcman, R.F. 11
 Zamarelli, L. 22
 Zanis, D.A. 23
 Zastowny, T. 8
 Zawertailo, L. 45
 Zawertailo, L.A. 36
 Zeiger, A. 18
 Zeller, M. 49
 Zernig, G. 43
 Zezyulin, O. 23, 38
 Zhang, X. 46
 Zhang, Y. 16, 32
 Zhao, N. 57
 Zheng, G. 45
 Zhou, L. 20
 Zhou, M. 16
 Zhou, W. 39
 Zhou, Y. 25, 80
 Ziedonis, D. 22
 Zolkowska, D. 51
 Zolot, L.M. 11
 Zosel, A.E. 37
 Zubaran, C. 14
 Zuniga, E.A. 26
 Zvartau, E. 3, 60
 Zvolensky, M.J. 64

SYMPOSIA

Sunday, June 21

PRESIDENTIAL SYMPOSIUM

Opioid Receptors from the Cutting Edge to the Clinic: Knockouts, Crosstalk and Behavior

Chair: Sharon L. Walsh

Opioid receptors are critical therapeutic targets for medication development relevant to the treatment of drug dependence and pain. With increased knowledge of opioid receptors as ligand-regulated protein complexes and their genetic characterization, new approaches for pharmacological manipulation of opioid complexes have emerged that promise to increase the effectiveness of opioid-receptor-mediated therapeutics. This symposium will provide a contemporary review of molecular mechanisms of opioid receptor signaling and mechanics and translate the importance of these actions to the underlying mechanisms of tolerance, analgesia and drug reward as well as to the design of efficacious pharmacotherapeutics. It is increasingly clear that opioid receptors, like many other signal-transducing receptors that function in the nervous system, are regulated by membrane trafficking through the endocytic pathway. Clinically relevant opioid drugs differ significantly in their effects on this regulatory mechanism, and there are also cell type-specific differences in regulated endocytosis that are only beginning to be understood. Additionally, the importance of opioid single nucleotide polymorphisms (SNPs) and their potential role in a variety of drug addiction and pain sensitivity phenotypes will be reviewed in both animal and human models. Thus, both in vitro and in vivo studies will explore the molecular and genetic underpinnings of opioid receptor-mediated events relevant to analgesia, tolerance and drug dependence.

I. How Does Stress Contribute to Addiction Vulnerability? Studies from Adolescent and Adult Samples

Chairs: Rajita Sinha and Kathleen T. Brady

Prospective evidence indicates that stress and cumulative adversity increases risk of addictive disorders. Gender differences in stress-related mechanisms may further contribute to such risk. While there is preclinical evidence indicating that stress-related factors alter the responses of the hypothalamic-pituitary-adrenal (HPA) axis and the mesolimbic reward pathways to increase such risk, evidence from human studies has been rare. This symposium will present new data from humans, using prospective longitudinal, laboratory-based and brain imaging approaches, to identify how stress may contribute to addiction vulnerability. Speakers will discuss the types of stress that increase addiction risk, the specific HPA axis and brain responses predictive of addiction vulnerability, and the contribution of gender, race and developmental stage (adolescent and adult) on these effects. Data on effects of stress, emotion regulation and race in prediction of addiction risk in young, low-income women will be presented as well as prospective longitudinal data from a large cohort of early adolescents to show HPA axis measures are predictive of later use and abuse of smoking and drinking. Stress-related HPA axis responses and association with substance use behaviors in prenatally cocaine exposed and non-exposed adolescent girls and boys will be discussed. Neuroimaging data on stress-related alteration in nucleus accumbens activity that is associated with maladaptive behaviors in adults will be presented. Findings will be summarized in the broader context of translational research on stress and addiction vulnerability and their implications for addiction prevention.

SYMPOSIA

II. Virtual Modeling: A New Frontier for Investigating Drug-Receptor Interactions

Chair: Christopher K. Surrat

Computer-based molecular modeling of drug receptors and their ligands has been a goal since the 1970s. The lack of reliable structural information precluded development of useful molecular models until the 1990s. Crystallization of the nicotinic acetylcholine receptor and the cloning of GPCRs and transporter proteins that recognize abused drugs opened the door to 3-D understanding of drug receptors. This symposium will outline how in silico approaches are elucidating relationships between small molecule ligands and their opiate, cocaine or nicotine receptors. The specific aims are to visualize in 3-D space drug receptors at amino acid residue level of resolution, to present 3-D representations of small molecule ligands, and to show plausible ligand-receptor docking scenarios that can be pharmacologically tested. New sigma receptor pharmacophores useful for novel ligand design, data that show how salvinorin A binds to a kappa opioid receptor site distinct from that of classic opiates, and new epibatidine analogs with selectivity for the primary and secondary substrate pockets of the monoamine transporters will be presented. Refined molecular models such as these may serve as virtual screening tools for new addiction management lead compounds, sifting millions of compounds in a structural library to yield a handful of candidates for preclinical testing.

Monday, June 22

III. Uncontrolled Intersection: Problem Gambling and Drug Abuse

Chairs: Ken Winters and Linda Cottler

The aims of this symposium are to highlight empirical research on the intersection of problem gambling (PG) and substance use disorders (SUDs). This co-association has several implications toward enhancing our understanding of addictive disorders in general and SUDs specifically. Symposium speakers will provide an overview of the various clinical literatures that have examined the association of PG and drug dependence, with a focus on the clinical similarities of PG and dependence, evaluate the effects of level of gambling on reductions in crack use at 4 and 12 months follow-up among a group of females crack users, and summarize the first two waves of data of a large-scale longitudinal survey that is tracking gambling involvement and other addictive behaviors in a community sample of Alberta residents. A discussion of these various studies in light of their implications for our understanding of addictive disorders will follow.

IV. Drug Withdrawal, Reinforcing Effects, and Vulnerability to Relapse: New Methods and Insights

Chair: Lance McMahon

Withdrawal that emerges upon abrupt discontinuation of chronic drug use is often considered a contributing factor to relapse. Moreover, the reinforcing effects of drugs are considered to vary as a function of current level of dependence and withdrawal. One practical implication of these proposed relationships is that pharmacotherapy leading to attenuation of withdrawal (cf. nicotine) plays a role in decreasing relapse and improving treatment outcomes. This symposium provides a critical review of correlations and causal relationships among withdrawal, reinforcing effects of drugs, and vulnerability to relapse. Evidence from the pre-clinical literature assessing relationships between drug withdrawal and reinforcing effects of drugs indexed in a variety of behavioral procedures including drug self-administration will be reviewed. Critical issues to be addressed include

SYMPOSIA

whether reinforcing effects vary as a function of drug withdrawal and whether pharmacologic attenuation of withdrawal is responsible for changes in self-administration and reinforcing effects of drugs. Evidence from the clinical literature assessing relationships between drug withdrawal and vulnerability to relapse and, in particular, the extent to which pharmacotherapy of withdrawal is responsible for decreased relapse and improved treatment outcomes will be presented.

V. Special Symposium Honoring the Memory of Billy Martin Hot Topics in Cannabinoid Research: From Chemistry to the Clinic

Chair: Mary Abood

Billy R. Martin, PhD, was internationally renowned for his research on the biological basis of drug addiction, especially for his pivotal work on understanding the mechanism of action of cannabinoids. He was an eminent scholar and scientist, a beloved teacher, mentor, inventor, and humanitarian. This symposium is dedicated to his memory and is designed to highlight recent advances in cannabinoid research, from medicinal chemistry and receptor and enzyme structure and function to the clinical basis of drug addiction.

VI. Preclinical Studies of Sex Differences in Response to Cocaine in Adolescents: Are They Different from Adults?

Chairs: Cora Lee Wetherington and Jill Becker

Over the past couple of decades, there has been a growing preclinical research literature on sex differences in response to cocaine, from behavioral studies of the reinforcing, rewarding and stimulant properties of cocaine to mechanistic studies of neurotransmitter function and the role of gonadal hormones. Research on whether these sex differences in adults also occur in adolescents has been largely unaddressed until recently. Thus, this symposium focuses on this emerging research and its implications. Presentations will include data from adolescent rats demonstrating sex differences in the acquisition of cocaine self-administration and progressive ratio performance, the role of ovarian hormones in mediating cocaine's reinforcing effects in females, sex differences in acquisition and reinstatement of cocaine-seeking behavior in adolescents versus adults, sex differences in the behavioral and neurochemical effects of social and environmental enrichment in adolescent rats, and the role of gonadal steroids on dopaminergic neurotransmission across adolescence. The discussion will present a broad conceptual context within which to understand and study the various biological mechanisms that contribute to the emergence and development of sex differences.

VII. International Research Priorities for Scaling Up Effective Interventions for Drug Use and Dependence

Chairs: V. Poznyak and Sharon Walsh

This symposium, jointly organized by CPDD and WHO, aims to facilitate and support a scaling up of effective interventions for drug use and dependence in different parts of the world. In spite of the significant disease burden attributable to drug use and dependence worldwide, the coverage of effective interventions remains low, particularly in lower and middle income countries, and research evidence used to inform treatment and policy development is mainly generated in industrialized countries. Main findings from the recent work on global estimates of the number of injecting drug users, the proportion living with HIV/AIDS, and priorities for improving quality and quantity of data will be presented. The major role that intravenous drug use is playing in the HIV epidemic in the Central and Eastern European region and important areas for translational research will be discussed. Gaps in the evidence and the main questions for further research in the area of

SYMPOSIA

pharmacotherapy of opioid dependence formulated in the process of developing the WHO guidelines on psychosocially assisted pharmacotherapy of opioid dependence will be addressed. In addition, future research implications of the main findings from the recent WHO multi-site international research project on effectiveness of screening and brief interventions for drug use and priorities for future international research focused on low and middle income countries will be discussed. The conclusions of the symposium will provide an important contribution to the process of agenda setting for international research to reduce the gap between the population needs and coverage of effective interventions in different parts of the world.

Tuesday, June 23

VIII. This Is Your Brain on Gambling (and Drugs) ... Parsing Drug and Addiction Influences by Contrasting "Behavioral" and Drug Addictions

Chairs: Marc N. Potenza and Robert Rogers

Considerable debate exists regarding whether non-drug disorders should be considered as addictions. DSM-V committees are considering pathological gambling within an addictions framework. Pathological gambling, unlike drug dependence, is devoid of chronic drug-upon-brain-substrate effects that may complicate understanding the core cognitive and neural bases of addiction. This symposium aims to enhance the audience's understanding of neurocognitive and neural features of addiction by comparing and contrasting pathological gambling with drug use disorders. Clinical data about drug-related behaviors of online casino gamblers and how forms of gambling (e.g., slot machines) may engage reinforcement circuits and neuromodulators implicated in substance misuse will be presented. fMRI findings will be described from gambling task studies involving individuals with substance use disorders with and without pathological gambling, implicating diminished ventromedial prefrontal cortical activation in individuals with addictions. Neurocognitive and brain imaging similarities and differences in impulsivity, cue reactivity, and reward/punishment processing in groups of individuals with pathological gambling, nicotine dependence, or alcohol dependence will be reported. Data will be reported from individuals with gambling or substance use problems in which individuals from both groups demonstrate overlapping impairments but only substance-dependent subjects demonstrate executive functioning impairment on tasks assessing working memory, suggesting a specific substance-related influence. Implications for conceptualization and categorization of addictive disorders and for treatment development will be discussed.

IX. The Acetylcholine System as Therapeutic Target in Drug Dependence: Molecular Biology, Neurochemistry, Animal and Human Behavioral Pharmacology

Chairs: Gerald Zernig and Richard De La Garza, II

The acetylcholine (ACh) system is involved in the acute and chronic effects produced by several drugs of abuse and appears to be an important target for medications development for drug dependence. In animal models, activation of muscarinic and nicotinic ACh receptors is necessary for the acquisition of drug (i.e., cocaine, morphine and remifentanyl) seeking, whereas in chronically self-administering animals, treatment with the acetylcholinesterase inhibitor (AChEI) tacrine, which increases synaptic availability of ACh, produces the opposite effect, i.e., decreases the reinforcing effects produced by cocaine in self-administration, an effect that can also be demonstrated in the conditioned place preference paradigm. In human neuroimaging studies, control- and cocaine-addicted subjects differ with respect to muscarinic and nicotinic receptor density in limbic areas and regional cerebral blood flow in the dorsolateral prefrontal cortex, insula, amygdala, midbrain, and hippocampus following physostigmine and/or scopolamine infusion. In the human behavioral

SYMPOSIA

laboratory, the AChEI rivastigmine decreases the positive subjective effects produced by administration of intravenous methamphetamine. These data serve as the first clinical evidence of the effectiveness of AChEIs as treatments for stimulant dependence.

X. Racial and Ethnic Disparities in Substance Abuse and Addiction: Native Americans and Native Hawaiians

Chairs: Rumi Kato Price and Lula A. Beatty

Health disparities research on substance abuse mostly focuses on racial and ethnic minority populations. A common misperception is that minorities use drugs more than Caucasians, but epidemiologic data do not support such a perception. Exceptions are Native populations. Large-scale national surveys suggest Native Americans are at the highest risk for substance use, abuse, and dependence among all racial groups in the U.S. Native Hawaiians report much higher levels of substance abuse than Asian subgroups. Although the NIH Roadmap aims to reshape clinical research to accelerate medical discovery and improve people's health, wide gaps remain between biomedical research that includes race/ethnicity information and social/behavioral health disparity research aiming to reduce racial/ethnic disparities in drug abuse and associated consequences. This mini-symposium organized by the Underrepresented Populations Committee (URPOP) aims to examine common and unique risk and protective factors that would provide some answers as to why Native populations are disproportionately afflicted by substance abuse problems, and to integrate neurobiological findings in these populations into efforts to reduce health disparities.

XI. HIV Risk Prevention in the NIDA Clinical Trials Network

Chair: Raul Mandler

The NIDA Clinical Trials Network (CTN) is an invaluable venue for implementing and evaluating evidence-based interventions for HIV prevention in diverse community drug treatment programs. This diversity allows for the examination of intervention effects within important subgroups of treatment programs. In this mini-symposium, we will examine differential effects of two effective HIV prevention interventions for two major treatment programs types, outpatient psychosocial (primarily serving cocaine and/or alcohol abusers) and methadone maintenance (primarily serving heroin dependent patients). Comparison of HIV prevention intervention between these two program types has important implications for drug treatment researchers and providers. There is widespread use of both modalities throughout the U.S., and there are considerable structural differences between these types of programs. In addition, cocaine and alcohol use are more widely associated with sexual risk behavior than opioid use. Comparative intervention effects across these types of programs for the CTN Safe Sex for Men and for the CTN Safe Sex for Women protocols will be presented. Focus will be on identification of any treatment program type differences related to sexual risk behavior prior to the intervention, intervention attendance, and intervention effectiveness. Implications of these results for future HIV prevention research efforts in drug treatment settings planned for the CTN will be discussed.

Wednesday, June 24

XII. Regulating Nicotine in Tobacco Products: State of the Science and Future Policy

Chairs: Dorothy Hatsukami and Jack Henningfield

The authority to reduce the yield of nicotine to non-addicting levels is one of the provisions in the legislation that is being considered by Congress to restore regulatory oversight of tobacco products to FDA. However, the scientific basis for determining the feasibility of the "nicotine reduction"

SYMPOSIA

approach is limited and the resulting population impact is unknown. In the past year, a workgroup of scientists and tobacco control experts has been meeting to discuss the current science, the scientific gaps and future research needs to bring clarity to whether or not regulating nicotine content in tobacco products is a feasible policy approach. The focus of this symposium will be to describe the most up-to-date research in this area and the key recommendations from the workgroup meetings. A regulatory policy framework for examining reduced nicotine cigarettes will be provided. Research on the impact of gradually reducing the levels of nicotine on smoking behavior, biomarkers of exposure and effect, nicotine addiction and cessation, evidence from laboratory behavioral, brain imaging, and smoking cessation studies that support the usefulness of denicotinized cigarettes as a cessation method will be presented. Animal models for determining nicotine dose thresholds for the acquisition and extinction of nicotine self-administration will also be discussed. The political and scientific challenges associated with nicotine regulation will be addressed.

XIII. Risk Management and Post-marketing Surveillance of CNS Drugs

Chair: Robert Balster

An important goal of drug regulation, including labeling and scheduling under the Controlled Substance Act, is to reduce unintended consequences. Risk management programs (RMP), including the congressionally promulgated Risk Evaluation and Mitigation Strategy (REMS) provides additional layers of control (e.g., restricted marketing, and enhanced education and post-marketing surveillance). In the late 1990s, the FDA began to require RMPs for drugs with special concerns, e.g., isotretinoin for acne, thalidomide for leprosy, tramadol approval without scheduling, transmucosal fentanyl, controlled release oxycodone, buprenorphine for opioid dependence, and transdermal methylphenidate. Although the concept of risk management is generally supported, the science base remains weak, thus, impeding effective and appropriate risk management implementation. Drugs with abuse potential pose special challenges including the goals of reducing abuse and diversion, which become more complicated for novel chemical entities and formulations. The CPDD convened a conference in October, 2008, to explore the challenges to research and regulation raised by the increasing application of risk management to CNS drugs with known or suspected abuse potential. Approximately 100 researchers, regulators, pharmaceutical developers, and research institution representatives, discussed issues, shared perspectives, and informed the development of recommendations for research and regulation by an Expert Panel. Commissioned papers were presented by leaders in key areas relevant to the science of risk management. These papers will be updated and presented in this symposium along with the Expert Panel recommendations. The symposium has implications for drug development, and prioritization of research and research funding.

XIV. Development of Protein-Based Pharmacotherapies for Drug Addiction

Chairs: Thomas R. Kosten and C. Nora Chiang

Currently, there are no FDA-approved medications for treating cocaine and methamphetamine addiction. Recent advances in biotechnology make it feasible for the development of large protein molecules as potential pharmacotherapies for drug addiction. Unlike small molecules targeting the neural pathways and receptors involved in drug addiction, these protein therapies target the drug itself, providing alternative strategies for medications development. Newly bioengineered drug-specific metabolizing enzymes have the potential to rapidly eliminate the drug from the body and thus are promising for treating drug overdose or addiction. New innovations in technology have facilitated the development of drug-protein conjugate vaccines, which elicit antibodies of high affinity that are specifically capable of neutralizing the drug in the body and attenuating its pharmacological effects. This symposium will review the current status and future perspectives of the use of these proteins for treating drug addiction.

SYMPOSIA

Thursday, June 25

XV. From Trials to Practice: The Implications of Inclusion and Exclusion Criteria in Clinical Trials of Pharmacotherapies to Treat Drug Dependence

Chairs: Howard Chilcoat and Anne Andorn

Clinical trials that test the efficacy of medications to treat drug dependence include numerous inclusion and exclusion criteria designed to maximize the detection of an efficacy signal as well as minimizing safety concerns. A negative consequence of these criteria is that the characteristics of clinical trial participants can be very different from those with drug dependence in the general population. Consequently, the efficacy of pharmacotherapies to treat drug dependence in individuals who would have been excluded from clinical trials can differ from results obtained in clinical trials. In addition, restrictive clinical trial criteria can result in difficulties in subject recruitment and can influence marketability of medications. This symposium will 1) assess empirically the impact of inclusion/exclusion criteria on generalizability of clinical trial results using data both from clinical trial and epidemiologic samples; 2) evaluate the utility of widely used inclusion/exclusion criteria; 3) address the implications of clinical trial results for public health and their import for research conducted by government, academic institutions, and industry. Contrasts between clinical trial and population samples and assessment of impact of clinical trial criteria will be presented for alcohol and nicotine dependence. The utility of clinical trial criteria for legal and illegal drug dependence and the impact of restrictive criteria on NIDA-sponsored research will be examined. A discussion will focus on the importance of the findings for research and regulatory and commercial implications.

XVI. Preclinical Research on Stress and Addiction

Chairs: John R. Mantsch and Klaus A. Miczek

Anecdotal reports as well as epidemiological and basic research findings suggest that stress plays a role in addiction. However, the mechanisms through which stressful stimuli regulate addiction-related processes and behaviors are not fully understood. This symposium will highlight current preclinical research findings investigating the relationship between stress and addiction. In addition to examining the neurobiological systems that may contribute to acute stressor-induced relapse (e.g., corticotropin releasing factor, dynorphins/kappa opioid receptors, arginine vasopressin, peptide YY3-36, orexins/hypocretins), the symposium will explore mechanisms through which repeated stress can predispose individuals to the effects of abused drugs and the processes through which repeated drug exposure can alter stressor-responsiveness to promote further drug use during periods of stress.

XVII. Cocaine Cocktails: The Impact of Concurrent Drug Use on Treatment of Cocaine Dependence

Chairs: Joy M. Schmitz and Alison Oliveto

Polysubstance use complicates the clinical presentation of cocaine dependence. Understanding clinical and neurobiological linkages between cocaine and other drugs of abuse are advancing the development of more targeted treatment approaches. This symposium will bring together new ideas toward broadening the scope of cocaine clinical trials by addressing concurrent patterns of drug use. Two recently completed clinical trials of pharmacotherapies for dual cocaine/alcohol dependence will provide evidence of efficacy, while identifying modifiers of outcome, including

SYMPOSIA

baseline and early drug use, gender, genotype, and medication compliance. Issues related to pharmacological approaches for reducing cocaine use in non opioid-dependent and opioid-dependent individuals will be discussed, using results of several disulfiram clinical trials to highlight differences in efficacy depending upon co-morbid opioid dependence status. In view of the fact that marijuana is the most commonly used illicit substance among cocaine abusers, yet arguably the least studied in medication development research, outcome data across a series of cocaine clinical trials will show how response to treatment differs according to level of concurrent cannabis use.

XVIII. Nicotinic Cholinergic Mechanisms in Drug Dependence: Receptor Subtypes and Ligands

Chairs: William A. Corrigall and David Shurtleff

This symposium will describe novel aspects of nicotinic cholinergic mechanisms at the receptor level. For nicotine dependence itself, the association with nicotinic cholinergic receptors (nAChRs) is obvious, and the alpha4beta2 nAChR subtype has always been considered critical. While it remains an important subtype in this disorder and other nicotinic mechanisms, recent studies have shown that accessory subunits in this receptor subtype alter its function markedly, with the sensitivity of (alpha4beta2)₂ receptors being highly dependent on the identity of the additional subunit in the receptor. In addition, it has recently been demonstrated that the alpha5 subunit influences dependence and disease risk, in that a common variant in the nAChR cluster on human chromosome 15q24 is associated with amount smoked, addiction and the prevalence of cancer. Still other nAChR subtypes are linked to drug dependence because they play a role in dopamine release, a cardinal feature of dependence, or because they are located within brain regions that have been linked to dependence mechanisms as the discovery of the relevant disease circuitry has been elaborated. With the greater delineation of subtypes of nAChRs and their roles in disease states, including dependence and mental health, greater emphasis is being placed on the development of novel ligands for use as research tools and as the basis for medications, using approaches such as structural modeling of the extracellular domain of the receptor and genetically modified organisms.

WORKSHOPS

Sunday, June 21

***I. Interventions for Parents with Substance Use Disorders:
New Findings from Clinical Research***

Chair: Nancy Suchman

Accumulating evidence suggests that changes in dopaminergically regulated reward systems resulting from chronic drug use may contribute to maladaptive parenting (e.g., parental neglect and compromised sensitivity). In the past few years, as psychosocial and neurobiological implications of chronic drug use for parenting become increasingly clear, the development of effective treatments for parents has become increasingly paramount. In this workshop, four experts on psychosocial treatment development and evaluation will report preliminary findings from ongoing trials testing the efficacy of four innovative interventions for substance-using parents. New findings from three controlled clinical trials testing (1) a contingency-management and relational therapy program for fathers, (2) a sobriety program for couples, and (3) an attachment-based program for mothers of infants and toddlers and one pilot study testing the preliminary efficacy of a contingency-management and interaction coaching program for mothers will be reported. Workshop participants can expect to develop a better understanding of the following:

- Four conceptually diverse approaches to intervention with substance-using parents
- The potential of each approach to improve parental functioning, psychiatric status, substance use, and child psychosocial adjustment
- New strategies for implementing clinical trials with substance-using parents and children
- Implications of trial results for future intervention development and evaluation

II. Fit to Be Tied: Abuse Potential of Anti-epileptics?

Chairs: Edward M. Sellers and Jack E. Henningfield

A few traditional anti-epileptic drugs are scheduled under the Controlled Substances Act (e.g., phenobarbital, benzodiazepines) many others are not. While many older drugs with sedative and other "abuse-related adverse events" may not have been as carefully evaluated pre-approval for their abuse liability, there is little evidence for their abuse. This has resulted in an assumption that anti-epileptic drugs have little or no abuse liability. New anti-epileptics with novel mechanisms of action may have a variety of clinical adverse events (e.g., euphoria, sedation, drunkenness, dizziness) suggesting abuse potential. In human abuse liability studies they may produce "liking at the moment", "high" and other subjective reports which could lead to scheduling. Recent studies with anti-epileptics raise some regulatory and scientific challenges. For example, levetiracetam in an initial human abuse liability study produced moderate "high" but no next day "liking" (Feltner et al, CPDD 2006). The aim of this workshop is to review the medical need for newer anti-epileptics and the regulatory perspective on such agents; to present and discuss clinical and human abuse liability data from representative newer anti-epileptics e.g., levetiracetam, lacosamide and retigabine; to discuss the potential that different factors above and beyond those within the regulatory framework are important from a scientific and public health perspective with anti-epileptics.

III. What's New at NIDA and NIH: A Peek into the Black Box

Chair: Gerald McLaughlin

This workshop is intended to provide an opportunity for participants to learn about new policies and procedures at NIH and NIDA that are relevant to them. Topics will include new policies resulting from the NIH lengthy examination of the peer review process, changes in the review process at NIDA and the Center for Scientific Review (CSR), tips on how to write a good grant application, and ways to get help on application preparation. Other topics and questions of interest to the

WORKSHOPS

audience will be addressed. This is very much an interactive, audience-directed activity. Although we will have a list of topics of interest, as is always the case with these presentations, audience members may ask about the budget, recent Advisory Council Reports, new research directions at NIDA, various NIH mechanisms, or any other subject.

IV. Leadership in the Making: Impact and Insights from Leadership Development Programs for Leaders of Addiction Services

Chairs: Anne Helene Skinstad and Pamela Waters

Leadership training and preparation is critical for the future of addiction service agencies. Historically, leaders have been promoted from clinical positions to leadership roles, with little opportunity for leadership education or development. With many changes facing this profession, such as the “graying” of the workforce, the need for strong leaders has become increasingly important. The presenters in this session collectively work to foster new leadership by organizing activities through which leadership can naturally develop. This workshop showcases leadership development efforts both within and outside the ATTC network, with specific focus on gender and cultural differences.

Monday, June 22

V. 15th Annual Contingency Management Working Group

Chairs: Stacey C. Sigmon and Kelly Dunn

The Annual Meeting of the Contingency Management Working Group represents an opportunity each year at CPDD for the dissemination and discussion of current research in the area of contingency management interventions for treating drug abuse. Contingency management procedures have been consistently demonstrated to be efficacious in reducing use of a wide range of drugs across a variety of populations, and the behavioral approach represents one of the most effective interventions for the treatment substance abuse. At the 15th Annual Meeting, junior and senior researchers will present preliminary data from ongoing studies. Participants and topics will be chosen during the spring of 2009 in order to capture the most hot-off-the-press data in contingency management research and clinical applications for presentation at our annual working group.

VI. Evaluating the Abuse Potential of Novel Compounds and Abuse-Resistant Formulations

Chair: Michael A. Nader

Clinical and preclinical research can be designed to evaluate the abuse liability of novel drugs thus informing the DEA as to the appropriate scheduling of compounds having abuse potential. DEA seizures show growing evidence for the abuse of new substances that are analogues of Schedule I drugs. DEA policy on scheduling substances and various formulations, forensic and epidemiological data on these seized compounds will be described, and the need for additional basic science on the mechanisms leading to abuse and the consequences of drug exposure will be addressed. NIDA has several avenues that can be explored in order to obtain the necessary data on mechanisms of abuse liability. Issues related to animal and human research involving assessment of abuse liability of novel compounds and abuse-resistant formulations will be discussed. In the end, this workshop is intended to formulate a viable approach and timeline to work within government and academic mechanisms to scientifically address the schedule and control issues of emerging drugs of abuse.

WORKSHOPS

VII. Substance Use Disorders in DSM-V: A Progress Report

Chairs: Thomas J. Crowley and Charles O'Brien

Studies indicating that DSM-IV's criteria for "Abuse" and "Dependence" do not form separate factors will be discussed, as will the Workgroup's consideration of combining the two diagnoses into one diagnosis, graded, e.g., as mild, moderate, or severe, probably by symptom count. Potential advantages of, and problems with, this proposal will be addressed. A proposal to include Cannabis Withdrawal Disorder and "withdrawal" as a criterion for Cannabis Dependence in the DSM-V will also be reviewed. The implications of this change on diagnostic, clinical, and epidemiological studies will be discussed. Additional issues related to diagnosis of other withdrawal and dependence disorders that became apparent during this process will be raised for discussion. A proposal to establish a category of "Addictive Disorders" in DSM-V will also be considered. Sub-categories would be "substance use disorders" and "non-substance addictions", each classified as mild, moderate or severe. "Abuse" and "Dependence" would not be used as they are now. "Dependence" would return to its original, single meaning: the clearly defined and normal "neuroadaptive" response to medications. The workshop will further include a discussion of incorporating indicators of heavy drinking patterns as a possible diagnostic criterion for alcohol use disorders for the DSMV in the US and in other populations. New data will be presented for emergency room patients in Argentina, Mexico, Poland and the United States showing DSM-IV alcohol use disorders with and without indicators of heavy drinking patterns.

VIII. Four Practical Interventions to Make Outpatient Treatment Attractive and Accountable – Translational Research in the Real World

Chairs: A. Thomas McLellan and David Festinger

With increasing acceptance that many cases of addiction will require chronic, continuing care, the ability to provide attractive, effective outpatient treatment becomes particularly important. Because of NIDA-funded research, there are now more effective treatment components available for outpatient treatment than ever before. But the reality across this country is that very few of these evidence-based components of care are being used. Outpatient treatment looks much as it did in 1970; and most importantly, the modal treatment episode in most outpatient programs is only 1 – 2 visits, less than 12% remain for even two months. This workshop will describe and discuss the translational research leading to system implementation of evidence-based treatment interventions to improve four important aspects of outpatient addiction treatment: Initiation, Transition, Supervision/Adaptation, Monitoring. Discussion will include describing principles of translation and human engineering necessary to adapt evidence based clinical practices to suit contemporary outpatient treatment systems.

NIDA International Research Posters

Chair: Steven W. Gust

This workshop will be similar to the ones conducted previously by the NIDA International Program, consisting of a poster session presenting drug abuse research being conducted outside of the United States. The primary goal is to provide a venue for CPDD members to meet, exchange ideas, and explore areas of mutual scientific interest with potential collaborators from other countries. Approximately 150 investigators will present research projects from around the globe, and NIDA divisions, offices, and programs will present posters outlining their international priorities and activities. This popular NIDA Workshop at CPDD is successful for both NIDA and CPDD; its success is reflected in substantial increases in participation and positive feedback on evaluation forms. Forging new collaborations among U.S. and foreign investigators is one of the primary goals of the NIDA International Program.

WORKSHOPS

Tuesday, June 23

***IX. Career Development: A Perspective from Junior
and Senior Researchers***

Chairs: Gerald McLaughlin, Scott Chen, Jose Ruiz, and Eliane Lazar-Wesley

Creating a career involves a series of decisions, decisions that often are made with limited information or assistance. The purpose of this workshop is to provide a forum for thinking more creatively and systematically about one's career decisions by inviting both junior and more senior scientists to reflect on their own career choices and experiences, as well as those of their colleagues, and encouraging substantial audience participation. Topics will include choosing a mentor; networking effectively at a professional meeting; moving to academia, industry or government positions; handling job interviews.

***X. Mathematical and Simulation Modeling in Biological and
Epidemiological Studies of Drug Addiction***

Chairs: Georgiy Bobashev and Boris Gurkin

This is the fourth Modeling Workshop in a series of very successful CPDD workshops that started in 2006. The purpose of the workshop is to showcase the spectrum of recent modeling approaches and to discuss their application to solve real-world problems in drug abuse. The workshop aims at fostering dialogue and collaborations between the substantive and computational scientists working in both epidemiological and biological areas of substance abuse and addiction. In epidemiology, modeling allows scientists to simulate the consequences of various intervention and prevention scenarios, while in biology modeling allows to describe and simulate complex neurophysiological processes.

***XI. Communicating the Risks of Opioid Analgesics:
How Can We Do Better?***

Chairs: Michael Wolf and Meredith Y. Smith

The misuse and abuse of prescription opioid analgesics is a significant public health challenge in the United States today. Successful efforts to mitigate this problem will depend, ultimately, on effective communication concerning the optimal use of opioid medications and the associated risks of overdose, misuse, abuse and diversion. Among the key constituencies to be targeted for such communication are pain patients, healthcare prescribers, and the general public. To date, many of the traditional risk communication vehicles have not been consistently successful in reducing risks, especially those associated with abuse and diversion. New Internet-based tools are increasingly being employed to communicate risk information associated with opioid analgesic use yet little data are available concerning the impact of these virtual approaches on patient and provider behavior. The specific aims of this workshop are 1) To identify methods, strategies and tools that can improve the consistency and effectiveness of communication regarding the benefits and risks associated with opioid analgesics, including ways to enhance traditional communication vehicles; 2) To discuss evaluating the effectiveness of such approaches; and 3) To highlight research that needs to be conducted in this area.

WORKSHOPS

XII. Advances in Implementation Science Related to Adolescent Substance Abuse Treatment

Chairs: Ashli J. Sheidow and Michael Dennis

Since 2002, The Society of Adolescent Substance Abuse Treatment Effectiveness (SASATE) has met at CPDD. This year's SASATE workshop focuses on how recent advances in research are impacting the dissemination of evidence-based practices. Presentations will include a recently completed meta-analysis of the effects of adolescent substance abuse treatment to examine the relationship between measures of the quality with which treatment is implemented and the magnitude of effects on substance use that result; NIDA-funded research testing therapist training protocols; Phase IV replication of MET/CBT5 in 36 sites and how the results varied by site, client characteristics, and implementation; a CSAT-funded project to replicate A-CRA in 32 sites and related NIAAA-funded implementation research. The session ends with a brief business meeting.

The following organizations have generously supported the work of the
College on Problems of Drug Dependence during the past year:

Abbott Labs

Acologic, Inc.

Astra Zeneca

Bristol Myers Squibb

CRS Associates

CSAT (Center for Substance Abuse Treatment)

Endo

Glaxo Smith Kline

Inflexxion

Javelin

Jazz Pharmaceuticals

Johnson & Johnson

NIDA (National Institute on Drug Abuse)

Pfizer Inc.

Pinney Associates, Inc.

Purdue Pharmaceuticals

Reckitt Benckiser Pharmaceuticals, Inc.

SAMHSA (Western Consultants)

Sanofi-Aventis, US

Shire US Inc.

Society for Research on Nicotine and Tobacco